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SUMMARY 
Maintenance of the hematopoietic system is dependent on hematopoietic 
stem cells (HSCs). During homeoastasis HSCs are quiescent. However upon 
injury, HSCs can efficiently be activated, leading to repair of the system. Signals 
leading to the activation of quiescent HSCs are still largely unknown. Recently 
our group has shown that administration of IFNα leads to activation of mouse 
HSCs in vivo. This is mediated by activation of IFNAR/STAT1 signaling followed 
by the up-regulation of Sca-1, however the exact mechanism of cell cycle 
activation remains unclear. To get further insight into this process we performed 
microarray analysis on HSCs after treatment with IFNα. This screen identified 
several candidate genes, which are potentially involved in HSC activation, 
including cell cycle regulators like p57KIP2, Maged1 and Reprimo as well as 
cytokines like Ccl5 and Cxcl10, which are key regulators of inflammatory 
responses. Furthermore we identified interferon response genes like Ifitm1, Ifitm3, 
Iigp1, Iigp3 or Ddx58, which were previously linked to regulation of proliferation 
in different contexts. Along these studies we uncovered that Ifitm1 and Ifitm3 
expression is highly enriched within hematopoietic stem and progenitor cells both 
on the RNA as well as on the protein level. Moreover expression is further 
induced by IFNα. However mice lacking the Ifitm family show normal 
hematopoiesis and normal HSC numbers and cycling behavior of HSCs in 
homeostatic conditions. Ifitm-deficient HSCs are capable to self-renew and 
differentiate similar to wild-type HSCs. This suggests that the Ifitm protein family is 
dispensable for HSCs during homeostasis. Notably Ifitm-deficient HSCs are also 




	   	  
efficiently activated by IFNα, similar to wild type HSCs. Microarray analysis of 
HSCs from Ifitm deficient mice, both during homeostasis and after administration 
of IFNα, showed no differences in the expression profiles, indicating a role for the 
Ifitm family as terminal effectors rather than regulatory proteins within HSCs. 
During our study it was shown by others that the Ifitm family is a potent viral 
restriction factor in endothelial cells. We are currently investigating whether Ifitm 
proteins have a similar role in the immune defense of HSCs. 
Thus far it is still unclear whether human HSCs are similarly activated by 
IFNα as mouse HSCs. To elucidate this we established a xenotransplantation 
model with human cord blood cells, which allows testing of the effects of IFNα 
on human HSCs in vivo. Surprisingly, unlike mouse HSCs, human HSCs are not 
activated by IFNα in this model. Notably human HSCs in this model are already 
less quiescent during homeostasis compared to their mouse counterparts. In the 
mouse also the bacterial endotoxin LPS can induce cell cycle activation in HSCs. 
Surprisingly LPS similarly activates human HSCs in our model. Gene expression 
analysis showed a high overlap between the genes induced in mouse and human 
HSCs after LPS treatment, while IFNα only affected cell cycle regulatory genes in 
murine HSCs. One explanation for this phenotype could be an impaired 
interaction of murine stromal niche cells with human HSCs and we are currently 
investigating this in more detail. 
Finally we examined the effect of IFNα on quiescent leukemic stem cells 
(LSCs). While IFNα is known to activate normal mouse HSCs, it is unclear 
whether also LSCs are similarly affected. To address this we investigated the 
effects of IFNα on LSCs in a mouse model for chronic myeloid leukemia. 
Surprisingly LSC were less efficiently activated compared to normal HSCs. This 
can be explained by down-regulation of the IFNAR by BCR-ABL kinase activity, 
which was previously described in vitro. This also highlights the importance of 
exact timing of LSC activation and treatment in combination therapy approaches. 
Our group is currently using this model to further identify and optimize new 
possible combination therapies.  




Hämatopoietische Stammzellen (HSCs) sind die Vorläuferzellen 
blutbildender Zellen und essentiell für die Erneuerung des Blutsystems. 
Normalerweise sind HSCs ruhend, können aber in Falle von Schädigungen des 
Blutsystems sehr schnell aktiviert werden. Die Signale, welche zu dieser 
Aktivierung von HSCs führen, sind weitgehend unbekannt. Kürzlich konnte 
unsere Gruppe zeigen, dass IFNα in der Maus HSCs aktivieren kann. Diese 
Aktivierung wird hauptsächlich durch den IFNAR/STAT1 Signalweg vermittelt, 
gefolgt von Überexpression des Stammzellantigens Sca-1. Der exakte 
Mechanismus der Aktivierung ist allerdings noch unbekannt. Um weitere 
Einblicke in diesen Aktivierungsprozess zu erlangen haben wir mRNA 
Expressionsanalysen von HSCs vor und nach IFNα Behandlung mit Hilfe von 
Microarrays durchgeführt. Hierbei haben wir mehrere Gene identifiziert, die 
möglicherweise eine Rolle in der Aktivierung von HSCs spielen könnten. Zu 
diesen gehören die Zellzyklus-Regulatoren p57KIP2, Maged1 und Reprimo, sowie 
die Cytokine Ccl5 und Cxcl10, welche wichtige Mediatoren entzündlicher 
Prozesse sind. Interessanterweise identifizierten wir darüber hinaus zahlreiche 
Interferon induzierte Gene wie z.B. Ifitm1, Ifitm3, Iigp1, Iigp3 und Ddx58, welche 
bereits in einem anderem Kontext in der Regulation der Proliferation beschrieben 
wurden. Anknüpfend an diese Studien konnten wir zeigen, dass die Expression 
von Ifitm1 und Ifitm3 in HSCs sowohl auf RNA als auch auf Protein Ebene bereits 




	   	  
in Homöostase stark erhöht sind. Darüber hinaus bewirkt IFNα-Gabe eine weitere 
Steigerung des Expressionslevels. Mäuse, die keine Ifitm Proteine besitzen, haben 
eine normale Blutbildung, eine normale Anzahl an HSC sowie ein normales 
Zellteilungsverhalten in HSCs im Vergleich zu Wildtyp-Mäusen. Zusätzlich hat 
die Ifitm-Defizienz in HSCs keine Auswirkungen auf die Selbsterneuerungsrate 
und Differenzierungsfähigkeit. Diese Ergebnisse deuten darauf hin, dass die Ifitm 
Protein Familie in HSCs während der Homöostase keine Rolle spielt. Gleichsam 
können Ifitm-defiziente HSCs ebenfalls mittels IFNα aktiviert werden. Microarray 
Analysen von HSCs Ifitm-defizienter Mäuse zeigten keine Unterschiede zu 
wildtyp HSCs, weder während der Homöostase noch nach Induktion mit IFNα. 
Dies legt nahe, dass Ifitm Proteine keine regulatorische Funktion in HSCs 
besitzen, sondern eher als terminale Effektoren fungieren. Während unserer Studie 
wurde tatsächlich eine Rolle der Ifitm Protein Familie als virale 
Restriktionsfaktoren in Endothelzellen nachgewiesen. Wir untersuchen zur Zeit ob 
Ifitm-Proteine in HSCs eine ähnliche Funktion haben. 
Es ist nicht bekannt ob, neben HSCs der Maus, auch menschliche HSCs 
durch IFNα aktiviert werden können. Um dies genauer zu untersuchen, haben wir 
ein Xeno-Transplantationsmodell entwickelt. Dabei wird humanes 
Nabelschnurblut in dem sich HSCs befinden in Mäuse transplantiert und durch 
IFNα−Gabe die Auswirkungen auf die humanen HSCs evaluiert. 
Unerwarteterweise werden in diesem Modell humane HSCs im Gegensatz zu 
HSCs der Maus nicht durch IFNα aktiviert. Interessanterweise proliferieren in 
diesem Modell humane HSCs bereits in der Homöostase stärker als HSCs der 
Maus. Ein weiterer Aktivator von Maus HSCs ist das bakterielle Endotoxin LPS 
(Lipopolysaccharid). Überraschenderweise führt LPS auch zur Aktivierung 
humaner HSCs in unserem Xeno-Transplantationsmodell. Geneexpressions-
analysen vor und nach LPS Behandlung zeigen eine große Überlappung zwischen 
den Genen, die in humanen und murinen HSCs durch LPS induziert werden. Im 
Gegensatz dazu weisen nur murine HSCs Veränderungen in Zellzyklus 
assoziierten Genen nach IFNα-Gabe auf. Eine Erklärung dafür könnte sein, dass 




	   	  
im Xeno-Transplantationsmodell die Interaktion zwischen murinen Nischenzellen 
und humanen HSCs gestört ist. Wir untersuchen dies derzeit genauer. 
Weiters haben wir untersucht ob leukämische Stammzellen (LSCs) von 
IFNα aktiviert werden können. Hierzu haben wir die Effekte von IFNα auf LSCs in 
einem Maus Modell für Chronische Myeloide Leukämie untersucht. Zu unserer 
Überraschung wurden LSCs weniger effizient aktiviert als normale HSCs. Die 
Erklärung dafür könnte eine Runterregulierung des IFNAR durch die BCR-ABL 
Kinase sein, die bisher in vitro beschrieben wurde. Dies unterstreicht im Weiteren 
die Wichtigkeit einer exakten Abstimmung der Behandlungszeitpunkte mit 
verschiedenen Substanzen in einer möglichen Kombinationstherapie. Unsere 
Gruppe nutzt dieses Modell momentan zum Austesten und zur Optimierung von 
weiteren möglichen Kombinationstherapien.  
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1 INTRODUCTION 
1.1 Stem cells in self-renewing tissues 
Stem cells are cells that have the intrinsic capability to self-renew, and 
therefore to produce more stem cells, as well as to differentiate, giving rise to 
more specialized cell types. They can be distinguished in embryonic stem cells 
(ES cells) and adult tissue stem cells. ES cells can only be found in the inner cell 
mass of the blastocyst. They are pluripotent and can give rise to cells of all three 
germ layers: endoderm, mesoderm and ectoderm. Contrarily adult or somatic 
stem cells are found in self-renewing adult tissues including the hematopoietic 
system, the skin and the intestinal epithelium. They are multi-potent stem cells, 
able to differentiate into different cells of their host tissue, and crucial for life-long 
tissue-maintenance. 
Adult tissue stem cells are located in special microenvironments called 
stem cell niches. While the exact components of these niches differ for different 
types of stem cells, in all of them cell-cell contact with surrounding niche cells as 
well as secreted factors including cytokines and chemokines are crucial for the 
regulation of stem cell maintenance and differentiation (reviewed in [Simons and 
Clevers, 2011]). As adult stem cells are crucial for tissue regeneration during the 
whole lifetime of an organism, it is important to minimize the damage caused by 
environmental stress for these cells. While stem cells have efficient DNA damage 
repair mechanisms, they still face the risk of accumulating DNA mutations with 
every cell division, which can subsequently lead to cancer [Blanpain et al., 
2011].  Hence many types of stem cells limit these hazardous impacts by dividing 




	   	  
very infrequently. Interestingly it was shown recently for hematopoietic stem cells 
(HSCs), skin stem cells in the hair follicle as well as intestinal stem cells, that for 
each of these stem cell populations a sub-population is quiescent or long-term 
dormant, while the majority of these cells cycle more actively [Li and Clevers, 
2010; Wilson et al., 2008]. Upon injury to the skin or to the hematopoietic 
system, the respective quiescent stem cells are rapidly activated and are crucial 
for tissue repair and regeneration, as described in more detail for the 
hematopoietic system in chapter 1.2.  
 
 
Figure	  1.1	  Stem	  cell	  locations	  in	  the	  hair	  follicle,	  intestine	  and	  bone	  marrow	  
(A)	  Structure	  of	  the	  hair	  follicle	  and	  location	  of	  stem	  cells	  in	  the	  bulge	  and	  hair	  germ	  region.	  While	  the	  bulge	  area	  
typically	  maintains	  quiescent	   stem	  cells,	   active	   stem	  and	  progenitor	   cells	   are	   found	   in	   the	  hair	   germ	  and	  dermal	  
papilla.	   During	   injury	   to	   the	   skin	   bulge	   stem	   cells	   give	   rise	   to	   stem	   cells	   of	   the	   epidermis.	   (B)	   Structure	   of	   the	  
intestinal	  crypt;	  quiescent	  stem	  cells	  reside	  in	  the	  +4	  region	  above	  the	  paneth	  cells,	  while	  active	  Lgr5+	  CBC	  cells	  are	  
lodged	   between	   the	   paneth	   cells.	   (C)	   Quiescent	   HSCs	   are	   located	   close	   to	   the	   endosteum,	   surrounded	   by	  
osteoblasts,	   endothelial,	   CAR	   and	   other	   cell	   types,	   while	   actively	   cycling	   homeostatic	   HSCs	   reside	   in	   the	   central	  
marrow	  region	  more	  distant	  from	  osteoblasts.	  [Li	  and	  Clevers,	  2010]	  




	   	  
1.2 Hematopoietic stem cells 
The murine hematopoietic stem cell (HSC) is to date one of the best 
characterized stem cells and serves as a model for other tissue stem cells. HSCs 
reside at the top of the hematopoietic hierarchy and are the only hematopoietic 
cells that have both the capability to self-renew as well as to differentiate into 
more committed cells (Fig 1.2). They can give rise to multi-potent progenitor cells 
(MPPs), which can rapidly amplify and are crucial for the expansion of the 
hematopoietic pool. They in turn differentiate into committed progenitor cells 
including common myeloid progenitor cells (CMP), megakaryocyte erythroid 
progenitor cells (MEP), granulocyte macrophage progenitor cells (GMP) and 
common lymphoid progenitor cells (CLP). These committed progenitor cells in 
turn give rise to the terminally differentiated cells of the hematopoietic system, 
including erythrocytes, platelets, granulocytes, macrophages, NK-cells or 
lymphocytes [Weissman and Shizuru, 2008]. 
Many terminally differentiated cells of the hematopoietic system, such as 
granulocytes, are only short-lived and need to be constantly replaced during 
homeostasis.  Additionally, during hematopoietic stress conditions such as 
bleeding, viral and bacterial infections or toxic insult, the demand for production 
of new blood cells is further increased. In order to maintain the integrity of the 
system also under such conditions, hematopoietic stem and progenitor cells have 
to be able to sense such injuries and rapidly produce new blood cells. 
The balance between the diverse differentiation pathways is tightly 
regulated by a network of transcription factors, which either promote or inhibit 
the differentiation in a specific lineage. In HSCs and multi-potent progenitor cells 
different transcription factors are simultaneously expressed at a low level, a state 
referred to as lineage priming [Ye et al., 2003]. Interestingly sub-fractions of HSCs 
and MPPs seem to be biased to preferentially differentiate in certain lineages, 
although they still possess the capability to differentiate in all lineages of the 
hematopoietic system [Dykstra et al., 2007; Luc et al., 2007; Mansson et al., 
2007]. Contrarily  many committed progenitor cells express only specific 




	   	  
transcription factors, e.g. C-EBPa promotes myeloid differentiation in GMPs while 
GATA-1 promotes differentiation towards the erythroid or megakaryocytic lineage 




Figure	  1.2	  Hierarchy	  of	  differentiation	  in	  the	  hematopoietic	  system	  
Hematopoietic	   stem	  cells	   (HSC)	  differentiate	   in	  a	   stepwise	  manner.	  During	   the	  differentiation	  process	  progenitor	  
cells	  gradually	  loose	  the	  potential	  to	  differentiate	  into	  all	  lineages.	  Multi-­‐potent	  progenitor	  cells	  (MPP)	  lack	  the	  self-­‐
renewal	   capacity	   of	   HSCs	   but	   are	   capable	   of	   differentiating	   in	   all	   hematopoietic	   lineages,	   while	   committed	  
progenitor	   cells	   can	   only	   give	   rise	   to	   one	   lineage.	   The	   final	   differentiation	   of	   committed	   progenitor	   cells	   to	  
terminally	   differentiated	   cells	   is	   a	   multi-­‐step	   process	   indicated	   by	   dashed	   arrows.	   CMP,	   common	   myeloid	  
progenitor;	   GMP,	   granulocyte-­‐macrophage	   progenitor;	   MEP,	   megakaryocyte-­‐erythrocyte	   progenitor;	   LMPP,	  
lymphoid	   primed	   multi-­‐potent	   progenitor;	   EP,	   erythrocyte	   progenitor;	   MkP,	   megakaryocyte	   progenitor;	   GP	  
granulocyte	  progenitor;	  MacP,	  macrophage	  progenitor;	  NK,	  natural	  killer	  cell.	  (adapted	  from	  [Cedar	  and	  Bergman,	  
2011]) 




	   	  
1.2.1 Identification of murine and human hematopoietic stem cells 
During homeostasis in adult mice, the majority of HSCs reside in the 
trabecular region of the bone marrow microenvironment, where they are 
protected from pathogens and toxic stress. In the previous decades, a combination 
of functional assays together with flow cytometric analysis has allowed the 
step-wise isolation of very pure fractions of hematopoietic stem cells [Weissman 
and Shizuru, 2008]. The most important assay to assess HSC function is the 
capability of an HSC to reconstitute the bone marrow of lethally irradiated hosts. 
In these assays, recipient mice are lethally irradiated with a dose that kills the 
majority of the hematopoietic cells of the recipient mouse, including the HSCs. 
Afterwards the recipient mouse is transplanted with cells from a donor mouse. 
The transplanted HSCs are able to rescue the host and to give life-long multi-
lineage engraftment, showing both the capability of these cells to self-renew as 
well as to differentiate into all hematopoietic lineages. In contrast, transplantation 
of short-term HSCs or more committed progenitor cells only leads to a temporary 
reconstitution of the system, as these cells lack the self-renewal capacities of HSCs 
(reviewed in [Weissman and Shizuru, 2008]). 
The first evidence for such bone marrow reconstitution by hematopoietic 
cells was already shown by Till and McCulloch, who could show efficient rescue 
of lethally irradiated mice by transplantation of bone marrow cells [McCulloch 
and Till, 1960].  Subsequently the combination of transplantation assays and 
advances in fluorescence activated cell sorting (FACS) techniques allowed 
identification of HSCs within the lineageneg Sca-1+ cKit+ (LSK) population of cells in 
the bone marrow [Uchida et al., 1994]. LSK cells do not express any cell surface 
markers of terminally differentiated cells (e.g. CD3, CD4 or CD8 expressed by 
lymphocytes or CD11b or Gr-1 expressed by granulocytes), but do express cKit as 
well as Sca-1 on their surface. This definition of HSCs was subsequently further 
refined by the addition of several newly identified markers, further enhancing the 
purity of long-term reconstituting stem cells. The CD34 negative fraction of LSK 
cells is highly enriched for HSCs, with more than one in five cells able to show 
long-term multi-lineage reconstitution in lethally irradiated mice [Osawa et al., 




	   	  
1996]. Recently the addition of the signal-lymphocyte-activating molecule (SLAM) 
markers CD150 and CD48 allowed even higher purification. Within the CD150 
positive and CD48 negative fraction of LSKCD34- cells  (LSKCD150+CD48-CD34-) 
close to 50% of the cells are long-term reconstituting HSCs, as shown in limiting 
dilution and single cell transplantation assays [Kiel et al., 2005; Wilson et al., 
2009]. The frequency of this population in the bone marrow is less than one in 
105 cells of the bone marrow, illustrating the low abundance of stem cells and the 
steep hierarchy within the hematopoietic system [Wilson et al., 2009]. 
Similar to murine HSCs also human HSCs reside mainly in the marrow of 
long bones and the hip bone. The cell surface phenotype of human HSCs has 
been less well characterized so far, compared to their mouse counterparts, in part 
due to the lack of feasibility of transplantation assays in human patients. Human 
HSCs were functionally assessed both using in vitro colony formation assays as 
well as in vivo xenotransplantation assays [Weissman and Shizuru, 2008]. In these 
xenotransplantation assays human hematopoietic cells are transplanted in 
sub-lethally irradiated immune-compromised mice. The use of 
immune-compromised mice in this setting is crucial in order to avoid rejection of 
transplanted cells due to an immune response of the host immune system towards 
the foreign graft. The most frequently used immune-compromised mouse strains 
include NOD/SCID mice, which lack T-cells and B-cells, and more recently the 
highly immune compromised NOD/SCID common gamma (NSG) mice. NSG 
mice lack in addition to T-cells and B-cells also functional natural killer cells, and 
are further impaired in several signaling pathways that are important in the innate 
immune response, allowing the development of functional human hemato-
lymphopoesis in these mice [Ishikawa et al., 2005]. 
Transplantation of human bone marrow cells into sub-lethally irradiated 
NOD/SCID mice showed that the lineage negative, CD34 positive and CD38 
negative population is highly enriched for hematopoietic stem cells with long 
term reconstitution capability [Bhatia et al., 1997a]. Notably the frequency of 
HSCs in the linnegCD34+CD38- population of human bone marrow is lower in 
comparison to the purity achievable for murine HSCs using the markers described 




	   	  
above.  Furthermore the cell surface protein Thy1 (CD90) has been shown to 
enrich for human HSCs in vitro as well as in transplantation experiments together 
with CD34 [Weissman and Shizuru, 2008]. However Thy1 was recently 
challenged as a marker for human HSCs as alpha-6-integrin (CD49f) has been 
shown to further enrich the purity of linnegCD34+CD38- HSC irrespective of their 
expression of Thy1 [Notta et al., 2011]. Concluding the search for human HSC 
markers is still ongoing, and currently the achievable purity of human HSCs is less 
compared to their mouse counterparts. 
 
1.2.2 The hematopoietic stem cell niche 
Hematopoietic stem cells are preferentially located in the trabecular 
cavities of long bones. Immuno-histological analysis of bone sections suggest that 
HSCs reside in the bone marrow as individual stem cells, however their exact 
localization within the bone marrow is still a highly controversial topic. It is 
important to notice that, due to the limited number of fluorochromes that can be 
used simultaneously, histological techniques don’t allow identification of HSCs as 
accurately as flow cytometry and hence distinction between HSCs and early 
progenitor cells is not possible. 
Putative HSCs have been identified both at the endosteum, the region 
located in immediate proximity to bone lining osteoblasts (OBs), as well as close 
to sinusoidal endothelium in more central regions of the bone marrow (Fig 1.3) 
[Ehninger and Trumpp, 2011]. While some sinusoids are also found in close 
proximity to the endosteum, the majority is located at a greater distance to the 
endosteal surface, suggesting the existence of two different HSC niches in the 
bone marrow; an endosteal niche and a perivascular niche [Kiel and Morrison, 
2008; Wilson and Trumpp, 2006]. The  exact relationship between these two 
types of HSC niches is currently still debated, and further experiments are needed 
to finally unravel whether they exists as distinct entities or whether HSCs might 
shuttle between the two niches. 
 




	   	  
Figure	  1.3	  Location	  of	  HSCs	  in	  the	  trabecular	  region	  of	  long	  bones	  
HSCs	   reside	   in	   the	   trabecular	   region	   of	   the	   bone	   marrow	   of	   long	   bones.	   HSCs	   are	   found	   both	   close	   to	   the	  
endosteum,	  which	   is	   lined	  by	  osteoblasts,	  as	  well	  close	  to	  sinusoids	   in	  more	  central	   regions	  of	   the	  bone	  marrow.	  
Perivascular	   nestin	   positive	   mesenchymal	   stem	   cells	   and	   CAR	   cells	   are	   crucial	   for	   the	   maintenance	   of	   HSCs.	  
[Ehninger	  and	  Trumpp,	  2011]	  	  
The interaction of HSCs with the surrounding stromal cells of the niche is 
crucial for HSC quiescence, self-renewal and maintenance. This interaction takes 
place both through direct cell-cell contact as well as by sensing of cytokines and 
chemokines produced by niche cells. Amongst the most important stromal cells 
for HSC maintenance are osteoblasts (OBs), MSCs and CAR cells. 
Bone-lining spindle-shaped osteoblasts, which can be identified by their 
CD45-CD31-Ter119-Sca-1-CD51+ phenotype, were the first stromal cells suggested 
to be a crucial component of the HSC niche. Depletion of osteoblasts leads to 
mobilization of HSCs to the spleen [Visnjic et al., 2004; Zhu et al., 2007]. 
Conversely genetically modified mice that have increased numbers of osteoblasts, 
show a similar increase in their HSC numbers [Calvi et al., 2003; Zhang et al., 
2003]. Osteoblasts express several cell surface proteins that are known to be 
important for HSCs maintenance and quiescence including N-cadherin, 
membrane-bound SCF and VCAM1. Additionally they are a source of secreted 
factors involved in regulation of HSCs including TPO, Ang-1, CXCL12 and OPN 




	   	  
(Fig 1.5) [Ehninger and Trumpp, 2011]. Together, these interactions with the 
niche environment are crucial for the maintenance of HSCs as well as keeping 




Figure	  1.4	  Location	  of	  HSCs	  in	  the	  trabecular	  region	  of	  long	  bones	  
Model	  depicting	  HSCs	  in	  the	  endosteal	  and	  perivascular	  niche	  of	  the	  bone	  marrow.	  Dormant	  HSCs	  are	  likely	  located	  
close	   to	   the	   endosteal	   surface	   lined	   by	   osteoblasts	   (OBs)	   and	   Nestin+	   MSCs,	   both	   of	   which	   supply	   crucial	   HSC	  
maintenance	  and	  quiescence	  factors	  including	  CXCL-­‐12,	  SCF,	  Ang-­‐1,	  VCAM-­‐1	  and	  TPO.	  MSCs	  can	  give	  rise	  to	  OBs	  as	  
well	   as	   to	   adipocytes	   and	   chondrocytes.	   The	   perivascular	   niche	   is	   located	   in	   more	   central	   regions	   of	   the	   bone	  
marrow	  around	  bone	  marrow	  sinusoids.	  Perivascular	  MSCs	  as	  well	  as	  CAR	  cells	  are	  crucial	  components	  of	  this	  niche,	  
while	   it	  does	  not	  contain	  any	  OBs.	  Factors	  secreted	  by	  CAR	  cells	  as	  well	  as	  Notch	   ligands	  expressed	  by	  sinusoidal	  
endothelial	   cells	   promote	   the	   self-­‐renewal	   activity	   of	   HSCs.	   Macrophages	   and	   osteomacs	   are	   crucial	   for	   the	  
maintenance	  of	  MSCs	  and	  OBs,	  respectively.	  The	  sympathetic	  nervous	  system	  (SNS)	  is	  crucial	  for	  regulation	  of	  MSC	  
proliferation	  and	  regulates	  circadian	  oscillation	  of	  CXCL-­‐12	  expression.	  [Ehninger	  and	  Trumpp,	  2011]	  
In addition to endosteal osteoblasts the presence of other cells, including 
nestin-expressing mesenchymal stem cells (nestin+ MSCs) as well as CXCL12 
abundant reticular (CAR) cells was recently shown to be crucial for HSC 
maintenance [Mendez-Ferrer et al., 2010]. Nestin+ MSCs are mainly found around 
blood vessels, and in lower abundance close to the endosteum. Strikingly MSCs 
express higher levels of HSCs maintenance factors including SCF, Ang-1, IL7, 
VCAM1 and OPN, compared to all other stromal cell types including osteoblasts. 




	   	  
Interestingly MSCs show several similarities to CAR cells, which are mesenchymal 
progenitor cells, which are more abundant and mainly located in the bone 
marrow itself. Depletion of either of these cells impairs HSC maintenance. Due to 
the many similarities of these two populations it is possible that they are, at least 




Figure	  1.5	  Crosstalk	  between	  osteoblasts	  and	  HSCs	  
Model	  of	  the	  endosteal	  niche-­‐HSC	  synapse,	  showing	  putative	  ligand-­‐receptor	  interactions	  between	  osteoblasts	  and	  
HSCs	   as	   well	   as	   intracellular	   pathways	   crucial	   for	   HSC	   maintenance.	   ANG1,	   angiopoietin-­‐1;	   BMI1,	   polycomb	  
repressor;	   BMP,	   bone	  morphogenetic	   protein;	   BMPR1A,	   BMP	   receptor	   1A;	   CSL,	   CBF1	   suppressor	   of	   Hairless	   and	  
LAG1;	  CXCL12,	  CXC-­‐chemokine	   ligand	  12;	  CXCR4,	  CXC-­‐chemokine	   receptor	  4;	   FAK,	   focal	   adhesion	   kinase;	  HOXB4,	  
homeobox	  B4;	  ICAM1,	  intercellular	  adhesion	  molecule	  1;	  LFA1,	  lymphocyte	  function-­‐associated	  antigen	  1;	  LRP,	  low-­‐
density-­‐lipoprotein-­‐receptor-­‐related	   protein;	   MAPK,	   mitogen-­‐activated	   protein	   kinase;	   OPN,	   osteopontin;	   PI3K,	  
phosphatidylinositol-­‐3	  kinase;	  PLC,	  phospholipase	  C;	  PKC,	  protein	  kinase	  C;	  PPR,	  PTH/PTH-­‐related	  protein	  receptor;	  
PTH,	  parathyroid	  hormone;	  SMADS,	  mothers	  against	  decapentaplegic-­‐related	  homologue;	  SNO,	  spindle-­‐shaped	  N-­‐
cadherin-­‐expressing	  osteoblast;	  TIE2,	  tyrosine	  kinase	  receptor	  2;	  VCAM1,	  vascular	  cell-­‐adhesion	  molecule	  1;	  VLA4,	  
very	  late	  antigen	  4.	  [Wilson	  and	  Trumpp,	  2006]	  




	   	  
In conclusion it is possible that two highly similar HSC niches exist in the 
bone marrow. The endosteal niche, harboring dormant HSCs close to osteoblasts 
and supporting dormancy by secreted factors as well as direct cell to cell contact, 
and the perivascular niche, harboring homeostatic HSCs close to sinusoidal 
endothelial cells and CAR cells, promoting HSC self-renewal (Fig 1.4). Nestin+ 
MSCs seem to be a crucial part of both of these niches [Ehninger and Trumpp, 
2011]. 
 
1.2.3 Key regulators of HSCs 
HSC functions are tightly controlled by both cell-autonomous as well as 
cell-extrinsic factors, including the interaction with stromal cells in the bone 
marrow niche and response to secreted cytokines and chemokines. Extensive 
research in the last years allowed the identification of several signaling pathways, 
transcription factors, cell cycle regulators and survival factors that are critical for 
HSC maintenance. 
 
Hematopoietic cytokines and secreted factors 
In recent years extensive effort was focused on in vitro expansion of HSCs, 
as source for clinical applications. In these approaches several cytokines were 
identified, which promote HSC maintenance and expand HSC numbers in vitro, 
including stem cell factor (SCF), FMS-like tyrosine kinase 3 (Flt3)-ligand, 
thrombopoietin (TPO) and the interleukins IL3, IL6 and IL11 [Bhatia et al., 1997b; 
Conneally et al., 1997; Gammaitoni et al., 2003; Miller and Eaves, 1997; 
Zandstra et al., 1997]. While SCF, TPO and IL6 are also crucial for HSC 
maintenance in vivo, the role of IL11 is less clear as mice deficient for the IL11-
receptor have no hematopoietic phenotype [Nandurkar et al., 1997]. SCF is the 
ligand of the c-kit receptor (CD117), which is highly expressed in hematopoietic 
stem and progenitor cells. Mice deficient for either SCF or c-kit are not viable and 
die already between embryonic day 14-16 due to severe anemia [Russell, 1979]. 
Mice with partial loss of c-kit show decreased numbers of LT-HSCs impaired HSC 




	   	  
quiescence [Thoren et al., 2008]. Mice that are deficient for either TPO or its 
receptor MPL have decreased numbers of HSCs [Carver-Moore et al., 1996; 
Kimura et al., 1998]. Furthermore HSC expansion post-transplantation is highly 
dependent on MPL and TPO, and similar to c-kit deficiency mice deficient for 
TPO show decreased HSCs quiescence and reduced expression of p57Kip2 and 
p19INK4D [Qian et al., 2007]. 
Another factor secreted by osteoblasts, which is crucial for HSC 
maintenance is the glycoprotein osteopontin (OPN). Mice deficient for OPN have 
increased numbers of HSCs. Furthermore OPN deficient mice transplanted with 
wild-type HSCs show a similar trend, indicating that OPN might function as a 
negative regulator of HSC expansion [Stier et al., 2005]. Interestingly HSCs of 
OPN deficient mice are highly cycling, suggesting that OPN might function at 
least in part by inhibiting the proliferation of HSCs [Nilsson et al., 2005]. 
Several angiopoetin-like proteins support the in vitro expansion of mouse 
and human HSCs [Zhang et al., 2006; Zhang et al., 2008a]. Interestingly 
interaction of the Tie2 receptor on HSCs with Angiopoietin1 (Ang1) induces 
cobblestone formation in vitro and maintains long-term repopulating activity of 
HSCs in vivo. Furthermore Ang-1 enhances quiescence of HSCs and induces 
adhesion to bone [Arai et al., 2004]. In summary the Tie2/Ang-1 pathway plays a 
crucial role in maintenance of HSCs in a quiescent state. 
 
Crucial signaling pathways 
 Interestingly many signaling pathways initially described during embryonic 
development have more recently been shown to be crucial for maintenance of 
adult stem cells including HSCs. The most crucial ones include the Notch 
pathway, the Wnt/wingless pathway and the TGFβ pathway. 
 Notch The notch signaling pathway controls many crucial aspects of cell 
fate decision and organogenesis during embryogenesis. Also in adult 
hematopoietic stem cells a crucial role of Notch signaling was demonstrated in 
both mouse and human HSCs. The Notch ligands Delta and Jagged can expand 
cultured mouse and human HSCs in vitro [Karanu et al., 2000; Ohishi et al., 




	   	  
2002a, b]. Furthermore constitutive activation of Notch signaling in vivo leads to 
increased HSC self-renewal, while contrarily expression of a dominant negative 
RBP-J DNA binding factor leads to depletion of HSCs [Duncan et al., 2005; Stier 
et al., 2002]. However the role of Notch signaling in adult HSCs is still 
controversial. Deletion of Jagged1 or Jagged1/Notch1 does not affect HSC 
maintenance, neither during homeostasis nor during stress conditions [Mancini et 
al., 2005]. Furthermore also expression of dominant-negative MAML1 or deletion 
of RBP-J did not affect HSC maintenance  These findings could potentially be 
explained in part by redundancy and functional compensation by other Notch 
family members. Nonetheless the role of Notch in HSCs currently is controversial 
and needs further elucidation.  
Wnt The Wnt signaling pathway is a known key regulator of different 
kinds of stem cells as well as cancer stem cells (reviewed in [Reya and Clevers, 
2005]). The first hints for a potential role of Wnt signaling in HSCs came from in 
vitro cultures, where Wnt family members support the expansion of mouse and 
human HSCs and furthermore constitutive overexpression of activated β-catenin 
leads to expansion of HSCs and MPPs [Austin et al., 1997; Reya et al., 2003; Van 
Den Berg et al., 1998]. Surprisingly however in vivo deletion of β-catenin alone or 
β-catenin and γ-catenin simultaneously has no apparent effect on HSC 
maintenance or transplantability [Cobas et al., 2004; Koch et al., 2008]. Therefore 
a role of canonical Wnt signaling in the maintenance of HSCs is unlikely. 
Interestingly however overexpression of the Wnt inhibitor Dkk1 in osteoblasts 
leads to a reduction in Wnt signaling, loss of HSC quiescence and reduced 
engraftment of HSCs upon transplantation [Fleming et al., 2008]. Notably Dkk1 
does not only inhibit canonical Wnt signaling, which is dependent on β-catenin 
and γ-catenin, but also non-canonical Wnt signaling, possibly explaining the 
controversial results. In summary there is no evidence for a role of canonical Wnt 
signaling in adult HSCs while non-canonical Wnt signaling appears to play a role 
in the maintenance of HSC quiescence.   




	   	  
Figure	  1.6	  Crucial	  signaling	  pathways	  governing	  HSC	  fate	  
(A)	  Notch	  pathway.	  The	  notch	  receptor	  is	  activated	  by	  ligands	  of	  the	  Delta	  or	  Jagged	  families,	  leading	  to	  proteolytic	  
cleavage	  of	  Notch	  by	  γ-­‐secretase.	  The	  Notch	  intracellular	  domain	  (NICD)	  translocates	  to	  the	  nucleus	  and	  activates	  
notch	   target	   genes	   e.g.	   Hes.	   (B)	   Wnt	   pathway.	   Wnt	   signaling	   is	   activated	   by	   binding	   of	   Wnt	   to	   Frizzled	   and	  
lipoprotein-­‐related	  protein	  (LRP)	  receptors.	  In	  the	  absence	  of	  Wnt,	  β-­‐catenin	  is	  degraded	  by	  a	  destruction	  complex	  
consisting	   of	   adenomatous	   polyposis	   coli	   (APC),	   Axin,	   Casein-­‐kinase	   1α	   (CK1α)	   and	   glycogen	   synthase	   kinase	  
(GSK3β).	  Upon	  binding	  of	  Wnt	  b-­‐catenin	   is	   stabilized	  and	  can	  translocate	   to	   the	  nucleus	  where	   it	  actives	  LEF/TCF	  
transcription	   factor	   family	  members.	   (C)	   TGFb	   pathway.	   Upon	   binding	   of	   TGFb,	   Activin	   or	   BMP	   to	   their	   specific	  
receptor,	   SMAD	  proteins	   are	  phosphorylated.	   Phosphorylated	   SMAD	  associate	  with	  Co-­‐Smads	  and	   translocate	   to	  
the	  nucleus	  where	  they	  activate	  target	  gene	  transcription.	  (modified	  from	  [Blank	  et	  al.,	  2008])	  




	   	  
TGFβ The transforming growth factor β superfamily, including TGFβ, 
activin and bone morphogenic protein (BMP), regulates a broad spectrum of 
processes both during embryogenesis as well as in adult organisms.  TGFβ1 
strongly inhibits expansion of HSCs in vitro and induces cell cycle arrest by 
inducing the cyclin-dependent kinase inhibitors p21 and p57 [Cheng et al., 2001; 
Scandura et al., 2004; Sitnicka et al., 1996]. However mice deficient for 
TGFβ type 1 receptor have no hematopoietic defects, neither during homeostasis 
nor during stress conditions [Larsson et al., 2003; Larsson et al., 2005]. 
Interestingly in vivo deletion of Smad4 leads to decreased repopulation ability of 
Smad4-deficient HSCs, suggesting a crucial role of Smad4 in HSC self-renewal 
[Karlsson et al., 2007]. Contrarily inhibition of Smad signaling in vivo by 
retro-viral overexpression of inhibitory Smad7 results in increased HSC 
self-renewal [Blank et al., 2006]. One possible explanation for this controversy 
might be a role of Smad4 independent of canonical Smad signaling. Interestingly 
Smad4 indeed was shown before to interact with Wnt as well as Notch signaling 
[Itoh et al., 2004; Labbe et al., 2000]. 
In summary the Notch, Wnt and TGFβ signaling pathways seem to be 
crucial regulators of HSCs. However the exact influence of these complex 
pathways on HSCs is still poorly understood and needs further elucidation. This is 
especially critical as there is both, high redundancy within each pathway, as well 




 Several transcription factors including Scl, Runx1, Gata1/2, Bmi1 or Myc 
play a crucial role in the maintenance of HSC quiescence, self-renewal, 
differentiation and survival. The polycomb group family member Bmi1 is crucial 
for HSC maintenance as HSCs from mice deficient for Bmi1 have defective self-
renewal, and furthermore only show short term engraftment upon transplantation 
[Park et al., 2003]. Scl, Runx1 as well as Gata-2 are crucial for the specification of 




	   	  
HSCs during embryogenesis [Chen et al., 2009; D'Souza et al., 2005; Ling et al., 
2004]. In adult HSCs Runx1 and Gata-2 promote HSC proliferation, whereas Scl 
seems to be dispensable for HSC maintenance [Ichikawa et al., 2008; Ling et al., 
2004; Mikkola et al., 2003]. The proto-oncogene Myc is another key regulator of 
HSCs. Deficiency for c-Myc results in accumulation of defective HSCs, probably 
due to niche-dependent defects in HSC differentiation [Wilson et al., 2004]. 
Strikingly deletion of both c-Myc as well as N-Myc results in pancytopenia and 
rapid death of mice [Laurenti et al., 2008].  
 
Cell cycle regulators 
During homeostasis the majority of HSCs are quiescent, resting in the G0 
phase of the cell cycle [Wilson et al., 2008]. Active proliferation of HSCs is tightly 
controlled, however crucial for both self-renewal as well as differentiation. To exit 
the G0 phase of the cell cycle the cyclinE-CDK2 complex is required, which is 
negatively regulated by the CIP/KIP family of cyclin dependent kinase inhibitors 
(CKIs), comprising p21CIP, p27KIP1 and p57KIP2 (Fig 1.7). The same family is also 
crucial in controlling the G1/S-transition by inhibiting the cyclinA-CDK2 complex. 
Another important family of CKIs is the INK4 family, which comprises p16INK4A, 
p15INK4B, p18INK4C and p19INK4D (Fig 1.3). The INK4 family inhibits cyclinD-CDK4/6 
complexes and thereby phosphorylation of the retinoblastoma protein (Rb). They 
are important regulators of cell cycle arrest in the early G1 phase, in response to 
cellular stress. 
Loss of the CIP/KIP family member p27Kip1 has no influence on HSC 
numbers, cell cycle distribution or self-renewal potential, however it results in an 
increased hematopoietic progenitor cell compartment [Cheng et al., 2000a]. 
Deletion of p21CIP leads to loss of HSC quiescence, which renders HSCs more 
sensitive to exhaustion by cytotoxic drugs [Cheng et al., 2000b]. Strikingly loss of 
p57KIP2 leads to severe loss of HSC self-renewal capacity as well as a reduction of 
quiescence cells within the HSC compartment, which could be rescued by 
expression of p27KIP1 from the p57 gene locus [Matsumoto et al., 2011]. These 
phenotypes were even further pronounced when p27KIP1 or p21CIP were deleted 




	   	  
simultaneously with p57KIP2 [Matsumoto et al., 2011; Zou et al., 2011]. In 
summary p57KIP2 appears to be the most crucial CKI of the CIP/KIP family in 
regulation of HSC maintenance and proliferation. 
Contrarily to the deletion of CIP/KIP family members loss of the INK4 
family member p18INK4C results in a similar increase in HSC numbers, but 
surprisingly also in an increase in long-term repopulating ability upon 
transplantation within these cells [Yu et al., 2006; Yuan et al., 2004]. This is 
especially striking as in most cases increased cycling of HSCs has detrimental 
effects on their repopulating capability. Expression of p16INK4A is increased during 
aging of mice as well as in response to cellular stress including exposure to 
reactive oxygen species or bone marrow transplantation [Janzen et al., 2006]. 
Interestingly HSCs from aged mice deficient of p16INK4A show increased 
repopulating capacities comparable to young wild type mice, suggesting that 
p16INK4A might negatively regulate HSC numbers during aging [Janzen et al., 
2006]. In summary p16INK4A seems to be a crucial regulator involved in the age-
dependent decline in HSC functions.  
 
 




	   	  
Figure	  1.7	  Crucial	  CDK	  inhibitors	  in	  HSCs	  
The	  cyclinD-­‐CDK4/6	  complex	   is	  crucial	   for	  phosphorylation	  of	   the	  retinoblastoma	  protein	   (Rb)	  and	   its	   subsequent	  
degradation.	   Both	   the	  CIP/KIP	   as	  well	   as	   the	   INK4	   family	   of	   CDK	   inhibitors	   targets	   this	   phosphorylation	   step	   and	  
thereby	  promotes	  cell	  cycle	  arrest	   in	  the	  G0	  or	  G1	  phase.	  Furthermore	  the	  CIP/KIP	  family	  of	  CKIs	   is	  crucial	   for	  the	  
regulation	  of	  reentry	  of	  the	  cell	  cycle	  from	  the	  G0	  phase	  by	  inhibiting	  the	  formation	  of	  cyclinE-­‐CDK2	  complexes	  and	  
for	  the	  G1/S-­‐transition	  by	  inhibiting	  cyclinA-­‐CDK2	  complexes.	  (adapted	  from	  [Tesio	  and	  Trumpp,	  2011])	  
 
 	  




	   	  
1.3 Dormancy and activation of HSCs 
Unlike embryonic HSCs and adult hematopoietic progenitor cells, which 
are highly proliferative, the majority of adult murine HSCs are only slowly cycling 
during homeostasis. Cell cycle analysis showed that during homeostasis more 
than 70% of LSK SLAM CD34- HSCs are in the G0 phase of the cell cycle, but only 
about 10% of multi-potent progenitors show a similar phenotype [Wilson et al., 
2008]. Notably this analysis only represents a current picture at the timepoint of 
analysis, but does not allow any further conclusions about the cycling behavior of 
these cells over time. 
This important question was recently addressed by label retaining assays, 
similar to those performed in the identification of label retaining cells in the 
intestine and skin (Fig 1.1) [Fuchs, 2009]. In these assays the stem cells were 
labeled either chemically by the thymidine analogue 5-bromo-2-deoxyuridine 
(BrdU) or genetically with a doxycycline inducible histone H2B coupled to GFP 
(H2B-GFP) mouse model [Foudi et al., 2009; Wilson et al., 2008]. In the 
following chase period, the label is effectively halved with every cell division, 
thus diluting the label in proliferating cells after four to five divisions. Only those 
cells that do not actively divide keep the label and are hence called label-
retaining cells (LRCs). To gain further insight into the cycling behavior of HSCs 
mice were chemically labeled using a BrdU pulse for 2 weeks, followed by a 
BrdU free chase of up to 300 days. While the majority of LSK SLAM CD34- HSCs 
is quiescent in Ki67/Hoechst cell cycle analysis, strikingly only a small proportion 
retained the label after this chase period [Wilson et al., 2008].  
Mathematical modeling of the loss of the label retention of either BrdU or 
H2B-GFP within the HSC fraction revealed that within this stem cell compartment 
there are two cell populations with different cycling behaviors. Although all HSCs 
are quiescent, the majority of about 85% of these cells divides more frequently, 
while subpopulation comprising about 15% of HSCs divides only around once 
every 150 days under homeostatic conditions [Wilson et al., 2008]. This small 
subpopulation, which is almost permanently in the G0 phase of the cell cycle, and 




	   	  
divides less than once in 5 months, or only about 5 times in the lifetime of a 
mouse is referred to as dormant HSCs, while the majority of HSCs which are 
quiescent but still slowly cycling is referred to as homeostatic HSCs [Foudi et al., 
2009; Wilson et al., 2008]. Interestingly dormant HSCs show the highest long-
term multi-lineage stem cell activity upon transplantation into lethally irradiated 
hosts, indicating that the most dormant HSCs are also the most potent ones and 
further linking dormancy to higher self-renewal capacity [Foudi et al., 2009; 
Wilson et al., 2008]. Notably the metabolic activity of dormant HSCs is highly 
reduced and their replication machinery inactive [Trumpp et al., 2010]. Dormant 
HSCs seem to have only a minor contribution to hematopoiesis during 
homeostasis, where they preserve their self-renewal capacity by avoiding cell 
divisions, but serve as an important reserve pool for emergency situations. 
Additionally their dormancy and very low metabolic profile offers them protection 
from various toxic substances. 
Stress to the hematopoietic system including bleeding, infections, 
inflammation, or chemotherapeutic substances lead to loss of hematopoietic cells, 
especially of highly cycling populations like progenitor cells. 
Treatment of mice with the chemotherapeutic agent 5-Fluoro-Uracil (5FU) 
efficiently kills proliferating cells of the hematopoietic system, including the 
highly proliferative progenitor cells, but does not harm the dormant HSC 
compartment. This depletion of myeloid cells leads to rapid entry of dormant 
HSCs into the cell cycle, which produce highly proliferative progenitor cells and 
finally to recovery of the hematopoietic system [Wilson et al., 2008]. A similar 
regulation seems to be the case also for human HSCs, as 5-FU chemotherapy also 
leads to rapid myelo-ablation, but the bone marrow quickly recovers after 
cessation of the treatment [Essers and Trumpp, 2010]. 
 
1.3.1 Activation and mobilization of HSCs by G-CSF 
Granulocyte-colony-stimulating-factor (G-CSF) was one of the first agents 
described to affect quiescent mouse HSCs. Treatment of mice with G-CSF leads to 




	   	  
a rapid entry of quiescent HSCs into the cell cycle, followed by mobilization of 
the cells out of the bone marrow into the blood stream and to the spleen 
[Morrison et al., 1997]. The exact mechanism of G-CSF induced activation of 
HSCs is not fully understood, however recent reports shed some more light on this 
process. Mobilization of HSCs following G-CSF treatment is induced by the 
release of proteolytic enzymes such as elastase, cathepsin G or matrix 
metalloproteases (MMPs) by neutrophils [Christopherson et al., 2003; Heissig et 
al., 2002; Levesque et al., 2001; Petit et al., 2002].  Upon release these enzymes 
cleave several interactions between HSCs and the osteoblasts in the stem cell 
niche, such as the binding of SDF1 with CXCR4, the interaction of VCAM-1 and 
VLA-4 or the dimerization of N-Cadherins on both sides of the niche. 
Furthermore, treatment with G-CSF leads to depletion of  endosteal macrophages 
as well as endosteal osteoblasts, which is accompanied by a marked reduction of 
HSC trophic cytokines [Christopher et al., 2011; Winkler et al., 2010]. Together, 
these events lead to the mobilization of the HSCs. Interestingly, once activated 
and mobilized by G-CSF, mouse HSCs become susceptible to chemotherapeutic 
treatments such as the anti-proliferative drug 5-FU or cytarabine and can then be 
efficiently eliminated.  
 
1.3.2 Activation of HSCs by interferons 
Interestingly recent findings showed that HSCs can also be pushed into an 
active cell cycle by interferon without previous myelo-ablation or subsequent 
mobilization. Within hours after in vivo administration of either the type I 
interferon IFNα or the type II interferon IFNγ in mice, quiescent HSCs enter an 
active cell cycle [Baldridge et al., 2010; Essers et al., 2009]. Strikingly even 
dormant label-retaining HSCs are efficiently activated in response to IFNα [Essers 
et al., 2009]. Interestingly, HSCs from mice deficient for IFNγ signaling have a 
decreased baseline proliferation rate, indicating a potential role of IFN signaling 
also during homeostasis [Baldridge et al., 2010]. 
 




	   	  
Figure	  1.8	  Activation	  of	  dormant	  HSCs	  by	  IFNα 	  
Treatment	  of	  mice	  with	  IFNα	  leads	  to	  rapid	  activation	  of	  both	  dormant	  as	  well	  as	  homeostatic	  HSCs.	  Binding	  of	  IFNα	  
to	  its	  receptor	  on	  the	  HSC	  leads	  to	  phosphorylation	  of	  protein	  kinase	  B	  (PKB)	  and	  signal	  transducer	  and	  activator	  of	  
transcription	  1	   (STAT1),	  as	  well	  as	   induced	  transcription	  of	   interferon	  target	  genes	  and	  up-­‐regulation	  of	  stem	  cell	  
antigen	   1	   (Sca-­‐1)	   on	   the	   cell	   surface.	   Together	   these	   events	   induce	   the	   proliferation	   of	   HSCs.	   The	   interferon	  α	  
receptor	  (IFNαR),	  STAT1	  and	  Sca-­‐1	  are	  crucial	  for	  the	  induction	  of	  proliferation	  as	  mice	  deficient	  for	  either	  of	  those	  
do	  not	  show	  cell	  cycle	  activation	  upon	  IFNα	  treatment	  [Trumpp	  et	  al.,	  2010].	  
Interferons were previously mainly described as important players in the 
activation of the immune system in the regulation of resistance to viral infections 
[Stark et al., 1998]. Strikingly in contrast to the effect of in vivo interferon 
treatment on HSCs, treatment of many cell lines as well as primary hematopoietic 
cells with interferon in vitro leads to an inhibition of proliferation of these cells. 
IFNα-induced activation of HSCs involves several key steps. IFNα binds to 
the IFNα-receptor on HSCs, which leads to phosphorylation of signal transducer 
and activator of transcription (STAT1) as well as protein kinase B (PKB)  as well as 
up-regulation of known interferon target genes (Fig 1.8). Furthermore, it is 
accompanied by up-regulation of the cell surface protein Sca-1. Interestingly the 




	   	  
IFNα-receptor, STAT1 as well as Sca-1 are crucial for IFNα induced activation of 
HSCs as mice deficient for either of those proteins do not show cell cycle 
induction in HSCs upon treatment with IFNα [Essers et al., 2009]. Contrarily to 
activation of HSCs by G-CSF treatment, HSCs activated by IFNα remain in the 
bone marrow and do not enter circulation [Essers et al., 2009]. 
Chronic treatment of mice with IFNα does not impair the function of their 
HSCs, since these HSCs still efficiently reconstitute upon transplantation. 
Interestingly however in a competitive setting chronically activated HSCs are 
outcompeted by HSCs that have not been previously activated [Essers et al., 
2009]. Similarly HSCs from mice lacking the Interferon Response Factor-2 (IRF2), 
a transcriptional repressor of IFNα signaling, are highly cycling during 
homeostasis and outcompeted in competitive repopulation assays. [Sato et al., 
2009]. While the reason for this competitive disadvantage is still unclear, one 
possible reason could be that the cycling HSCs are outcompeted for dormant 
niche space by the HSCs unresponsive to IFN signaling. 
 
1.3.3 Other potential mechanisms of HSC activation 
Beside interferons also the endotoxin lipopolysaccharide (LPS) and the 
cytokine tumor necrosis factor alpha (TNFα) have recently been implicated in 
regulation of HSC quiescence in the course of infections. Infection with the 
gram-negative bacterium Escherichia Coli stimulates expansion and mobilization 
of both human as well as mouse HSPCs via TNFα and NFκB signaling [Kim et al., 
2004; Quinton et al., 2002; Shahbazian et al., 2004; Zhang et al., 2008c]. 
Both human as well as mouse HSPCs express a variety of Toll-like 
receptors, including TLR4, which is crucial for responses to LPS [Nagai et al., 
2006; Sioud et al., 2006]. Indeed in vivo administration of LPS induced a transient 
increase in the number of LSK cells as well as an increase in self-renewal capacity 
and proliferation of HSCs [Scumpia et al., 2010; Takizawa et al., 2011]. The exact 
mechanism of HSC activation by LPS however is still not fully understood and it is 
likely that the observed effects are mediated by a combination of different 




	   	  
signaling pathways. Interestingly investigations from our laboratory showed that 
LPS, contrarily to IFNα, activates HSCs not directly but rather by an indirect 
mechanism via monocytes [Marieke Essers, personal communication]. 
Similar to IFNα also TNFα has anti-proliferative effects on both human as 
well as mouse HSCs in vitro and furthermore inhibits their colony formation as 
well as ability to reconstitute upon transplantation [Dybedal et al., 2001; Jacobsen 
et al., 1994; Jacobsen et al., 1992; Rusten et al., 1994; Zhang et al., 1995]. Mice 
deficient for both TNF receptors show normal proportions of HSCs during steady 
state, however upon transplantation TNF-receptor deficient HSCs outcompete 
their wildtype counterparts [Pronk et al., 2011]. Interestingly in vivo treatment of 
mice with TNFα leads to rapid decrease in bone marrow cellularity, similar to 
treatment with LPS. Moreover HSCs from TNFα treated mice were outperformed 
by HSCs from PBS treated mice in competitive transplantation assays [Pronk et al., 
2011]. In summary the effects of TNFα on HSCs in vivo are currently still unclear, 
as no detailed cell cycle analysis was yet performed, however the available data 
indicates that TNFα could play a role similar to IFNα or LPS in activation of HSCs 








	   	  
Figure	  1.9	  Inflammatory	  pathways	  involved	  in	  HSCs	  activation	  
IFNα	  binds	  to	  the	  type	  I	  interferon	  receptor	  and	  activates	  TYK2	  and	  JAK1	  to	  phosphorylate	  STAT1	  and	  STAT2.	  Upon	  
phosphorylation	   STAT1	   and	   STAT2	   heterodimerize	   and	   associate	   with	   IRF9	   and	   bind	   to	   IFN-­‐stimulated	   response	  
elements	   (ISREs)	   to	   activate	   transcription.	   Similarly	   IFNγ	   binds	   to	   type	   II	   interferon	   receptors,	   JAK1	   and	   JAK2	  
phosphorylate	  STAT1,	  which	  homodimerizes	  and	  translocates	  to	  the	  nucleus,	  where	  it	  activates	  IFNγ	  activated	  (GAS)	  
sequences.	   Binding	   of	   TNFα	   to	   the	   TNF-­‐receptor	   causes	   TRADD	   to	   recruit	   RIP	   and	   TRAF2,	   which	   activate	   IKK	   to	  
phosphorylate	  IκBα,	  leading	  to	  a	  release	  of	  NFκB.	  TNFα	  signaling	  also	  activates	  MEKK1,	  which	  leads	  to	  activation	  of	  
AP-­‐1	  and	  ATF2,	  via	  JNK.	  AP-­‐1	  binds	  TPA	  DNA-­‐response	  elements	  (TRE),	  while	  ATF2	  binds	  cAMP-­‐responsive	  elements	  
(CRE).	  LPS	  binds	  to	  TLR4	  and	  signals	  through	  Myd88	  and	  TRIF.	  This	  recruits	  IRAK,	  which	  binds	  TRAF6	  and	  activates	  
NFκB	  and	  JNK	  pathways	  similar	  to	  TNF-­‐receptor	  signaling.	  There	  is	  extensive	  cross-­‐talk	  between	  TNF-­‐receptor	  and	  








	   	  
1.4 Targeting leukemic stem cells by breaking their dormancy 
Similar to the normal self-renewing tissues also many leukemias and solid 
tumors are hierarchically organized, with only a small population of cells able to 
give rise to new tumors upon transplantation, while the majority of cells can not 
propagate the disease. These cells capable of initiating a new tumor are called 
tumor initiating cells or cancer stem cells (CSCs).  
 
1.4.1 The concept of cancer stem cells 
The first evidence for the existence of CSCs came from observations in 
acute myeloid leukemia (AML), where only a small fraction of leukemic cells is 
capable of transplanting the disease in immune-compromised mice [Bonnet and 
Dick, 1997; Lapidot et al., 1994]. Interestingly these cells show the same 
CD34+CD38- cell surface phenotype as normal HSCs. In contrast, transplantation 
of cells from the bulk of the leukemia with either CD34+CD38+ or CD34- 
phenotype, containing the more differentiated leukemic progeny, does not lead to 
development of AML [Bonnet and Dick, 1997; Lapidot et al., 1994]. After this 
initial observation in AML similar hierarchical organization within tumors was 
shown in several other forms of leukemia, for example chronic myeloid leukemia 
(CML), as well as many other types of solid cancers like breast cancer, colon 
cancer, prostate cancer and brain tumors [Cho and Clarke, 2008; Reya et al., 
2001; Trumpp and Wiestler, 2008].  
The abundance of these CSCs differs largely between different types of 
tumors, different stages of the disease as well as between individual patients. 
While in some malignancies the majority of cells has tumor initiating capacity, in 
others CSCs appear to be very rare, with less that 1 in 10.000 or 1 in 100.000 
cells able to propagate the disease [Ishizawa et al., 2010; Quintana et al., 2008]. 
Interestingly recent experiments suggest that during tumor progression from a 
more benign to a more malignant and aggressive stage, the hierarchy within the 
different cell types of the tumor flattens, with more differentiated tumor cells 




	   	  
starting to show tumor initiating cell properties as well [Kelly et al., 2007; 
Passegue et al., 2009; Quintana et al., 2008]. 
Importantly the term cancer stem cell does not imply that a tumor 
necessarily originates from a stem cell. In fact many, especially more aggressive 
tumors, originate from more differentiated cells that regain self-renewing 
capabilities which are normally restricted to stem cells [Visvader, 2011]. 
Furthermore many CSCs show many other traits usually associated with stem 
cells, including quiescence, efficient DNA damage repair and high resistance to 
radiotherapy as well as anti-proliferative chemotherapy [Trumpp and Wiestler, 
2008]. Therefore while many conventional therapies dramatically reduce the size 
of a tumor by eliminating the bulk of the tumor cells, due to their relative 
quiescence and increased resistance CSCs are less efficiently targeted and often 
survive. These residual CSCs are thought to be the main cause for relapse and 
metastasis formation following an initial successful therapy.  
 
1.4.2 Chronic myeloid leukemia and leukemic stem cells 
After the initial description of leukemic stem cells (LSCs) in AML, several 
other hematological malignancies including chronic myeloid leukemia (CML) 
were shown to be hierarchically organized and similarly contain rare LSCs, often 
with a similar phenotype as normal HSCs (reviewed in [Huntly and Gilliland, 
2005]). Notably the exact phenotype of LSCs is often still controversially 
discussed. While LSC in AML where initially described to be exclusively found 
within the CD34+CD38- population, recent development and use of more 
sensitive transplantation models such as NSG mice demonstrated the presence of 
LSCs also in other populations [Taussig et al., 2008]. 
Chronic myeloid leukemia is characterized by the unregulated growth of 
predominantly myeloid cells in the bone marrow. It was the first malignancy that 
was linked to a specific genetic abnormality, a single chromosomal translocation 
between chromosome 9 and chromosome 22, leading to the formation of the 
Philadelphia Chromosome and the constitutively active protein kinase BCR-ABL 




	   	  
[Ren, 2005]. Depending on the exact breakpoint the size of the resulting fusion 
protein varies, ranging from 185 to 210kDa with p210 BCR-ABL being the 
clinically most important isoform. The fusion protein BCR-ABL is causative and 
sufficient for driving the development of the disease, and therefore became an 
ideal drug target [Daley et al., 1990; Ren, 2005]. This lead to the development of 
the tyrosine kinase inhibitor (TKI) Imatinib mesylate (also known as Gleevec), that 
specifically inhibits the BCR-ABL kinase, as well as to a lower degree c-kit and 
PDGF-receptor [Druker et al., 2001; Druker et al., 1996]. 
Based on clinical characteristics CML can be divided into three phases, a 
latent chronic phase with only mild symptoms where the majority of patients is 
diagnosed, an accelerated phase characterized by an increase of myeloid blasts 
and finally blast crisis, which rapidly progresses and resembles acute leukemia 
(Fig. 1.10). While the mechanisms of disease progression are not yet fully 
understood, one frequent event during the progression to advanced disease is the 
activation of β−catenin signaling in highly proliferative GMPs, giving them self-
renewal potential usually restricted to HSCs [Jamieson et al., 2004; Minami et al., 
2008; Zhao et al., 2007].  
Imatinib mesylate efficiently targets BCR-ABL positive leukemic cells and 
leads to rapid hematologic and cytogenic response [O'Brien et al., 2003]. 
Nonetheless, even after years of Imatinib treatment, residual leukemic cells 
remain, which can lead to a relapse of the disease on cessation of treatment as 
well as due to acquisition of resistance mutations [Chu et al., 2011]. To overcome 
resistance to Imatinib the second generation TKI inhibitors Dasatinib and 
Nilotinib were developed, which show both increased potency as well as the 
ability to inhibit the majority of Imatinib-resistant mutations [Hantschel et al., 
2008; Quintas-Cardama et al., 2007]. The reason for resistance of CML stem cells 
to treatment with TKIs is still highly debated and several mechanisms have been 
suggested. 
  




	   	  
Figure	  1.10	  Leukemic	  stem	  cells	  in	  Chronic	  Myeloid	  Leukemia	  
Within	  normal	  hematopoiesis	  only	  HSCs	  are	  capable	  of	  self-­‐renewal	  as	  well	  as	  to	  give	  rise	  to	  progenitor	  cells,	  which	  
in	  turn	  give	  rise	  to	  the	  terminally	  differentiated	  cells	  of	  the	  hematopoietic	  system.	  In	  Chronic	  Myeloid	  Leukemia	  the	  
abundance	  of	  leukemic	  clones	  capable	  of	  self-­‐renewing	  depends	  on	  the	  stage	  of	  the	  disease.	  In	  chronic	  phase	  CML	  
LSCs	   give	   rise	   to	   progenitor	   cells	   that	   are	   slightly	  more	   proliferative	   compared	   to	   normal	   HSCs.	  While	   leukemic	  
progenitors	  are	  still	  differentiating	  the	  myeloid	  compartment	  is	  increased	  due	  to	  the	  higher	  proliferation	  of	  LSCs.	  In	  
advanced	  phase	  disease	  more	  differentiated	  granulocyte	  macrophage	  progenitors	  acquire	  self-­‐renewal	  capabilities	  
due	   to	   additional	   mutations,	   radically	   increase	   proliferation	   and	   arrest	   differentiation,	   together	   leading	   to	  
accumulation	  of	  immature	  leukemic	  blasts.	  [Savona	  and	  Talpaz,	  2008]	  
1.4.3 Mechanisms of resistance in CML stem cells 
Despite the efficiency of TKIs in the treatment of CML, CML stem cells are 
largely resistant not only to treatment with conventional chemotherapy but also to 
treatment with TKIs. One potential explanation for resistance could insufficient 
inhibition of BCR-ABL kinase signaling within CML stem cells. Indeed CML stem 
cells were reported to express higher levels of BCR-ABL compared to more 
differentiated cells [Jiang et al., 2007]. Furthermore CML stem cells show 
decreased expression of the ABC transporter OCT1 which is crucial for uptake of 
Imatinib, as well as increased levels of MDR and ABCG2, which are both crucial 
in the efflux of many chemotherapeutic drugs [Engler et al., 2010; Jiang et al., 
2007]. Taken together a lower uptake, increased efflux and higher levels of BCR-
ABL could all lead to insufficient inhibition of BCR-ABL within CML stem cells. 
Another potential explanation for the resistance of CML stem cells might 
be  their relative quiescence, similar to the resistance of normal dormant HSCs to 
different toxic treatments. Interestingly quiescent CML stem cells are not only 




	   	  
resistant to in vitro treatment with Imatinib but furthermore Imatinib drives these 
cells further into quiescence [Graham et al., 2002]. Hence breaking their 
dormancy and interfering with the Imatinib-induced quiescence might be a way 
to sensitize these cells to chemotherapy. This concept is further supported by 
mathematical models of the effect of drug treatment on CML clones, which  
suggest that one explanation for the resistance of CML stem cells might be a 
selective effect of Imatinib solely on proliferating leukemic cells [Roeder et al., 
2006]. Interestingly these models further suggest that sustained TKI treatment 
might eventually lead to eradication of all leukemic clones, if no Imatinib 
resistance-mutations are acquired. Notably this would require an extended period 
of continuous treatment, until all leukemic stem cells have entered proliferation as 
part of normal cycling behavior and thus becoming susceptible to Imatinib 
[Roeder et al., 2006]. Strikingly, these models further support the hypothesis that 
cell-cycle-activation of leukemic stem cells in combination with Imatinib 
treatment might be an efficient way of eliminating CML stem cells [Roeder et al., 
2006].  
 
1.4.4 Activating LSCs to break their resistance 
While normal HSCs are relatively resistant to treatment with the 
chemotherapeutic drug 5-Fluoro-Uracil (5-FU) due to their low proliferation, they 
are efficiently eliminated after activation by IFNα. This combined treatment 
rapidly leads to death of mice due to severe pancytopenia and depletion of the 
HSC pool [Essers et al., 2009]. Strikingly the susceptibility of HSCs to elimination 
by 5-FU in this assay highly correlates with their cycling behavior, rendering them 
vulnerable only as long as they are actively cycling [Essers et al., 2009]. Unlike 
for normal HSCs it is not fully understood whether LSCs are activated by similar 
mechanisms, and similarly become more susceptible to elimination by 
chemotherapy or other treatment like TKIs. 
G-CSF was one of the first agents described to induce cycling of HSCs, and 
several studies have been carried out to test the combination of G-CSF induced 




	   	  
activation and mobilization and chemotherapy to eradicate LSCs, both in AML as 
well as CML models (Fig 1.11). 
In a xenotransplantation model for AML treatment of the mice with G-CSF 
in vivo efficiently activated quiescent AML stem cells. Moreover combination of 
G-CSF treatment with administration of the chemotherapeutic agent cytarabine 
lead to a pronounced reduction of AML stem cells and increased survival of the 
mice [Saito et al., 2010]. Notably normal HSCs were less affected by the 
combination treatment of G-CSF with cytarabine, suggesting a therapeutic 
window where toxicity is already reached for LSCs but normal HSCs survive. 
Interestingly pre-treatment of CML stem cells, which are resistant to 
Imatinib treatment at least in part due to their relative quiescence, with G-CSF in 
vitro leads to cell cycle activation and renders them more susceptible to 
elimination by Imatinib [Jorgensen et al., 2006]. However the first clinical trial of 
combined administration of G-CSF and Imatinib did not lead to efficient 
elimination of leukemic clones in patients [Drummond et al., 2009]. A possible 
explanation for the failure of this trial could be sub-optimal timing of the two 
drugs. As Imatinib itself has anti-proliferative effects on LSCs it might counteract 
the activation by G-CSF and therefore prevent efficient cell cycle entry. 
Another approach to eliminate CML stem cells by breaking their 
quiescence was suggested recently by inhibiting the tumor suppressor 
promyelocytic leukemia (PML) (Fig 1.11) [Ito et al., 2008]. Inhibition of PML by 
arsenic trioxide (As2O3), which leads to proteosomal degradation of PML, has 
previously been used successfully to treat acute promyelocytic leukemia, a form 
of leukemia driven by the PML-retinoic acid receptor (RARα) fusion protein [de 
The and Chen, 2010]. PML is highly expressed in mouse HSCs and loss of PML in 
mice induces increased activity of the mTOR pathway and increased cycling of 
HSCs [Ito et al., 2008]. Similarly pharmacological inhibition of PML by Arsenic 
trioxide (As2O3) leads to increased proliferation of human HSCs in vitro [Ito et al., 
2008]. Interestingly loss of PML a mouse model for CML similarly resulted in a 
strong increase in cycling CML stem cells. Furthermore inhibition of PML by 
As2O3 treatment in combination with the chemotherapeutic drug Ara-C leads to 




	   	  
activation of LSCs and their elimination by Ara-C in a CML mouse model as well 
as in primary human AML cells in vitro [Ito et al., 2008]. Similar to the 
combination of G-CSF and cytarabine described above this suggests a possible 
therapeutic window for a combination therapy of cell cycle induction in LSCs by 
a block of PML in combination with chemotherapeutic drugs. 
 
Figure	  1.11	  Combined	  therapy	  approaches	  to	  eliminate	  LSCs	  
(A)	  Both	  normal	  HSCs	  as	  well	  as	  LSCs	  show	  a	  significant	  resistance	  to	  treatment	  with	  conventional	  anti-­‐proliferative	  
chemotherapy.	  One	  possible	   reason	   for	   this	   resistance	  might	  be	   the	   relatively	  quiescent	   state	  of	   LSCs,	   similar	   to	  
their	  normal	  HSCs	  counterparts.	  (B)	  HSCs	  can	  be	  efficiently	  activated	  by	  IFNα	  and	  subsequently	  become	  susceptible	  
to	  elimination	  by	  5-­‐FU	  treatment.	  (C)	  LSCs	  can	  be	  activated	  by	  pharmacological	  inhibition	  of	  PML	  by	  arsenic	  trioxide	  
(As2O3),	  which	  renders	  them	  vulnerable	  to	  treatment	  with	  the	  cytotoxic	  agent	  Ara-­‐C.	  (D)	  Activation	  of	  LSCs	  by	  G-­‐CSF	  
in	   combination	   with	   Imatinib	   efficiently	   kills	   LSCs	   in	   vitro,	   while	   combination	   of	   G-­‐CSF	   and	   cytarabine	   leads	   to	  
pronounced	  reduction	  of	  LSCs	   in	  a	  xenograft	  model	   for	  AML,	  while	  normal	  HSCs	  are	  spared.	   [Essers	  and	  Trumpp,	  
2010]	  




	   	  
As the effects of interferons on HSCs has only recently been discovered, it 
is currently unclear whether leukemic stem cells are activated in a similar 
manner. Interestingly IFNα has been used as standard first line treatment for CML 
before the introduction of Imatinib, which quickly replaced it due to its 
superiority in all outcome measures [Goldman, 2010]. Strikingly however despite 
the high efficiency of Imatinib in reducing the tumor load, patients quickly relapse 
after cessation of the treatment. Contrarily treatment with IFNα leads to a low but 
reproducible rate of curative effects in some patients [Kujawski and Talpaz, 
2007].  
A few clinical trials were performed testing combination treatments of 
IFNα and Imatinib, which showed promising initial results. These included higher 
major molecular response rates, which indicate a lower level of minimal residual 
disease, as well a the ability to overcome resistance to either of the drugs alone 
[Nicolini et al., 2011; Preudhomme et al., 2010; Simonsson et al., 2011]. Notably 
it is not yet clear whether this can be attributed to effect of IFNα on LSCs or other 
complimentary effects e.g. on the immune system. It will be crucial to investigate 
the effects of IFNα on CML stem cells in vivo to better understand the outcome of 
these clinical trials and to optimize the timing for the administration of the two 
drugs. 
In summary, it is not yet clear whether LSCs can be similarly activated 
compared to HSCs. However several lines of evidence suggest that breaking the 
dormancy of LSCs might be en effective approach to break their resistance to 
other treatments like chemotherapy or TKIs. 
 

 - 49 - 
2 AIM OF THE THESIS 
It was recently shown that in vivo administration of IFNα in the mouse very 
efficiently leads to activation of hematopoietic stem cells [Essers et al., 2009]. The 
exact mechanism underlying this activation however is still unclear. One central 
aim of this thesis was to get further insight into the IFNα-induced HSC activation 
and to identify and characterize potential candidate genes involved in the 
activation process. Moreover, so far IFNα was only shown to activate HSCs in the 
mouse. To address the effects of IFNα on human HSCs in vivo we sought to 
investigate the effects of interferon on human HSCs in a xenotransplantation 
model in immune incompetent mice. Therefore one aim was to establish 
transplantation of human cord blood samples into mice and to investigate the 
cycling behavior of human HSC populations in the mouse in steady state as well 
as after treatment with IFNα. Furthermore combination therapies combining 
leukemic stem cell activation by IFNα and cytotoxic treatment is a very interesting 
possibility to treat leukemia, however it is still unresolved whether IFNα has the 
same effects on leukemic stem cells as on normal HSCs. To address this one aim 
was to investigate the effects of IFNα on HSCs in a mouse model of CML, where 
the mice express the BCR-Abl transgene in HSPCs and develop a CML like 
disease. Finally another open question is whether IFNα also activates stem cells 
outside of the hematopoietic system. Therefore the final aim of this thesis was to 
investigate activation of stem cells of the skin by treatment with IFNα. 
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3 RESULTS 
3.1 Gene expression in HSCs following IFNα  and LPS treatment 
During homeostasis dormant HSCs serve as an important reserve pool, that 
can be rapidly activated upon injury to the hematopoietic system [Wilson et al., 
2008]. The signals regulating the balance between dormant and activated HSCs 
are still largely unknown. Previous work from our group has shown that mouse 
HSCs become activated following in vivo administration of IFNα [Essers et al., 
2009]. This activation is dependent on the interferon−α−receptor (IFNAR), STAT1 
as well as Sca-1, as mice deficient for either of those do not show HSC activation 
[Essers et al., 2009]. Besides IFNα, which is mainly induced during viral 
infections, more recently also LPS, which is found in the outer membrane of 
gram-negative bacteria, was shown to drive HSCs into proliferation. In the case of 
LPS the activation is mediated via an indirect mechanism via monocytes rather 
than direct activation of HSCs [Stefanie Thamm, Raphael Lutz and Marieke Essers, 
personal communication]. However for both IFNα as well as LPS the exact 
mechanisms of activation of HSCs are still poorly understood. To gain further 
insight into this, we isolated LK SLAM (lineagenegCD117+CD150+CD48-) HSCs 
from C57BL/6 mice, 16 hours after i.p. injection of PBS, IFNα (10.000u/mouse) or 
LPS (5µg/mouse). From these samples we isolated RNA and performed microarray 
analysis. We analyzed gene expression and compared the datasets of genes 
differentially regulated with a fold change (FC) above 1,5 and a false discovery 
rate (FDR) below 5%. According to these criteria we found 600 genes to be 




	   	  
differentially regulated following IFNα administration and 903 following 
administration of LPS. The samples from each respective treatment condition were 
clustering together in a hierarchical cluster analysis, with the samples isolated 
from IFNα and LPS treated mice being more similar to each other than to the ones 
isolated from PBS treated mice (Fig 3.1).  
 
Figure	  3.1	  Microarray	  analysis	  16	  hours	  after	  administration	  of	  PBS,	  IFNα 	  or	  LPS	  
Hierarchical	   clustering	   analysis	   of	   samples	   after	   treatment	   with	   PBS,	   IFNα	   or	   LPS	   based	   in	   genes	   significantly	  
changed	   between	   PBS	   and	   IFNα	   treated	  mice;	   false	   discovery	   rate	   (FDR)	   <5%	   and	   fold	   change	   >2.	   LPS	   5µg	   per	  
mouse,	  IFNα	  10.000U	  per	  mouse,	  injected	  i.p.	  16	  hours	  before	  analysis.	  
3.1.1 Differentially expressed genes following IFNα treatment in vivo 
As expected gene ontology analysis following in vivo IFNα treatment 
highlighted immune responses and responses to viral infections as the most 
significantly changed pathways and processes in LK SLAM HSCs (Fig 3.2 and 3.3). 




	   	  
A large proportion of the genes differentially regulated are known IFN response 
genes (Tab. 3.1), which play a crucial role in the regulation of the interferon 
response (e.g. Irf7, Irf9 or Usp18), RNA sensing (e.g. Oas genes or Ifit3) or in the 
host response to viral infections (e.g. Ifitm1, Ifitm3 or Mx1). Furthermore we could 
confirm the transcriptional up-regulation of Stat1 (2,6x up) and Stat2 (3,0x up) as 
well as Sca-1 (6,0x up), as already previously described [Essers et al., 2009]. 
Amongst the strongest induced genes we also found transcripts of the 
cytokines CXCL-10 (IP10, 8,6x up) and CCL5 (RANTES, 2,9x up). CXCL-10 was 
shown to act as a chemo-attractant for many different cell types including 
monocytes, lymphocytes, NK-cells as well as dendritic cells. Moreover it was 
shown to promote attachment of lymphocytes to endothelial cells [Dufour et al., 
2002]. Similar to CXCL-10 also CCL5 was shown to be chemotactic for 
lymphocytes. Furthermore CCL5 is involved in activation and proliferation of 
NK-cells [Maghazachi et al., 1996]. The influence of these cytokines on HSCs is 
currently unknown. Whether they play a role in recruitment or activation of HSCs 
similar to lymphocytes or NK-cells needs to be investigated. 
Surprisingly, we found only few cell cycle related genes to be differentially 
regulated. The cyclin dependent kinase inhibitor p57KIP2 (3,5x down) as well as 
the cell cycle regulator Reprimo (3,5x down) were down-regulated in both 
treatment conditions. P57KIP2 was recently shown to be a key regulator of HSCs 
quiescence, preventing CyclinD1 from entering the nucleus and allowing G1 
progression through the cell cycle [Matsumoto et al., 2011; Zou et al., 2011]. 
Down-regulation of p57KIP2 might therefore be a key event following 
IFNα induced activation, which might be necessary in quiescent HSCs to enter 
the SG2M phase. The function of Reprimo has been less well described so far, 
however it has been proposed to be involved in p53 dependent G2 arrest of the 
cell cycle [Ohki et al., 2000], suggesting a link between decreased Reprimo 
expression and active proliferation. Interestingly p57KIP2 and Reprimo inhibit cell 
cycle progression at different check-points and hence down-regulation of both 
might be required for cell cycle induction.  




	   	  
Fold	  change	   Symbol	   Definition	   Synonyms	  
12.00	   Ifit3	   interferon-­‐induced	  protein	  with	  tetratricopeptide	  repeats	  3	   Ifi49	  
11.51	   Oas2	   2'-­‐5'	  oligoadenylate	  synthetase	  2	   Oasl11	  
11.01	   Usp18	   ubiquitin	  specific	  peptidase	  18	   UBP43;	  Ubp15	  
9.87	   LOC623121	   PREDICTED:	  similar	  to	  Interferon-­‐activatable	  protein	  203	  
	  
8.58	   Cxcl10	   chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  10	   Scyb10;	  IP10;	  Ifi10	  
6.08	   Ly6a	   lymphocyte	  antigen	  6	  complex,	  locus	  A	   Ly-­‐6A.2;	  Sca-­‐1;	  Ly-­‐6A/E	  
5.04	   Irgb10	   PREDICTED:	  interferon-­‐gamma-­‐inducible	  p47	  GTPase	  
	  
4.36	   Ifi27	   interferon,	  alpha-­‐inducible	  protein	  27	   Isg12	  
4.31	   Oasl2	   2'-­‐5'	  oligoadenylate	  synthetase-­‐like	  2	   Mmu-­‐OASL;	  Oasl	  
4.26	   Oas3	   2'-­‐5'	  oligoadenylate	  synthetase	  3	   Oasl10	  
4.09	   Ifi44	   interferon-­‐induced	  protein	  44	   p44	  
4.02	   Oasl1	   2'-­‐5'	  oligoadenylate	  synthetase-­‐like	  1	   oasl9	  
3.94	   Oas1g	   2'-­‐5'	  oligoadenylate	  synthetase	  1G	   Oas1a;	  Oias1;	  Mmu-­‐L2	  
3.93	   Igtp	   interferon	  gamma	  induced	  GTPase	   AW558444	  
3.88	   LOC435565	   similar	  to	  interferon-­‐inducible	  GTPase	  	  
	  
3.48	   Isg20	   interferon-­‐stimulated	  protein	   20kDa;	  HEM45;	  DnaQL;	  
3.41	   Irgm	   immunity-­‐related	  GTPase	  family,	  M	   Ifi1;	  LRG-­‐47;	  Iipg3;	  Iigp3	  
3.39	   Gvin1	   GTPase,	  very	  large	  interferon	  inducible	  1,	  transcript	  variant	  B	   Iigs1;	  VLIG;	  VLIG-­‐1	  
3.03	   Stat2	   signal	  transducer	  and	  activator	  of	  transcription	  2	   AW496480	  
2.90	   Ccl5	   chemokine	  (C-­‐C	  motif)	  ligand	  5	   SISd;	  Scya5;	  RANTES	  
2.62	   Stat1	   signal	  transducer	  and	  activator	  of	  transcription	  1	   AA408197	  
2.53	   Irf7	   interferon	  regulatory	  factor	  7	  
	  
2.50	   Iigp2	   interferon	  inducible	  GTPase	  2	   GTPI	  
2.36	   Oas1a	   2'-­‐5'	  oligoadenylate	  synthetase	  1A	   L3	  
2.33	   LOC100040462	   PREDICTED:	  similar	  to	  interferon-­‐activatable	  protein	  
	  
2.13	   Ifitm1	   interferon	  induced	  transmembrane	  protein	  1	   Mil2	  
2.12	   Mx2	  
	   	  
2.10	   LOC100044430	   PREDICTED:	  similar	  to	  Interferon	  activated	  gene	  205	  
	  
2.07	   Mx1	   myxovirus	  (influenza	  virus)	  resistance	  1	   AI893580;	  Mx-­‐1;	  Mx	  
1.70	   Irf9	   interferon	  regulatory	  factor	  9	  (Irf9)	   Irf-­‐9;	  p48	  
1.70	   Ifitm3	   interferon	  induced	  transmembrane	  protein	  3	   mil-­‐1;	  IP15;	  Cd225	  
-­‐2.52	   Ptn	   pleiotrophin	   Osf-­‐1;	  HBGF-­‐8;	  HBNF	  	  
-­‐3.52	   Cdkn1c	   cyclin-­‐dependent	  kinase	  inhibitor	  1C	  (P57)	   p57Kip2;	  Kip2;	  CDKI	  
-­‐3.53	   Rprm	   reprimo,	  TP53	  dependent	  G2	  arrest	  mediator	  candidate	   Reprimo	  
-­‐11.91	   Matn4	   matrilin	  4	   matrilin-­‐4	  
Table	  3.1	  Selection	  of	  differentially	  regulated	  genes	  in	  LK	  SLAM	  HSCs	  16h	  after	  treatment	  with	  IFNα 	  in	  vivo	  
Comparison	  of	  SLAM	  HSCs	  sorted	  from	  IFNα	  treated	  C57BL/6	  mice	  to	  SLAM	  HSCs	  from	  PBS	  treated	  C57BL/6	  mice;	  
False	   discovery	   rate	   (FDR)	   <5%;	   blue	   banded	   rows	   mark	   known	   interferon	   response	   genes;	   IFNα	   10.000U	   per	  
mouse.	  




	   	  
Fold	  change	   Symbol	   Definition	   Synonyms	  
18.07	   Cxcl9	   chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  9	   Scyb9;	  crg-­‐10;	  Mig	  
15.68	   Ly6a	   lymphocyte	  antigen	  6	  complex,	  locus	  A	   Ly-­‐6A.2;	  Sca-­‐1;	  Ly-­‐6A/E	  
11.14	   Gbp2	   guanylate	  nucleotide	  binding	  protein	  2	  
	  8.00	   Igtp	   interferon	  gamma	  induced	  GTPase	   AW558444	  
5.23	   Ccl5	   chemokine	  (C-­‐C	  motif)	  ligand	  5	   SISd;	  Scya5;	  RANTES	  
3.82	   Oasl2	   2'-­‐5'	  oligoadenylate	  synthetase-­‐like	  2	   Mmu-­‐OASL	  
3.81	   Irgm	   immunity-­‐related	  GTPase	  family,	  M	   Ifi1;	  LRG-­‐47;	  Iipg3;	  Iigp3	  
3.51	   Iigp2	   interferon	  inducible	  GTPase	  2	   AI481100;	  GTPI	  
3.09	   Irgb10	   PREDICTED:	  interferon-­‐gamma-­‐inducible	  p47	  GTPase	  
	  2.63	   Irf1	   interferon	  regulatory	  factor	  1	   AU020929;	  Irf-­‐1	  
2.25	   Ifitm1	   interferon	  induced	  transmembrane	  protein	  1	   Mil2	  
2.18	   Ifi44	   interferon-­‐induced	  protein	  44	   p44;	  MTAP44	  
2.08	   Stat1	   signal	  transducer	  and	  activator	  of	  transcription	  1	   AA408197;	  
1.96	   Isg20	   interferon-­‐stimulated	  protein	   HEM45;	  DnaQL	  
1.94	   Stat2	   signal	  transducer	  and	  activator	  of	  transcription	  2	   AW496480	  
1.89	   Ifi47	   interferon	  gamma	  inducible	  protein	  47	   Iigp4;	  Olfr56;	  IRG-­‐47	  
1.59	   Ifitm3	   interferon	  induced	  transmembrane	  protein	  3	   mil-­‐1;	  IP15;	  Cd225	  
-­‐1.98	   Rprm	   reprimo,	  TP53	  dependent	  G2	  arrest	  mediator	  candidate	   Reprimo	  
-­‐2.51	   Ptn	   pleiotrophin	   Osf-­‐1;	  HBGF-­‐8;	  HB-­‐GAM	  
-­‐3.13	   Cdkn1c	   cyclin-­‐dependent	  kinase	  inhibitor	  1C	  (P57)	   p57Kip2;	  Kip2;	  CDKI	  
-­‐4.15	   Cxcl4	   chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  4	   Pf4;	  Scyb4	  
-­‐10.61	   Matn4	   matrilin	  4	   matrilin-­‐4	  
Table	  3.2	  Selection	  of	  differentially	  regulated	  genes	  in	  LK	  SLAM	  HSCs	  of	  IFNAR-­‐/-­‐	  mice,	  16h	  after	  treatment	  with	  
LPS	  in	  vivo	  
Comparison	  of	   SLAM	  HSCs	   sorted	   from	   LPS	   treated	   IFNAR-­‐/-­‐	  mice	   to	   SLAM	  HSCs	   from	  PBS	   treated	   IFNAR-­‐/-­‐	  mice;	  
False	  discovery	  rate	  (FDR	  )	  <5%;	  blue	  banded	  rows	  mark	  known	  interferon	  response	  genes	  	  
Taken together the up-regulation of many IFN response genes as well as 
IFN signaling cascades within the LK SLAM HSCs indicate a direct effect of IFNα 
on the hematopoietic stem cells. Surprisingly we found only few genes involved 
in regulation of the cell cycle to be differentially regulated. This could be due to 
regulation of these genes on the post-transcriptional or post-translational level 
rather than at the transcriptional. To gain more insight into this, further analysis on 
the protein level – e.g. by proteomics analysis – will be needed.  
  




	   	  
Figure	  3.2	  Gene	  ontology	  analysis	  of	  LK	  SLAM	  HSCs	  16h	  after	  in	  vivo	  treatment	  with	  IFNα 	  or	  LPS	  
Most	   significantly	   changed	  GO	  pathway	  maps	   (A)	   and	  GO	  processes	   (B),	   analyzed	  with	  Metacore	   software	  V6.10	  
(Thomson	  Reuters).	  Orange	   bars	   represent	   p-­‐values	   for	   LK	   SLAM	  HSCs	   after	   IFNα	   treatment,	   blue	   bars	   after	   LPS	  
treatment.	  Fold	  change	  >1.5	  and	  FDR<5%	  
  




	   	  
3.1.2 RNA expression patterns in LPS- and IFNα activated HSC are highly 
overlapping 
Following in vivo treatment with LPS we interestingly found a large overlap 
of differentially regulated genes in SLAM HSCs, compared to activation by  IFNα. 
These included the induction of many interferon target genes as well as down-





Figure	  3.3	  Activation	  of	  IFN	  signaling	  in	  LK	  SLAM	  HSCs	  16h	  after	  in	  vivo	  treatment	  with	  IFNα 	  or	  LPS	  
Pathway	  map	  “antiviral	  action	  of	  interferons”	  (Metacore);	  genes	  differentially	  regulated	  after	  treatment	  with	  IFNα	  
(1)	  or	  LPS	  (2)	  in	  vivo	  are	  highlighted	  by	  red	  circles;	  red	  bars	  next	  to	  the	  respective	  genes	  indicate	  the	  level	  of	  gene	  
induction	  for	  IFNα	  (1)	  or	  LPS	  (2).	  Fold	  change	  >1.5	  and	  FDR<5%	  




	   	  
Experiments by colleagues in the lab showed that in vivo treatment of mice 
with LPS leads to activation of the Mx promoter in a reporter mouse model 
[Marieke Essers, personal communication]. As the Mx promoter is strongly 
induced by IFNα this observation indicates that in vivo LPS administration leads 
to production of interferon. Therefore the observed similarities between the 
expression profiles following IFNα and LPS treatment could be explained by 
either production of interferon α following treatment with LPS, or through IFNα 
independent activation of the same pathways within the HSC.  
To investigate the effects of LPS on HSCs without the influence of IFNα-
signaling, we performed microarray analysis of HSCs sorted from IFNAR-/- mice, 
treated either with PBS, IFNα or LPS. IFNAR-/- mice lack the interferon-α-receptor, 
which is crucial for the binding of IFNα and the induction of the signaling 
cascade. As expected we found no genes to be significantly changed (FDR 5%, 
FC > 1,5) in SLAM HSCs of IFNAR-/- mice after treatment of IFNα. This confirms 
that the observed changes in wild type mice are a specific result of direct 
signaling of IFNα via the IFNAR without any detectable off target effects. 
Additionally it shows that all genes differentially regulated by LPS in IFNAR-/- mice 
are affected independent of IFNα. 
Interestingly after treatment with LPS we found 385 genes to be 
significantly changed in SLAM HSCs of IFNAR-/- mice (Tab 3.2). The expression 
pattern was very similar to the one observed in wild type mice treated with either 
IFNα or LPS, including induction of Sca-1 (15,7x up) or CCL5 (5,2x up) as well as 
down-regulation of Reprimo (2,0x down), Pleiotrophin  (2,5x down) or p57KIP2 
(3,1x down). Interestingly we also observed the induction of many typical IFN 
response genes including Igtp (8,0x up), Oasl2 (3,8x up), Irgm (3,8x up), Ifitm1 
(2,2x up) and Ifitm3 (1,6x up) or Ifi44 (2,2x up) despite the lack of the IFNα 
signaling. Notably we did not observe induction of the RNA sensors Ifit1 and 3, 
the interferon regulatory genes IRF7 and IRF9 and the chemokine CXCL-10 
contrary to the induction by IFNα. 




	   	  
The highest down-regulated gene was Matrilin4 (Matn4; 10,6x down), 
similar to the down-regulation after IFNα treatment of wild type mice. Matrilin 4 
belongs to a family of 4 non-collagenous extracellular matrix proteins [Klatt et al., 
2002]. Neither the function of Matrilin-4 in the ECM nor expression in the 
hematopoietic compartment has been previously described. 
Taken together this data suggests that the programs triggered within the 
HSCs are very similar for activation by IFNα and by LPS, including the induction 
of typical IFN response genes after administration of both IFNα as well as LPS, 
suggesting a general activation mechanism. The expression changes following LPS 
treatment could be either totally independent of IFN signaling, or alternatively 
mediated by the production of type 2 or type 3 interferons after LPS 
administration. Notably IFNγ was recently shown to activate quiescent HSCs in 
the course of bacterial infections [Baldridge et al., 2010]. To ultimately rule out a 
role of IFNs in the LPS mediated activation of HSCs, analysis would need to be 
performed in IFNAR-/-IFNGR-/- double knock-out mice lacking the capability to 









	   	  
3.2 Role of Sca-1 in IFNα  and LPS induced HSC activation 
 Sca-1, also known as Ly6a (lymphocyte antigen 6 complex, locus A) is a 
small (14kDa) protein. It is a member of a family of type V 
glycophosphatidylinositol  (GPI) anchored cell surface proteins. Sca-1 was one of 
the first cell surface proteins shown to be highly enriched in stem and progenitor 
cells of the hematopoietic system, and is often used in combination with lineage 
markers and the tyrosine-protein kinase c-kit (CD117) to characterize LSK stem 
and progenitor cells [Weissman and Shizuru, 2008]. Sca-1 is strongly induced 
upon cellular activation and interestingly expression of Sca-1 is crucial for 
activation of HSCs following both treatments with IFNα as well as with LPS 
[Essers et al., 2009]. Mice lacking Sca-1 expression show a normal hematopoietic 
system, but HSCs from Sca-1-/- mice perform less well than wildtype counterparts 
in competitive as well as serial transplantation assays, indicating impaired 
self-renewal capacity [Ito et al., 2003]. Furthermore BM from Sca-1-/- mice has 
decreased multipotential granulocyte, erythroid, macrophage and megakaryocyte 
colony forming units (GEMM-CFU) and colony forming unit spleen (CFU-S) 
activity [Ito et al., 2003]. 
 To elucidate the role of Sca-1 in HSC activation we performed microarray 
analysis of LK SLAM HSCs of Sca-1-/- mice and compared the expression profile 
with wild type C57Bl/6 mice. Following PBS injection we detected 8 differentially 
expressed genes (FDR < 5%, FC > 1,5) between wild type C57Bl/6 mice and 
Sca-1 KO mice. Only 3 genes were changed more than 2 fold, including the 
transcription factor Pbx1 (pre B cell leukemia homeobox 1) which was expressed 
3,13 fold higher in Sca-1-/- HSCs. Interestingly Pbx1 has been shown before to be 
important for maintaining the quiescence of HSCs. Conditional inactivation of 
Pbx1 leads to loss of long term HSCs, reduction in their quiescence as well as loss 
of self-renewal capacity [Ficara et al., 2008]. 
Following in vivo administration of IFNα we detected 213 differentially 
regulated genes in Sca-1-/- SLAM HSCs. The expression pattern was very similar to 




	   	  
the one observed in C57Bl/6 mice (Fig 3.4). Similar to wild type HSCs we 
detected increased expression of many IFN target genes in Sca-1-/- HSCs including 
Ifit3 (10,9x up), Oas2 (7,7x up), Igtp (4,8x up), Oas3 (4,1x up), Irgm (3,5x up) or 
ifitm1 (2,2x up). Furthermore we also observed differential expression of Usp18 
(6,2x up), Cxcl10 (6,2x up), Stat2 (3,2x up), Pml (2,8x up), Stat1 (2,1x up) or 
Cxcl4 (1,5x down). 
Hierarchical clustering analysis showed a high overlap between the 
expression pattern of wild type and Sca-1-/- HSCs (Fig 3.4). Wild type and Sca-1 
deficient HSCs from PBS treated mice clustered together with HSCs from IFNAR-/- 
mice treated with either PBS or IFNα. This indicates a high similarity of the 
expression profiles of the different genetic backgrounds during homeostasis as 
well as in the IFN-receptor deficient background after treatment with IFNα. 
Similarly HSCs from wild type and Sca-1-/- mice again clustered together after 
administration of IFNα, before clustering with HSCs from LPS treated wild type or 
IFNAR-/- mice (Fig 3.3). Taken together the expression profiles of Sca-1-/- mice are 
very similar to the ones from wild type mice both during homeostasis as well as 
after IFNα treatment, indicating that Sca-1 is not a major transcriptional regulator 
in HSCs in these conditions. 
The similar induction of IFN response genes as well as STAT1 and STAT2 
signaling was expected, as Sca-1 is known to be regulated downstream of STAT1 
signaling [Essers et al., 2009]. Interestingly the cell cycle regulators p57KIP2 and 
Reprimo, which show decreased expression after IFNα treatment in wild type 
HSCs, were not significantly changed in Sca-1-/- HSCs, correlating with the lack of 
cell cycle induction. Furthermore also Matrilin-4, the highest down-regulated 
gene after both IFNα as well as LPS treatment in wild type HSCs, was not 
significantly changed. 




	   	  
Figure	  3.4	  Microarray	  analysis	  of	  HSCs	  from	  wild	  type,	  IFNAR-­‐/-­‐	  and	  Sca-­‐1-­‐/-­‐	  mice	  treated	  with	  PBS,	  IFNα 	  or	  LPS	  
Hierarchical	   clustering	  of	   samples	  according	   to	  genes	   significantly	   changed	  between	  PBS	  and	  LPS	   treated	  wildtyp	  
C57Bl/6	  mice,	   false	  discovery	   rate	   (FDR)	  <5%	  and	   fold	   change	  >2.	   LPS	  5µg	  per	  mouse,	   IFNα	   10.000U	  per	  mouse,	  
injected	  i.p.	  16	  hours	  before	  analysis.	  	  
Interestingly the transcription factor Evi1 (Ectopic viral integration site 1) 
was amongst the highest differentially expressed genes comparing IFNα treated 
HSCs from wild type mice to Sca-1-/- mice. Evi1 expression was 3,0x lower in wild 
type HSCs than in HSCs of Sca-1-/- mice. Evi1 is predominantly expresses in long 
term HSCs and essential for HSCs self-renewal [Kataoka et al., 2011]. It regulates 
proliferation of HSC as well as leukemic stem cells through GATA2 expression 
and is frequently mutated in myeloid leukemia [Goyama et al., 2008; Yuasa et al., 




	   	  
2005].  The decrease in Evi1 following activation could indicate a loss of 
self-renewal capacity and induction of differentiation of a part of the activated 
HSC population. 
While there is no role of Maged1 described in the hematopoietic system 
yet, it has been implicated to play a role in the regulation of differentiation and 
proliferation in other cell types. Maged1 is required for myoblast differentiation 
and muscle regeneration. Myoblasts from Maged1 knock out mice show 
decreased p21CIP levels and defective cell cycle exit [Nguyen et al., 2010]. 
Similarly also in breast cancer cells Maged1 inhibits proliferation, migration and 
invasion by positively regulating p53 and p21CIP expression [Du et al., 2009]. 
Whether Maged1 has similar functions in hematopoietic stem cells still needs to 
be determined. Pleiotrophin is a 18kDa growth factor which was recently shown 
to be involved in the regulation of HSC expansion and regeneration by activation 
of PI3K signaling and by β-Catenin independent activation of Cyclin D1 [Himburg 
et al., 2010; Istvanffy et al., 2011]. While the function of PEDF in the 
hematopoietic system is still elusive, it was shown be a niche-derived regulator of 
neural stem cells and to promote self-renewal of adult neural stem cells [Ramirez-
Castillejo et al., 2006]. 
Overall the expression profile of wild type and Sca-1-/- HSCs share many 
similarities following activation by IFNα, including expression of IFN target genes 
and induction of JAK/STAT signaling. The differential regulation of Evi1, Hoxa7, 
p57KIP2 or Reprimo is the first evidence for transcription factors and cell cycle 
regulators being controlled downstream of Sca-1 signaling. Nonetheless the exact 
mechanism of HSC activation needs to be further investigated. It is possible that 
many changes occurring in the activation process happen not on a transcriptional 
level, but post transcriptionally or even at the level of posttranslational 
modification. To investigate further it will be interesting to imply techniques like 
proteomics analysis to get more insight on the events on the protein level. 
  
  




	   	  
3.3 The Ifitm protein family as candidate regulators of HSCs 
activation 
 One of the most interesting families of proteins, which is induced after 
both IFNα as well as LPS treatment in our microarray screens, is the Ifitm family of 
proteins. It comprises five family members in the mouse: Ifitm1, 2, 3, 5 and 6. 
Ifitms are short two transmembrane spanning proteins of 5 to 18 kDa (Fig 3.5). 
We found the expression of two family members – Ifitm1 and Ifitm3 – increased in 
LK SLAM HSCs following IFNα as well as LPS administration. 
We decided to investigate the role of the ifitm protein family in HSCs in 
more detail, as there was evidence that the family might play a role in regulation 
of stem cells as well as proliferation.  
The ifitm family was initially thought to play a role in homing and 
repulsion of primordeal germ cells by modulating cell adhesion, however they are 
dispensable for germ cell development as deletion of all five family members does 
not impair germ line establishment [Lange et al., 2008; Tanaka et al., 2005]. 
Furthermore Ifitm expression has been identified as a prognostic marker in several 
cancers including colorectal cancer, glioma and chronic myeloid leukemia 
[Akyerli et al., 2005; Andreu et al., 2006; Yu et al., 
2011]. Interestingly Ifitm3 binds osteopontin (Opn) in 
vitro, and expression of Ifitm3 in vivo leads to reduction 
of Opn expression [El-Tanani et al., 2010]. Osteopontin 
is an important component of the HSC niche and a 
negative regulator of HSC proliferation [Nilsson et al., 
2005]. Therefore the increased expression of Ifitm3 
following IFNα treatment might ultimately lead to 
activation of HSC proliferation by downregulation of 
Opn.  
Figure	  3.5	  Predicted	  structure	  of	  Ifitm3	  
[Yount	  et	  al.,	  2010]	  




	   	  
Moreover expression of Ifitm1 as well as Ifitm3 inhibits cell proliferation in 
vitro [Brem et al., 2003]. Notably Ifitm1 is crucial for IFNγ mediated cell cycle 
arrest, as suppression of Ifitm1 blocked the anti-proliferative actions of IFNγ [Yang 
et al., 2007]. 
Concluding from this data we hypothesized that the Ifitm family might play 
a crucial role in cell cycle activation of HSCs after in vivo treatment with IFNα. 
3.3.1 IFNα and LPS induce expression of Ifitm family members  
To get further insight into the induction of the expression of Ifitm family 
members and to validate our microarray expression data, we performed qPCR 
analysis of unfractionated total bone marrow cells as well as FACS sorted LK 
SLAM HSCs, 16 hours after treatment with PBS, IFNα or LPS. We observed 
increased expression of ifitm1 and ifitm3 in LK SLAM HSCs, both after treatment 
with IFNα as well as LPS. Expression of Ifitm2 was not influenced, while the 
expression of ifitm5 and ifitm6 in LK SLAM HSCs was lower in IFNα and LPS 
treated mice (Fig 3.6 A). Interestingly contrary to the expression in HSCs, in 
unfractionated bone marrow cells the expression of all five ifitm family members 
was induced by both IFNα as well as LPS (Fig 3.6 B). This indicates a different 
mechanism of regulation of Ifitm expression in HSCs and more differentiated 
cells. 
3.3.2 Expression of Ifitm family members is enriched in HSPCs 
To elucidate the abundance of the Ifitm family of proteins in the 
hematopoietic system we performed qPCR analysis on FACS sorted 
LSKCD150+CD48-CD34- HSCs, MPPs, lineage committed progenitor cell  fractions 
as well as differentiated cells. We detected transcripts of all five Ifitm family 
members in HSPCs, but only Ifitm1, 2 and 3 were expressed at levels comparable 
to the house keeping genes (Fig 3.7 A), while the expression levels of Ifitm 5 and 
6 were very low (data not shown). Interestingly the expression of Ifitm1 and 3 was 
highly enriched in hematopoietic stem cells and early progenitor cells and 
decreasing in more committed progenitor cells. Expression was higher in common 




	   	  
myeloid progenitors compared to lymphoid-committed progenitors. All Ifitm 
family members except Ifitm 5 were expressed in CD11b+Gr1+ cells enriched for 
granulocytes and macrophages, with Ifitm 6 showing exclusive expression in this 
compartment (Fig 3.7 B). This is in concordance with a possible role of Ifitm 6 in 
macrophages [Han et al., 2011]. Ifitm3 was also expressed at a low level in 
Ter119+ erythrocytes (Fig 3.5 B).  
 
Figure	  3.6	  qPCR	  quantification	  of	  ifitm	  mRNA	  expression	  16	  hours	  after	  injections	  of	  IFNa	  or	  LPS	  
Quantification	  of	  Ifitm1,	  2,	  3,	  5	  and	  6	  relative	  to	  the	  house	  keeping	  genes	  sdha	  (succinate	  dehydrogenase	  complex	  
subunit	  A)	  and	  oaz1	   (ornithine	  decarboxylase	  antizyme	  1).	  All	  expression	   levels	  normalized	   to	   the	   respective	  PBS	  
treated	  control.	  Dotted	  line	  indicates	  the	  expression	  level	  of	  PBS	  treated	  samples.	  (A)	  Expression	  in	  FACS	  sorted	  LK	  
SLAM	  HSCs	  (LKCD150+CD48-­‐)	  (B)	  Expression	  in	  unfractionated	  total	  bone	  marrow	  cells.	  




	   	  
Figure	  3.7	  qPCR	  quantification	  of	  ifitm	  mRNA	  expression	  in	  HSPCs	  and	  differentiated	  cells	  
Quantification	  of	   genes	   relative	   to	   the	  house	   keeping	   genes	   sdha	   (succinate	  dehydrogenase	   complex	   subunit	  A),	  
oaz1	   (ornithine	   decarboxylase	   antizyme	   1)	   and	   b2m	   (beta-­‐2-­‐microglobulin).	   Dotted	   line	   indicates	   the	   average	  
expression	  in	  total	  bone	  marrow	  samples.	  (A)	  Expression	  of	  Ifitm1,	  2	  and	  3	  in	  HSCs	  (LSKCD150+CD48-­‐CD34-­‐),	  MPP1/2	  
(LSKCD150+CD48+),	  MPP3/4	  (LSKCD150-­‐),	  CMPs	  (linnegCD117+Sca-­‐1-­‐IL7R-­‐CD34+FcgRlo),	  GMPs	  (linnegCD117+Sca-­‐1-­‐IL7R-­‐
CD34+FcgRhi),	  MEPs	  (linnegCD117+Sca-­‐1-­‐IL7R-­‐CD34-­‐FcgRlo)	  and	  CLPs	  (linnegCD117loSca-­‐1loIL7R+CD135+).	  (B)	  Expression	  
of	   Ifitm	   family	  members	   in	   Ter119+	   erythrocytes,	   CD11b+Gr1+	   granulocytes	   and	  macrophages,	   B220+	   B-­‐cells	   and	  
CD4+/8+	  lymphocytes.	  
To get further insight on the expression of Ifitm3 in individual cells we 
used a mouse model, where the Ifitm3 gene was disrupted by in-frame insertion of 
EGFP [Lange et al., 2008]. Mice heterozygous for the Knock-in (Ifitm3EGFP+/T) 
express one allele of Ifitm3 and one allele of EGFP. EGFP expression can thus be 
used as an indication of Ifitm3 mRNA expression, while mice homozygous for the 
Knock-in (Ifitm3EGFPT/T) lack Ifitm3 expression (Fig 3.8 A, more detailed 
description of the model in the Materials and Methods Section). 
 
 




	   	  
 
  




	   	  
Figure	  3.8	  EGFP	  expression	  in	  the	  hematopoietic	  compartment	  of	  Ifitm3EGFP	  Knock-­‐in	  mice	  
(A)	  The	  Ifitm3EGFP	  mouse	  model;	  The	  Ifitm3	  gene	  is	  disrupted	  by	  in-­‐frame	  insertion	  of	  EGFP	  in	  the	  first	  exon	  of	  the	  
ifitm3	  gene.	  (B)	  Expression	  of	  EGFP	  in	  lineage	  negative	  cells	  (negative	  for	  expression	  of	  CD11b,	  Gr-­‐1,	  CD4,	  CD8,	  B220	  
and	  Ter119),	  LSK	  cells,	  LSKCD150+CD48-­‐	  HSCs	  and	  LSKCD150+CD48-­‐CD34-­‐	  HSCs.	  (C)	  Overlay	  of	  EGFP	  expression	  from	  
lineage	   negative	   cells	   (green),	   LSK	   cells	   (blue)	   and	   LSKCD150+CD48-­‐CD34-­‐	   HSCs	   (red);	   MFI	   =	   mean	   fluorescence	  
intensity	   of	   EGFP	   channel.	   (D)	   Gating	   scheme	   of	   common	   myeloid	   (linnegCD117+Sca-­‐1-­‐FcgRloCD34+),	   myeloid-­‐
erythroid	   (linnegCD117+Sca-­‐1-­‐FcgR-­‐CD34-­‐)	   and	   granulocyte-­‐macrophage	   (linnegCD117+Sca-­‐1-­‐FcgRhiCD34+)	   progenitor	  
cell	   populations	   and	   EGFP	   expression	   levels	   in	   the	   respective	   populations	   (E)	   Expression	   of	   EGFP	   in	   common	  
lymphoid	   progenitor	   cells	   (CLP;	   linnegCD117loSca-­‐1loCD135+IL7R+).	   (F)	   EGFP	   expression	   in	   CD4	   and	   CD8	   positive	  
lymphocytes,	  B220	  positive	  B-­‐cells,	  CD11b	  and	  Gr-­‐1	  positive	  granulocytes	  and	  Ter119	  positive	  erythrocytes.	  




	   	  
We found only a small population of less than 10% of lineage negative 
cells (lacking expression of CD11b, Gr-1, CD4, CD8, B220 and Ter119) to 
express EGFP (Fig 3.8 B). Interestingly the proportion of cells positive for EGFP 
expression increased for earlier progenitor populations to about 40% and was 
highest in long-term hematopoietic stem cells (LSK SLAM CD34-), with more than 
half of the cells expressing EGFP (Fig 3.8 B). Similarly we also noticed an increase 
in the mean fluorescence intensity (MFI) from more towards less differentiated 
populations, with HSCs again showing a six-fold higher MFI compared to lineage 
negative cells (Fig 3.8 C). This indicates both an increase in the frequency of cells 
expressing Ifitm3 within the HSC population as well as an increased expression of 
Ifitm3 in individual cells. 
We next analyzed myeloid and lymphoid committed progenitor cells for 
expression of EGFP. We detected expression of EGFP in common myeloid (CMP), 
granulocyte-macrophage committed (GMP), myeloid-erythroid committed (MEP) 
as well as common lymphoid committed (CLP) progenitors at a level comparable 
to LSK cells (Fig 3.8 D+E). The proportion of positive cells as well as the MFI of 
the EGFP signal was highest in the CMP population compared to other committed 
progenitor populations. This was reflected also on the level of terminally 
differentiated cells, where only few CD4 or CD8 positive lymphocytes, B220 
positive B-cells or Ter119 positive erythrocytes expressed EGFP. In contrast the 
expression of EGFP was very high in CD11b/Gr-1 expressing granulocytes and 
macrophages, confirming the high expression of Ifitm3 determined by qPCR in 
this population (Fig 3.8 F). 
In summary the expression of EGFP in Ifitm3EGFP+/T mice correlates highly 
with the mRNA expression quantified by qPCR. RNA expression of Ifitm1 and 3 is 
highly enriched in HSCs and gradually declines in more differentiated cells, with 
the exception of granulocytes. Interestingly the expression of Ifitm3 is enriched in 
HSCs in both frequency of cells expressing Ifitm3, as determined by EGFP 
expression in Ifitm3EGFP+/T mice, as well as intensity of expression in individual 
cells within the HSC compartment. Strikingly however even in HSC populations 
enriched for Ifitm3 expression still nearly half of the cells are negative for 




	   	  
expression of EGFP. This raises the question whether there are functional 
differences between Ifitm3 positive and negative HSCs. 
 
3.3.3 Ifitm3EGFP expression is differentially induced after IFNα and LPS 
treatment 
Since the analysis of Ifitm3EGFP Knock-in mice showed a high 
heterogeneity in regards to expression of EGFP within each hematopoietic cell 
compartment, we next investigated whether also the stress-induced induction of 
Ifitm3 expression is regulated differently within each compartment. Therefore we 
analyzed the expression of EGFP in Ifitm3EGFP+/T mice 16 hours after in vivo 
administration of IFNα or LPS. 
Expression of EGFP was increased in LSK as well as LK SLAM HSCs after 
both treatments (Fig 3.9 A+B). This increase was observed both in the intensity of 
the EGFP signal within the EGFP-positive cells, as well as in the proportion of 
HSCs positive for EGFP expression. The increase in expression was stronger in 
HSCs of mice treated with IFNα compared to LPS. Interestingly in differentiated 
cells the induction of EGFP expression was different between the two treatments. 
Both IFNα as well as LPS lead to increased expression of EGFP in monocytes, 
while only IFNα induced expression of EGFP in B-cells and CD4 or CD8 positive 
T-cells (Fig 3.9 C). Notably expression of EGFP was induced only in a small 
proportion of B-cells and T-cells, while the majority of cells remained EGFP 
negative. 
Taken together these results suggest that while both IFNα and LPS can 
induce expression of Ifitm3, the underlying mechanisms are different, as LPS 
contrarily to IFNα does not lead to induction of Ifitm3 expression in B-cells and 
T-cells. Furthermore the triggers leading to the induction of Ifitm3 expression is 
differentially regulated between hematopoietic stem and progenitor cells 
compared to more differentiated cells, suggesting that Ifitm3 expression is induced 
in HSPCs under different conditions. 
 




	   	  
Figure	  3.9	  Induction	  of	  EGFP-­‐expression	  in	  the	  hematopoietic	  compartment	  of	  Ifitm3EGFP	  Knock-­‐in	  mice	  
Histogram	  of	  EGFP	  expression	  in	  LSK	  and	  LK	  SLAM	  HSCs	  16	  hours	  after	  in	  vivo	  treatment	  with	  IFNα	  (A)	  or	  LPS	  (B).	  (C)	  
EGFP	  expression	  16	  hours	  after	  in	  vivo	  IFNα	  or	  LPS	  treatment	  in	  B-­‐cells	  (B220+),	  CD4	  and	  CD8	  positive	  T-­‐cells	  (CD4+	  
and	  CD8+)	  and	  monocytes,	  granulocytes	  and	  macrophages	  (CD11b+Gr-­‐1+).	  
 	  




	   	  
3.3.4 Ifitm3 protein expression in the hematopoietic system 
As higher mRNA expression does not necessarily indicate higher protein 
expression of Ifitm3 in HSCs, we next investigated the expression of Ifitm3 protein 
in the hematopoietic system. Therefore we performed immune-fluorescence 
staining for Ifitm3 on cytospins of unfractionated total bone marrow cells as well 
as sorted LK SLAM HSCs and differentiated cells of the hematopoietic system. 
Interestingly only few cells within the bone marrow stained positive for 
Ifitm3, while sorted LK SLAM HSCs were highly enriched for Ifitm3 protein 
expression, with the majority of cells staining positively (Fig 3.10 A). Notably the 
staining pattern appeared to be on the membrane of the cells as well as within the 
cells organized in a clustered structure. This correlates with recent reports, 
showing localization of overexpressed Ifitm3 in human HeLa cells both on the 
membrane as well as within the endoplasmatic reticulum [Yount et al., 2010].   
To investigate whether Ifitm3 protein expression is induced by IFNα 
similarly to the RNA expression, we next analyzed LK SLAM HSCs 16 hours after 
in vivo treatment with poly-(I)-(C). Similar to the up-regulation of Ifitm3 mRNA, 
also the protein expression was highly induced. Moreover the clustered 
expression pattern was more pronounced after activation of the cells compared to 
homeostasis (Fig 3.10 B). Notably in concordance with the induction of EGFP 
expression in our Ifitm3EGFP mouse model, only very few B-cells and T-cells 
stained positive for ifitm3 during homeostasis, while a larger proportion of cells 
showed expression following administration of IFNα (data not shown). Overall the 
expression of Ifitm3 protein correlated highly with the expression of Ifitm3 mRNA 
observed before. 
In conclusion within the hematopoietic system expression of the Ifitm 
family is highly enriched in HSCs during homeostasis, both on the RNA as well as 
on the protein level. Moreover both RNA and protein expression is further 
induced by IFNα. This suggests that the Ifitm protein family might play a crucial 
role in HSCs. 




	   	  
 
Figure	  3.10	  Ifitm3	  protein	  expression	  in	  HSCs	  and	  unfractionated	  bone	  marrow	  
(A)	   Immune	   fluorescence	  staining	   for	   Ifitm3	   (red)	  and	  DNA	   (DAPI,	  blue)	   in	  unfractionated	  bone	  marrow	  cells	  and	  
FACS	  sorted	  LK	  SLAM	  HSCs	  from	  C57BL/6	  mice	  at	  homeostasis.	  (B)	  Staining	  for	  Ifitm3	  (red)	  and	  DNA	  (DAPI,	  blue)	  in	  
LK	  SLAM	  HSCs	  16	  hours	  after	  in	  vivo	  administration	  of	  PBS	  or	  pIC.	  Expression	  of	  Ifitm3	  in	  LK	  SLAM	  HSCs	  PBS	  appears	  
lower	  in	  (B)	  as	  exposure	  was	  shorter	  to	  highlight	  increase	  of	  signal	  after	  pIC	  treatment.	  	   	  




	   	  
3.3.5 Ifitm deficient mice have no hematopoietic phenotype 
To elucidate the functional role of Ifitm3 in the hematopoietic system, we 
isolated bone marrow from Ifitm3EGFPT/T mice, which are deficient for Ifitm3 
expression, and analyzed the hematopoietic compartment. Ifitm3 deficient mice 
had unchanged bone marrow cellularity and normal numbers of hematopoietic 
stem and progenitor cells as well as B-cells, lymphocytes and granulocytes 
compared to heterozygous Ifitm3EGFP+/T littermate controls (data not shown). 
As the different members of the Ifitm protein family share high similarities, 
it is possible that there is functional redundancy between the different family 
members. Therefore deletion of Ifitm3 alone might be compensated by expression 
of other Ifitm family members. To address the effect of absence of the complete 
Ifitm protein family, we analyzed the hematopoietic system of IfitmDEL-/- mice 
[Lange et al., 2008]. In these mice the whole Ifitm family gene cluster, including 
Ifitm1, Ifitm2, Ifitm3, Ifitm5 and Ifitm6, has been deleted (Fig 3.11 A). IfitmDEL-/- 
mice mice show normal development and are viable and fertile, however the 
number of homozygous IfitmDEL mutant animals obtained from intercrosses of 
heterozygous IfitmDEL mice was reported to be slightly reduced from the 
expected Mendelian ratio, with only 17% homozygous IfitmDel mutant mice 
obtained at weaning age [Lange et al., 2008]. Strikingly, we observed an even 
lower rate of homozygous mutant IfitmDEL animals at weaning age in our 
intercrosses of IfitmDEL+/- mice, with only 2% of mice having an IfitmDEL-/- 
genotype, while 75% were IfitmDEL+/- and 23% IfitmDEL+/+ (n=139). As previous 
reports suggested normal development during embryogenesis [Lange et al., 2008], 
we reasoned that IfitmDEL-/- mice might die more frequently between birth and 
weaning age. To investigate this, we genotyped newly born litters from IfitmDEL+/- 
intercrosses at postnatal day 1. Interestingly we observed a ratio of only 3% 
IfitmDEL-/-, 61% IfitmDEL+/- and 36% IfitmDEL+/+ (n=64) closely matching the 
reduced frequency observed at weaning age.  




	   	  
Figure	  3.11	  Comparison	  of	  the	  hematopoietic	  system	  of	  wild	  type	  and	  Ifitm	  family	  deficient	  mice	  	  
(A)	  Schematic	  of	  the	  targeting	  strategy	  for	  the	  deletion	  of	  the	  Ifitm	  family	  cluster.	  Example	  of	  IfitmDEL	  wild	  type	  and	  
mutant	  mice	   (adapted	   from	  [Lange	  et	  al.,	  2008]).	   (B)	  Comparison	  of	   LSK,	   LSK	  SLAM	  and	  LSK	  SLAM	  CD34-­‐	  HSCs	  of	  
IfitmDEL+/+	  and	  IfitmDEL-­‐/-­‐	  mice.	  (C)	  Comparison	  of	  lymphocytes	  (CD4+	  and	  CD8+),	  granulocytes	  (CD11b+Gr-­‐1+)	  and	  B-­‐
cells	  (B220+)	  from	  IfitmDEL+/+	  and	  IfitmDEL-­‐/-­‐	  mice.	  




	   	  
As IfitmDEL mice develop normally until embryonic day E17.5 [Lange et al., 
2008], this indicates that a large proportion of IfitmDEL-/- mice likely die during or 
shortly after birth. Due to the very low frequency of IfitmDEL-/- mice we obtained, 
we performed some of the following experiments with IfitmDEL-/- bone marrow 
chimeras where specified (Fig 3.12 A). Therefore wild type C57BL/6 mice were 
lethally irradiated and transplanted with bone marrow from IfitmDEL-/- mice. 
Notably IfitmDEL-/- bone marrow chimeras are deficient for the Ifitm family 
exclusively in hematopoietic cells, while the stromal compartment originates from 
wild type C57BL/6 hosts. 
Similar to Ifitm3 deficient mice also IfitmDEL-/- mice deficient for the whole 
ifitm family showed normal numbers of hematopoietic stem and progenitor cells 
(Fig 3.11 B). Furthermore also the numbers of CD4+ and CD8+ lymphocytes, 
CD11+Gr-1+ granulocytes and B220+ B-cells were not affected by the absence of 
the ifitm family (Fig 3.11 C). 
3.3.6 Characterization of stem cell properties of Ifitm-deficient HSCs 
We next investigated the functional characteristics of HSCs of Ifitm-
deficient mice. We observed no differences in the cycling behavior between 
Ifitm3-deficient and wild type LSK SLAM HSCs as analyzed by Ki67/Hoechst cell 
cycle analysis (Fig 3.12 B). Furthermore also IfitmDEL-/- LSK SLAM HSCs, isolated 
from IfitmDEL bone marrow chimeras, showed a similar cell cycle distribution 
during homeostasis compared to wild type controls (Fig 3.12 C). 
Despite the large proportion of stem cells which reside in the G0 phase of 
the cell cycle during homeostasis, only a small proportion of these cells is 
long-term dormant in the mouse [Wilson et al., 2008]. To investigate whether 
dormant HSCs are affected by loss of Ifitm3 we performed label-retaining assays 
with BrdU. Mice were supplied with BrdU in the drinking water for 10 days to 
label all HSCs (pulse period), followed by a BrdU-free chase period of 107 days. 
In this assay dividing cells dilute the initial BrdU label out, while only cells that 
don’t undergo active cell cycle retain the label [Wilson et al., 2008]. 




	   	  
We did not observe any difference in the number of label retaining cells 
between Ifitm3 wild type and Ifitm3 deficient mice (Fig. 3.12 D). In conclusion 
deletion of either Ifitm3 or the whole Ifitm-family cluster does not affect the 
cycling behavior of HSCs during homeostasis. 
We next assessed whether the capabilities of HSCs to differentiate and self-
renew are affected the in absence of Ifitm family members. Therefore we isolated 
bone marrow from IfitmDEL+/+ and IfitmDEL-/- bone marrow chimeras and 
performed in vitro colony formation assays. We did not observe any effect on 
colony formation capacity of HSCs in the absence of the Ifitm family proteins (Fig 
3.12 E).  
Since in vitro colony formation does not allow any conclusion about the 
self-renewal capability or the lineage contribution of HSCs we next performed 
competitive bone marrow transplantation assays (Fig 3.12 A). In these assays bone 
marrow cells from IfitmDEL+/+ or IfitmDEL-/- mice were isolated and mixed with an 
equal number of bone marrow cells from C57BL/6 Ly5.1 wild type mice (Fig 3.12 
A). Hematopoietic cells from IfitmDEL mice express the CD45 isoform CD45.2, 
while cells from C57BL/6 Ly5.1 mice express the CD45 isoform CD45.1. 
Therefore the contribution of IfitmDEL-/- and wild type cells to the hematopoietic 
system of the host mouse can be analyzed by using antibodies specific for 
CD45.1 or CD45.2 in FACS analysis. This mixture of bone marrow cells was 
transplanted intravenously into lethally irradiated C57BL/6 Ly5.1 mice. 14 weeks 
later the contribution of IfitmDEL+/+ and IfitmDEL-/- cells to hematopoiesis was 
analyzed by FACS analysis. We did not observe any difference in contribution to 
either myeloid (granulocytes) or lymphoid (CD4 and CD8 positive lymphocytes, 
B-cells) lineages between Ifitm-deficient HSCs and wild type HSCs (Fig 3.12 F). 
In summary deletion of the whole Ifitm family gene cluster does not affect 
cycling behavior, differentiation potential, engraftment potential or self-renewal 
capacity of HSCs. In conclusion the Ifitm protein family is not required for 
hematopoiesis during homeostasis.  
 
  




	   	  
Figure	  3.12	  Characterization	  of	  Ifitm-­‐deficient	  HSCs	  	  
(A)	   Schematic	   for	   the	   generation	  of	   competitive	   50:50	  bone	  marrow	   chimeras	  of	  wild	   type	   and	   IfitmDEL	  mutant	  
mice.	  (B)	  Ki67/Hoechst	  cell	  cycle	  profile	  of	  LSK	  SLAM	  HSCs	  from	  Ifitm3EGFP	  heterozygous	  or	  homozygous	  mutant	  
mice.	  (C)	  Ki67/Hoechst	  cell	  cycle	  profile	  of	  LSK	  SLAM	  HSCs	  from	  IfitmDEL	  mutant	  and	  wild	  type	  C57BL/6	  mice.	  (D)	  
Quantification	  of	  BrdU	   label-­‐retaining	  cells	   (LRCs)	  of	  LSK	  SLAM	  CD34-­‐	  wild	   type	  or	   Ifitm3-­‐deficient	  HSCs	  after	  107	  
days	   of	   BrdU-­‐free	   chase.	   (E)	  Quantification	  of	   colonies	   formed	   from	  10.000	  plated	   IfitmDEL	  wild	   type	  or	  mutant	  
unfractionated	   bone	   marrow	   cells;	   in	   vitro	   MethoCult	   colony	   forming	   cell	   assay	   (Stem	   Cell	   Technologies).	   (F)	  
Analysis	  of	  chimerism	  14	  weeks	  after	  competitive	  bone	  marrow	  transplantation	  of	   IfitmDEL	  (CD45.2)	  wild	  type	  or	  
mutant	   bone	  marrow	   cells	   with	   C57BL/6	   Ly5.1	   (CD45.1)	   bone	  marrow	   cells.	   Quantification	   of	   the	   proportion	   of	  
CD11b+Gr-­‐1+	  granulocytes,	  B220+	  B-­‐cells	  and	  CD4+/CD8+	  lymphocytes	  derived	  from	  IfitmDEL	  mice	  (expression	  the	  
CD45.2	  isoform	  of	  CD45).	  




	   	  
3.3.7 Stress induced activation of Ifitm-deficient HSCs 
As previously described stress signals like IFNα lead to the activation of 
usually quiescent HSCs [Essers et al., 2009]. Similarly also the expression of Ifitm1 
and Ifitm3 is induced upon in vivo treatment with IFNα as well as LPS. To address 
whether the Ifitm family plays a role in the activation of HSCs, we performed 
BrdU incorporation assays as well as cell cycle analysis on HSCs of Ifitm deficient 
mice after in vivo treatment with IFNα or LPS. Therefore mice were injected 
intraperitoneally with 100µg poly-(I)-(C), which leads to production of IFNα, or 
5µg LPS 16 hours before analysis. Additionally mice were pulsed with 400µg 
BrdU 12 hours before analysis. Cells that undergo the S phase of the cell cycle 
and synthesize new DNA between the timepoint of BrdU injection and the 
timepoint of analysis, incorporate BrdU in their DNA, which can be detected with 
BrdU specific antibodies and analyzed by FACS. 
We did not detect any difference in BrdU incorporation between 
Ifitm3EGFP heterozygous and mutant LSK SLAM HSCs after poly-(I)-(C) injection 
(Fig 3.13 A). Both wild type as well as Ifitm3 deficient HSCs showed a high 
increase in BrdU incorporation following poly-(I)-(C) treatment, indicating an 
increase in cell proliferation. Furthermore administration of poly-(I)-(C), as well as 
LPS, also efficiently activated LSK SLAM HSCs from IfitmDEL-/- mice (Fig 3.13 
B+C). 
Another crucial process during the activation of HSCs is the shutdown of 
the activation response and reacquisition of quiescence. To address whether the 
Ifitm protein family plays a role in this process we analyzed BrdU incorporation at 
several timepoints after injection of poly-(I)-(C) in mixed IfitmDEL bone marrow 
chimeras (Fig 3.12 A). Wild type and Ifitm-deficient LSK SLAM HSCs were 
similarly activated after poly-(I)-(C) administration (Fig 3.13 D). Furthermore the 
level of BrdU incorporation decreased similarly by day 5 after injection and was 
close to baseline at day 7 after injection (Fig 3.12 D). 
 




	   	  
Figure	  3.13	  Activation	  of	  Ifitm-­‐deficient	  HSCs	  by	  IFNα 	  and	  LPS	  
(A)	  BrdU	  incorporation	  in	  LSK	  SLAM	  HSCs,	  16h	  after	   in	  vivo	  administration	  of	  100µg	  poly-­‐(I)-­‐(C)	  (pIC)	  in	  Ifitm3EGFP	  
wildtype	  and	  mutant	  mice.	  (B)	  BrdU	  incorporation	  in	  LSK	  SLAM	  HSCs	  after	  2	  shots	  of	  100	  µg	  pIC	  16	  hours	  and	  3	  days	  
before	   analysis	   in	  wild	   type	   C57BL/6	  mice	   and	   IfitmDEL-­‐/-­‐	   bone	  marrow	   chimeras.	   (C)	   BrdU	   incorporation	   in	   LSK	  
SLAM	  HSCs	  of	  IfitmDEL-­‐/-­‐	  bone	  marrow	  chimeras,	  24	  hours	  after	  injection	  with	  100µg	  pIC	  or	  5µg	  LPS.	  (D)	  Timecourse	  
of	  BrdU	  incorporation	  in	  mixed	  bone	  marrow	  chimeras	  after	  two	  shots	  of	  100µg	  pIC	  (day	  -­‐2	  and	  day	  0).	  (E)	  Analysis	  
of	   CD11b+Gr-­‐1+	   granulocyte-­‐chimerism	   from	   peripheral	   blood	   before	   and	   after	   serial	   treatment	   with	   PBS	   or	   pIC	  
(100µg).	   PBS	   or	   pIC	   was	   administered	   intraperitoneally	   every	   second	   day	   for	   a	   total	   of	   eight	   injections,	   and	  
chimerism	  analyzed	  one	  week	  after	  the	  last	  injection.	  
 
Previous experiments from our group showed that chronically activated 
HSCs are outcompeted in a competitive setting by HSCs, which can not respond 
to the activation stimulus [Essers et al., 2009]. To address whether IfitmDEL-/- 




	   	  
HSCs have a competitive advantage or disadvantage during chronic stimulation 
compared to wild type cells, we analyzed the effect of chronic IFNα stimulation 
on IfitmDEL 50:50 bone marrow chimeras (Fig 3.12 A). Therefore the peripheral 
blood chimerism of the mice was determined at the start of the experiment. 
Subsequently the mice were intra-peritoneally injected every second day with 
100µg of poly-(I)-(C) for a total of 8 injections. One week after the last injection 
the chimerism was analyzed again. We did not detect any significant differences 
between the chimerism before and after the chronic HSC activation, indicating 
that IfitmDEL-/- HSCs are similarly activated by chronic IFNα exposure compared 
to wild type HSCs (Fig 3.13 E). 
In summary the Ifitm protein family is not crucial for the activation of HSCs 
by IFNα or LPS, neither it is required for the reacquisition of quiescence after the 
activation response. Finally also in a setting of chronic activation no differences 
could be observed between Ifitm-deficient and wild type HSCs. This raises the 
question whether the Ifitm protein family might have regulatory or effector 
functions unrelated to maintenance and cell cycle activation in HSCs. To gain 
further insight into this possibility we next performed gene expression analysis in 
wild type and Ifitm deficient HSCs. 
 
3.3.8 Gene expression profile of Ifitm-deficient HSCs 
Despite previous reports, which indicated an influence of Ifitm family 
members on components of the HSC niche as well as on IFN induced cell cycle 
control [El-Tanani et al., 2010; Yang et al., 2007], we did not observe any 
phenotype on cycling behavior of HSCs during homeostasis, activation of HSCs 
by stress signals or stem cell properties of HSCs in the absence of Ifitm3 or the 
whole ifitm family. To get further insight in which processes the Ifitm family might 
be involved in hematopoietic stem cells, we performed microarray analysis of 
FACS sorted LK SLAM HSCs from IfitmDEL+/+ and IfitmDEL-/- bone marrow 
chimeras, 16 hours after in vivo treatment with PBS or IFNα. 
 




	   	  
 
Figure	  3.14	  Microarray	  of	  IfitmDEL	  wild	  type	  and	  mutant	  LK	  SLAM	  HSCs	  
Hierarchical	  clustering	  of	  samples	  of	  FACS-­‐sorted	  LK	  SLAM	  HSCs	  isolated	  from	  IfitmDEL+/+	  (wt)	  and	  IfitmDEL-­‐/-­‐	   (KO)	  
bone	  marrow	  chimeras,	  16	  hours	  after	   in	  vivo	  administration	  of	  PBS	  or	  IFNα.	  Clustering	  according	  to	  differentially	  
changes	  genes	  between	  HSCs	  from	  PBS	  and	  IFNα	  treated	  IfitmDEL+/+	  bone	  marrow	  chimeras.	  FDR<5%	  
Interestingly HSCs from PBS treated and from IFNα treated mice were 
clustering together, irrespective of their IfitmDEL genotype (Fig 3.14). This 
indicates a high similarity between the expression profiles of IfitmDEL+/+ and 
IfitmDEL-/- HSCs, both during homeostasis as well as after IFNα-induced HSC 
activation. 
We found 8228 genes to be significantly changed between HSCs from 
PBS-treated and IFNα-treated IfitmDEL+/+ bone marrow chimeras, with 180 genes 




	   	  
changed more that 1,5 fold (FDR <5%). As expected the majority of differentially 
regulated genes was similar to the ones observed in our previous arrays from 
C57BL/6 wild type mice. The strikingly higher number of significantly changed 
genes in this experiment can be explained by the analysis of bone marrow 
chimeras, which harbor HSCs originating from the same donor mice, compared to 
litter mate controls in previous experiments. Therefore the variability between the 
different samples was very low. 
Interestingly only 8 genes were changed significantly (FDR<5%) between 
IfitmDEL+/+ and IfitmDEL-/- LK SLAM HSCs during homeostasis. Of these strikingly 
only three genes were changed more that 1,5 fold: Ifitm1 (3,7x down in IfitmDEL-/- 
HSCs), Ifitm2 (5,2x down) and Ifitm3 (8,4x down). This nicely confirms the 
deletion of Ifitm1, 2 and 3 in IfitmDEL-/- HSCs, as only these three family members 
are expressed in HSCs as described before. As expected we did not detect 
reduced expression of ifitm5 and 6 as they are not expressed in HSCs. 
Interestingly despite the large number of genes changed after administration of 
IFNα in IfitmDEL+/+ LK SLAM HSCs, only 11 genes were differentially expressed 
between IfitmDEL+/+ and IfitmDEL-/- HSCs following treatment with IFNα. Of these 
again only Ifitm1 (8,3x down in IfitmDEL-/- HSCs), Ifitm2 (3,5x down) and Ifitm3 
(11.8x down) were changed more than 1,5 fold. 
In summary we could not detect any significantly changed genes (FDR<5% 
and FC>1,5) between IfitmDEL wild type and mutant HSCs, neither during 
homeostasis nor following IFNα-induced HSC activation, with exception of the 
Ifitm gene family itself. This data strongly suggests that the ifitm family does not 
play a role in transcriptional regulation within HSCs, but rather has terminal 
effector functions. It cannot be excluded however that the Ifitm family regulates 
expression of other genes on a post transcriptional level. 
In line with our study it was recently shown that Ifitm1, 2 and 3 play a 
crucial role as host restriction factors during viral infections with a variety of 
diverse viral pathogens including HCV, Dengue virus or HIV [Brass et al., 2009; 
Huang et al., 2011; Lu et al., 2011]. As we observed not only an induction of 




	   	  
Ifitm-expression in HSCs by IFNα, but also a high level of expression already at 
homeostasis, it is tempting to speculate that the Ifitm family could play a crucial 
role in protecting HSCs from viral or bacterial pathogens. 
Since not only Ifitm family members but also other genes involved in 
immune defense mechanisms were increased in our microarray screens of IFNα 
induced HSCs, we decided to investigate whether expression of immune defense 
related genes are generally enriched within HSCs already during homeostasis, or 
whether this enrichment is unique for the ifitm family of proteins. 
 	  




	   	  
3.4 Expression of immune defense associated genes in HSPCs 
In the course of viral as well as bacterial infections, IFNα is produced by 
host cells and inhibits spread of pathogens by a variety of mechanisms including 
activation of immune cells and interference with viral replication [Stark et al., 
1998]. As expected, in our microarray analysis of FACS sorted HSCs we observed 
the induction of many genes involved in immune responses, including Ifitm1 and 
Ifitm3, within HSCs after treatment of mice with IFNα in vivo (Tab 3.1). 
Interestingly however the expression of Ifitm1 and Ifitm3 in HSCs was not only 
induced by IFNα, but already highly enriched for during homeostasis. 
To address whether HSCs are generally enriched for the expression of viral 
effector proteins during homeostasis, we selected some of the proteins involved in 
different steps of immune responses against intracellular pathogens, which were 
strongly induced in our microarray analysis of HSCs after treatment with IFNα: 
Ifit1 and Ifit3, Ddx58 (RIG-I), Oas3 and Iigp-1. Ifit1 (Interferon-induced protein 
with tetratricopeptide repeats 1) and Ddx58 (DEAD box polypeptide 58; also 
RIG-I) play crucial roles in the recognition of viral RNA by host cells [Pichlmair et 
al., 2011; Pichlmair et al., 2006]. Oas3 is a member of the 2',5'-oligoadenylate 
synthetase family, of which several members were highly induced by IFNα. The 
Oas family and its downstream effector RNase L play important roles in host 
defense against virus infection [Lin et al., 2009]. Iigp1 (interferon inducible 
GTPase 1) is a member of the interferon-inducible immunity-related family of p47 
GTPases, which play a crucial role as resistance factors during infections by intra-
cellular pathogens [Liesenfeld et al., 2011; Pawlowski et al., 2011]. 
To verify the induction of these genes by IFNα within HSCs, we isolated 
RNA from LK SLAM HSCs of C57BL/6 mice, 16 hours after in vivo treatment with 
PBS or pIC and analyzed gene expression by quantitative Real-time PCR. 
  




	   	  
Figure	  3.15	  Quantification	  of	  immune	  defense	  related	  genes	  in	  HSPCs	  
(A)	   Expression	  of	   Ifit1,	   Ifit3,	  Ddx58,	  Oas3	  and	   Iigp1	   in	  unfractionated	  bone	  marrow	  cells	  and	  LK	  SLAM	  HSCs	   from	  
C57BL/6	  mice,	  16	  hours	  after	  injection	  of	  PBS	  or	  pIC,	  quantified	  per	  qPCR.	  Ratio	  of	  target	  gene	  expression	  relative	  to	  
house	  keeping	  genes	  Shda	  and	  Oaz1.	  (B)	  Expression	  Ifit1,	  Ifit3,	  Ddx58,	  Oas3	  and	  Iigp1	  in	  different	  cell	  types	  of	  the	  
hematopoietic	   system	   relative	   to	   expression	   of	   Sdha,	   Oaz1	   and	   B2m.	   HSCs	   (LSKCD150+CD48-­‐CD34-­‐),	   MPP1/2	  
(LSKCD150+CD48+),	  MPP3/4	  (LSKCD150-­‐),	  CMPs	  (linnegCD117+Sca-­‐1-­‐IL7R-­‐CD34+FcgRlo),	  GMPs	  (linnegCD117+Sca-­‐1-­‐IL7R-­‐
CD34+FcgRhi),	   MEPs	   (linnegCD117+Sca-­‐1-­‐IL7R-­‐CD34-­‐FcgRlo),	   CLPs	   (linnegCD117loSca-­‐1loIL7R+CD135+),	   erythrocytes	  
(Ter119+),	  granulocytes	  (CD11b+Gr1+),	  B-­‐cells	  (B220+)	  and	  lymphocytes	  (CD4+/8+).	  




	   	  
Expression of all five genes – Ifit1, Ifit3, Ddx58, Oas3 and Iigp1 – was 
highly induced after IFNα treatment, and to a lower extent also LPS treatment (Fig 
3.15 A). Notably during homeostasis only Iigp1 showed a higher expression 
within LK SLAM HSCs compared to unfractionated total bone marrow.  
To gain further understanding on the expression of these genes within 
hematopoietic stem and progenitor cells during homeostasis, we analyzed FACS 
sorted LSK SLAM CD34- HSCs, MPPs, CMPs, GMP, MEPs, CLPs, as well as 
differentiated cells by qPCR. Ifit3, Ifit1, Ddx58 and Oas3 were all expressed at 
similar levels in HSCs compared to early multi-potent progenitor cells. 
Interestingly there was a striking difference between the expression levels in 
multi-potent (HSCs, MPP1/2 and MPP3/4) versus committed (CMP, GMP, CLP and 
MEPs) progenitor cells, with higher expression within the multi-potent HSPC 
compartment (Fig 3.15 B). Interestingly this correlates with recent findings from 
our laboratory, which showed enrichment of a signature of immune-defense 
related proteins within multi-potent LSK cells, compared to lineage committed LK 
Sca−1- progenitor cells in a proteomics screen [Klimmeck et al., 2012]. The 
expression levels of these genes in HSPCs were however low compared to the 
expression in differentiated cells. All four genes were expressed highly in 
granulocytes, Ifit3 additionally also in CD41+ megakaryocytes, and Ifit1 and Oas3 
in erythrocytes (Fig 3.15 B). The only exception was Iigp1, which was expressed 
highest in HSCs and MPPs, with low expression in differentiated cells with the 
exception of lymphocytes. 
In summary we observed a higher expression of immune defense 
associated genes within multi-potent HSPCs compared to committed progenitor 
cells, however with the exception of Iigp1 the expression level was low compared 
to more differentiated cells. 
To gain more insight whether immune defense related genes are 
specifically enriched in the transcriptome of HSCs compared to all other cell types 
of the bone marrow, we performed microarray analysis of unfractionated bone 
marrow cells and FACS sorted LK SLAM HSCs, 16 hours after in vivo treatment 
with PBS or IFNα. 




	   	  
Figure	  3.16	  Comparison	  of	  the	  transcriptome	  of	  unfractionated	  bone	  marrow	  cells	  with	  LK	  SLAM	  HSCs	  
(A)	   Gene	  ontology	   analysis	   of	   significantly	   changed	   genes	   (FDR<5%,	   Fold	   change>2)	   between	   total	   bone	  marrow	  
cells	   and	   FACS	   sorted	   LK	   SLAM	   HSCs,	   16	   hours	   after	   injection	   of	   PBS.	  Most	   significantly	   changed	   GO	   processes	  
analyzed	  with	  Metacore	   software	  V6.10	   (Thomson	  Reuters).	   (B)	  Microarray	   expression	  data	   from	   selected	   genes	  
from	  samples	  of	  total	  bone	  marrow	  cells	  and	  FACS	  sorted	  LK	  SLAM	  HSCs,	  16	  hours	  after	  treatment	  with	  PBS	  or	  IFNα.	  
We found 1910 genes to be enriched in LK SLAM HSCs compared to total 
bone marrow (FC>2, FDR<5%) during homeostasis. Gene ontology analysis 
showed that the most significantly enriched processes in HSCs are related to 
cellular metabolism, self-renewal, cell cycle control and DNA damage repair (Fig 
3.16 A). As expected we found known HSC markers highly enriched within the 
HSC fraction, including c-kit, Sca-1 and CD150 (Fig 3.16 B and data not shown). 




	   	  
Strikingly the transcript levels following administration of IFNα highly reflected 
the level of protein expression observed by FACS analysis, with c-kit being 
down-regulated, Sca-1 up-regulated and CD150 expression unaffected by IFNα. 
Furthermore we found several genes, identified as candidate regulators of HSC 
activation in our previous screen, to be highly enriched within LK SLAM HSCs 
during homeostasis (Tab 3.1 and Chapter 3.2). These included the cell cycle 
regulators Reprimo and Pleiotropin, as well as Matrilin-4 and Maged1 (Fig 3.16 B 
and data not shown). All of these genes were expressed at high levels within HSCs 
during homeostasis but are strongly down-regulated following IFNα treatment (Fig 
3.16 B).  
Interestingly we also found a strong enrichment for transcripts associated 
with blood coagulation and platelet aggregation in LK SLAM HSCs during 
homeostasis (Fig 3.16 A). These included expression of Von Willebrand Factor 
(Vwf), Platelet Factor 4 (CXCL4) and Coagulation factor II receptor (F2r). Strikingly 
this correlates with recent reports of enriched expression of megakaryocyte-
erythrocyte genes in HSCs compared to lymphoid-primed multi-potent progenitor 
cells (LMPPs) [Mansson et al., 2007]. 
In conclusion we did not find a general enrichment of immune-defense 
associated transcripts within HSCs. Notable exceptions were Ifitm1, 
interferon-induced protein 44 (Ifi44) and interferon gamma inducible protein 47 
(Ifi47 or Iigp4). Ifi44 has previously been implicated in cell cycle arrest during 
hepatitis C virus infections, while Ifi47 – another member of the p47 GTPase 
family – plays a role in clearance of protozoan and bacterial infections [Collazo et 
al., 2001; Hallen et al., 2007]. Thus we found no evidence that the expression of 
immune defense genes is generally enriched in HSCs compared to total bone 
marrow cells during homeostasis. Instead only the Ifitm protein family (Ifitm1, 2 
and 3), as well as the family of p47 GTPases (Iigp1 and Iigp4), is enriched in LK 
SLAM HSCs. Whether these protein families are crucial for HSC-specific defense 
mechanism against viral or bacterial pathogens remains to be determined. 
  




	   	  
3.5 Activation of human HSCs in a xenotransplantation model 
So far, activation of HSCs by IFNα, IFNγ as well LPS was only shown in the 
mouse. IFNα is widely used in the clinic to treat patients with symptoms including 
hepatitis B and C viral infection, multiple sclerosis, melanoma as well as several 
hematological malignancies including chronic myeloid leukemia, hairy cell 
leukemia and different kinds of lymphoma [Cooksley, 2004; Goldstein and 
Laszlo, 1988; Hauschild et al., 2008; Paolicelli et al., 2009; Shepherd et al., 
2000]. Elucidating whether human HSCs are activated by IFNα similarly to their 
mouse counterparts is not only highly relevant for a better understanding of the 
effects as well as side effects of these treatments, but also crucial for the design of 
combination therapies to better target quiescent cancer stem cells in 
hematopoietic malignancies. 
While in vitro treatment of cells with IFNα has anti-proliferative effects, 
only in vivo administration of IFNα leads to activation of HSCs in the mouse 
[Essers et al., 2009]. Thus it is crucial to investigate the effects of human IFNα on 
human HSCs in an in vivo model, where human HSCs reside in a bone marrow 
niche environment. We therefore established a xenotransplantation mouse model 
with human cord blood cells. As host mice for the xenotransplantation the 
immune compromised NSG strain was chosen, which readily accepts human 
grafts without rejection [Ishikawa et al., 2005; Shultz et al., 2005]. 
Human cord blood cells were enriched for CD34 expression by magnetic 
bead separation (Miltenyi Biotech). NSG mice were sub-lethally irradiated 24 
hours before the transplantation to ablate mouse HSCs, and human CD34 
enriched cord blood cells were transplanted by intra-femural injection. This 
injection technique allows engraftment independent of an HSCs homing process 
and leads to better engraftment of human HSCs compared to intra-venous 
injection [Zhan and Zhao, 2008].  




	   	  
Figure	  3.17	  Setup	  of	  a	  xenotransplantation	  mouse	  model	  for	  analysis	  of	  human	  HSCs	  
(A)	   Scheme	   for	   the	   workflow	   of	   generation	   and	   analysis	   of	   mouse/human	   bone	   marrow	   chimeras	   (B)	   Gating	  
strategy	  on	  mouse	  and	  human	  CD45	  positive	  cells	  by	  FACS	  analysis;	  bone	  marrow	  cells	  of	  transplanted	  NSG	  mouse	  
(C)	   Gating	   strategy	   on	  human	   stem	   (HSC)	   and	  progenitor	   cells	   (MPP)	   pre-­‐gated	  on	   lineage	   negative	   cells.	  Gating	  





We monitored engraftment efficiency of human cells in the mouse by 
FACS analysis of cells isolated from the peripheral blood from eight weeks post 
transplantation and performed analysis of the mice after different treatments from 
12 to 14 weeks after transplantation (Fig 3.17 A). 
To identify human cells, antibodies specific for mouse or human CD45, 
the common leukocyte antigen, which is present on almost all hematopoietic 
cells, were used (Fig 3.17 B). Human HSCs were defined as 
hCD45+linnegCD34+CD38- (CD34+CD38-) and progenitor cells as 
hCD45+linnegCD34+CD38+ (CD34+CD38+). Ki67/Hoechst cell cycle analysis 
showed that a higher proportion of HSCs were in the G0-phase of the cell cycle 
(Ki67loHoechstlo) compared to progenitor cells (Fig 3.17 C). Similarly a smaller 
fraction of HSCs was in S-phase of the cell cycle (Ki67hiHoechsthi) compared to 
progenitor cells. As Thy-1 (CD90) was proposed to enrich for human HSCs in 
combination with CD34 [Murray et al., 1995], we compared the cell cycle profile 




	   	  
of CD34+CD38-CD90+ cells with CD34+CD38- HSCs, but did not observe any 
further enrichment for quiescent cells (data not shown).  
 Notably the proportion of quiescent human HSCs was much lower than in 
mouse HSCs. While about 80% of mouse LSK SLAM HSCs are in the G0 phase of 
the cell cycle during homeostasis, only about 20% of human CD34+CD38- HSCs 
were found to be in G0 in xenotransplanted mice (Fig 3.19 C). To determine 
whether, similar to mouse HSCs, also a proportion of human HSCs in our 
xenotransplantation assays is long term dormant, we performed BrdU label 
retaining assays. Therefore mice were supplied with BrdU in the drinking water 
for 10 days to label all HSCs, followed by a BrdU-free chase period of 3 weeks, in 
which cells dividing in this time frame loose their label. We did not detect any 
BrdU positive human HSCs after the chase period, indicating that there are no 
human HSCs in the mouse that remain long term quiescent (data not shown). 
Notably this absence of quiescent cells cannot be explained by the 
transplantation process itself, as mouse HSCs show cell cycle distributions similar 
to homeostatic conditions 12 weeks after transplantation (Fig 3.12 C).  
 
3.5.1 Effect of human type I interferon on human HSCs 
Currently there are more than 13 different subtypes of IFNα described in 
humans, with IFNα 2a and IFNα 2b being the most commonly used in the clinic 
[Genin et al., 2009; Woelk et al., 2007]. Therefore we decided to use IFNα 2a to 
elucidate the effect of type I IFN on human HSCs. To investigate whether human 
IFNα activates human HSCs we injected xenotransplanted mice 12-20 weeks after 
transplantation with PBS or 10.000 of IFNα 2a (Roche) subcutaneously, and 
analyzed the cell cycle distribution and BrdU incorporation by FACS analysis 16 
hours later. We observed neither differences in cell cycle distribution by 
Ki67/Hoechst analysis nor an increase in BrdU incorporation (Fig 3.18 and data 
not shown). As the dosage of IFNα is critical for activation of HSCs we next 
administered IFNα in different doses, ranging from 10.000 to 100.000U, but did 
not observe any activation with any of these doses (Fig 3.18). Notably murine 




	   	  
HSCs are activated already by IFNα doses as low as 10U and are fully activated 
with 1000U [Essers et al., 2009]. 
Activation of HSCs in the mouse by IFNα is very rapid, with HSCs entering 
an active cell cycle already 16 hours after injection of IFNα. Notably kinetic 
analysis of BrdU uptake in mouse HSCs showed that the proportion of BrdU 
positive HSCs still increased until 48 hours after the injection [Essers et al., 2009]. 
To investigate whether human HSCs might be activated at a later time point after 
injection of IFNα, we performed a kinetic analysis. Therefore xenotransplanted 
mice were injected twice with IFNα 48 hours apart, and Ki67/Hoechst cell cycle 
analysis was performed 24 hours, 48 hours and 72 hours after the 2nd IFNα 
injection. We did not observe any decrease in the proportion of human HSCs in 
the G0 phase of the cell cycle at any of these time points (Fig 3.18).  
 
 
Figure	  3.18	  Ki67/Hoechst	  analysis	  of	  quiescent	  human	  HSCs	  following	  different	  treatments	  with	  IFNα 	  
Proportion	  of	  linnegCD34+CD38-­‐	  HSCs	  in	  the	  G0	  phase	  of	  the	  cell	  cycle	  in	  a	  Ki67/Hoechst	  FACS	  analysis,	  isolated	  from	  
the	  bone	  marrow	  of	  xenotransplanted	  NSG	  mice.	  16	  hours	  after	  subcutaneous	  injection	  of	  PBS,	  10.000,	  50.000	  or	  
100.000U	  of	   IFNα	  2a;	  48	  and	  72	  hours	  after	   two	   injections	  of	   IFNα	  at	   -­‐48	  hours	  and	  0	  hour	  time	  point;	  16	  hours	  
after	  injection	  of	  pegylated	  IFNα	  2b	  (Intron	  A)	  and	  16	  hour	  after	  i.p.	  injection	  of	  poly-­‐(I)-­‐(C)	  or	  i.p.	  injection	  of	  poly-­‐






















































	   	  
The half-life of IFNα in human patients is very short, declining within 
hours after injection. Attachment of a polyethylene glycol moiety to IFNα results 
in a compound (pegylated IFNα) that has sustained absorption, a slower rate of 
clearance, and a longer half-life than unmodified IFNα [Nieforth et al., 1996; 
Reddy, 2004]. Due to these benefits pegylated IFNα replaced the use of 
recombinant IFNα in many clinical applications including treatment for hepatitis 
B and C viral infections [Zeuzem et al., 2000]. To address whether pegylated 
IFNα showed more prominent effects on human HSCs we injected 
xenotransplanted mice with PBS or pegylated IFNα 2b. Similarly to recombinant 
IFNα we did not observe cell cycle activation in human HSCs (Fig 3.18).  
One major difference between mouse and human HSCs in our 
xenotransplantation model is the foreign mouse niche environment for human 
HSCs. Notably the bone marrow niche does play a crucial role in the activation of 
murine HSCs, however its exact contribution to the activation process is currently  
unknown. It is possible that human IFNα does not efficiently activate the mouse 
niche cells and therefore signals by niche cells are missing that are required for 
activation of human HSCs. To exclude this possibility, xenotransplanted mice 
were injected subcutaneous with human IFNα 2a and intraperitoneal with pIC, 16 
hours before analysis. This additional injection of pIC activates mouse HSCs and 
potentially niche cells at the time point of treatment with human IFNα. 
Ki67/Hoechst analysis as well as BrdU incorporation showed efficient activation 
of mouse HSCs after treatment with pIC as well as pIC and IFNα, whereas we did 
not observe any effect on quiescent human HSCs (Fig 3.18 and data not shown).  
Human IFNα 1 was previously reported to have cross-species activity in 
mouse and humans cells and was shown to induce the Mx promoter in the MxCre 
mouse line [Kuhn et al., 1995]. Therefore we further tested the effects of this 
subtype on human HSCs in our xenotransplantation model. Mice were injected 
subcutaneously with 100.000U of IFNα 1b and 16 hours later the cell cycle 
profile was analyzed by FACS analysis. Similar to treatment with other IFNα 
subtypes we did not observe activation of human HSCs with neither IFNα 1b nor 




	   	  
combination of IFNα 1b + pIC (Fig 3.19 A+C). Interestingly mouse HSCs were not 
only activated following treatment with IFNα 1b + pIC but also to a lower degree 
by IFNα 1b alone, confirming the cross species specificity of this interferon alpha 
subtype (Fig 3.19 B+C). 
 
Figure	  3.19	  Ki67/Hoechst	  cell	  cycle	  analysis	  of	  human	  HSCs	  following	  different	  treatments	  with	  IFNα  1b	  
Cell	  cycle	  analysis	  of	  human	  linnegCD34+CD38-­‐	  HSCs	  (A)	  and	  mouse	  LSK	  SLAM	  HSCs	  (B)	  16	  hours	  after	  treatment	  of	  
xenotransplanted	   mice	   with	   PBS	   or	   pIC	   +	   human	   IFNα	   1b.	   (C)	   Quantification	   of	   human	   linnegCD34+CD38-­‐	   HSCs,	  
linnegCD34+CD117+	  HSCs	  and	  mouse	  LSK	  SLAM	  HSCs	  in	  the	  G0	  phase	  of	  the	  cell	  cycle	  16	  hours	  after	  injection	  of	  PBS,	  
IFNα	  1b	  or	  pIC	  +	  IFNα	  1b.	  




	   	  
In summary in vivo administration of human IFNα did not lead to cell 
cycle activation of human HSCs in our xenotransplantation mouse model, neither 
alone nor in combination with pIC. 
 
3.5.2 Activation of human HSCs by LPS 
Administration of LPS in vivo leads to activation of mouse HSCs, at least 
partially independent of interferon type I and type II signaling [Marieke Essers, 
personal communication]. To elucidate the effects of LPS on human HSCs we 
injected xenotransplanted mice with LPS (5µg/mouse) and analyzed the 
phenotype as well as the cell cycle profile of human HSCs 24 hours later by FACS 
analysis. Strikingly the population of CD34+CD38- HSCs disappeared nearly 
entirely, very likely due to up-regulation of CD38 expression in previously 
CD34+CD38- HSCs (Fig 3.20 A). Interestingly expression of CD38 has previously 
been linked to activation of a variety of different hematopoietic cells types 
including B-cells, T-cells and Chronic lymphocytic leukemia cells [Deaglio et al., 
2010; Funaro et al., 1997; Funaro et al., 1990; Sandoval-Montes and Santos-
Argumedo, 2005]. 
Due to the induction of CD38 expression after LPS treatment, comparison 
of the cell cycle profile of CD34+CD38- HSCs in homeostasis and activated state is 
not possible. We therefore decided to define the human HSCs as CD34+CD117+ 
as we observed a strong inverse correlation between expression of CD38 and 
expression of CD117 in CD34+ human HSPCs (Fig 3.20 B) and expression of 
CD117 was less affected (slightly decreased) following LPS treatment. Back-gating 
analysis confirmed that CD34+CD38- HSCs were almost exclusively CD117+, 
while CD117- cells contained nearly no CD34+CD38- HSCs (Fig 3.20 C). As 
expected a larger proportion of CD34+CD117+ human HSCs was in G0 phase of 
the cell cycle during homeostasis compared to CD34+CD117- progenitor cells 
(data not shown). 
Strikingly Ki67/Hoechst cell cycle analysis showed a marked decrease in 
quiescent CD34+CD117+ human HSCs following in vivo treatment with LPS (Fig. 




	   	  
3.20 D+E). Thus unlike IFNα, LPS can activate human HSCs in our 
xenotransplantation model. 
 
Figure	  3.20	  Activation	  of	  human	  HSCs	  by	  LPS	  
(A)	  Polychromatic	  FACS	  blot	  of	  human	  lineage	  negative	  cells	  24	  hours	  after	   in	  vivo	  treatment	  with	  PBS	  or	  LPS.	  (B)	  
Correlation	  of	  expression	  of	  CD38	  and	  CD117	  within	  linnegCD34+	  (C)	  Back-­‐gating	  analysis	  of	  CD117+	  and	  CD117-­‐	  cells	  
on	  human	  lineage	  negative	  cells.	  (D)	  Example	  for	  cell	  cycle	  distribution	  of	  human	  linnegCD34+CD117+	  HSCs	  24	  hours	  
after	  treatment	  with	  PBS	  or	  LPS.	  (E)	  Quantification	  of	  human	  linnegCD34+CD117+	  HSCs	  in	  G0	  phase	  of	  the	  cell	  cycle,	  
24	  hours	  after	  treatment	  with	  PBS	  or	  LPS.	  




	   	  
3.5.3 Effects of type II and type III interferon and TNFα on human HSCs 
Beside IFNα and LPS, also IFNγ has recently been shown to activate HSCs 
in the mouse in vivo [Baldridge et al., 2010]. Moreover also TNFα was proposed 
as another potential regulator of HSC activation [Baldridge et al., 2011]. While 
similar to IFNα and IFNγ also TNFα inhibits proliferation of HSPCs in vitro 
[Jacobsen et al., 1994; Jacobsen et al., 1992; Zhang et al., 1995], recent reports 
suggest that its functions in vivo might be different [Pronk et al., 2011; Rezzoug et 
al., 2008]. 
To elucidate the effects of type II and type III interferon as well as TNFα on 
human HSCs, we injected xenotransplanted mice subcutaneously with human 
IFNγ (100.000U/mouse), IFNλ (IL28; 5µg/mouse), TNFα (10µg/mouse) or LPS, and 
analyzed the cycling behavior of mouse and human HSCs 24 hours later. Mouse 
HSCs were activated by treatment with IFNλ, TNFα as well as LPS, while we did 
not observe activation by IFNγ (Fig 3.21 A). Notably the activation by LPS was 
much stronger than by IFNλ or TNFα. Contrarily to mouse HSCs, human HSCs 
were only activated by LPS while we did not observe a decrease of cells in G0 
phase of the cell cycle with either IFNγ, IFNλ or TNFα. 
 
3.5.4 Gene expression profile of activated human HSCs  
As described above, we observed cell cycle activation of human HSCs in 
xenotransplanted mice only after treatment with LPS but not by type I, II and III 
interferons or TNFα, contrary to observations in mouse HSCs. One explanation 
for these differences between mouse and human HSCs is the foreign mouse niche 
environment for human HSCs in our xenotransplantation model, where critical 
direct cell-cell interaction or secreted factors, which are present in a human HSC 
niche, might be missing to achieve activation of human HSCs. As activation of 
HSCs by IFNα is complex and requires several signaling steps it could well be that 
human HSCs are not fully activated in the foreign niche, although their response 
to IFNα might still be partly intact.  
 




	   	  
Figure	  3.21	  Cell	  cycle	  profile	  of	  mouse	  and	  human	  HSCs	  following	  treatments	  with	  IFNγ ,  	  IFNλ ,	  TNFα 	  and	  LPS	  
Ki67/Hoechst	  cell	  cycle	  profile	  of	  mouse	  LSK	  CD150+	  and	  LSK	  SLAM	  HSCs	  (A)	  as	  well	  as	  of	  human	  linnegCD34+CD117+	  
HSCs	  (B)	  24	  hours	  after	  injection	  of	  IFNγ	  (100.000U/mouse),	  IFNλ (5µg/mouse),	  TNFα	  (10µg/mouse)	  and	  LPS.	  
To address this question and to gain more insight into the processes 
involved in activation of human HSCs, we performed microarray analysis of 
human hCD45+linnegCD34+CD117+ HSCs. Xenotransplanted mice were injected 
with PBS, IFNα 1b (100.000U), IFNα 1b (100.000U) + pIC or LPS. 16 hours later 
cells were isolated from the bone marrow and linnegCD34+CD117+ HSCs were 
sorted by FACS. Next RNA was isolated from these cells and microarray analysis 
performed.  
Comparison of gene expression data showed a higher variability between 
biological samples compared to the microarrays of mouse HSCs we performed 
earlier. Therefore we decided to accept a higher false discovery rate of 10% (5% 
for previous arrays) to be able to perform gene ontology analyses. We found 771 




	   	  
genes to be differentially regulated following administration of IFNα (10% FDR; 
23 genes 5% FDR), with 260 changed more than 1,5 fold, 1435 genes 
differentially regulated following administration of IFNα and pIC (10% FDR; 91 
genes 5% FDR), with 145 changed more than 1,5 fold and 411 genes following 
treatment with LPS (10% FDR; 108 genes 5% FDR), 107 changed more than 1,5 
fold. 
We found 260 genes to be differentially regulated (FDR 10%, FC>1,5) in 
human CD34+CD117+ HSC following IFNα treatment. Surprisingly only 2 of those 
genes showed increased expression, IFN inducible protein 27 (IFI27; 2,0x up) and 
IFN inducible gene 6 (IFI6; 1,7x up). On the contrary we observed induction of 
known interferon target genes after simultaneous treatment with IFNα + pIC as 
well as after treatment with LPS, similar to the changes previously observed in 
mouse HSCs (Tab 3.3 and 3.4). We therefore only included samples from mice 
treated simultaneously with IFNα + pIC or LPS in our gene ontology analysis. 
Interestingly STAT1 as well as several IFN target genes including IFIT3, 
OAS3 and other OAS family members and ISG15 were found amongst the highest 
induced genes after both treatment conditions. These results are highly similar to 
the genes up-regulated in mouse HSCs after activation by IFNα or LPS. Further 
similarities between mouse and human HSCs are the induction of CXCL10 after 
IFNα + pIC and CXCL9 after LPS stimulation. Surprisingly defensin genes were the 
strongest down-regulated genes on both conditions. Defensins are small proteins, 
which function as host defense peptides against viruses and bacteria and are 
induced during inflammatory processes in many tissues [Lehrer and Lu, 2012]. 
 
  




	   	  
Fold	  change	   Symbol	   Definition	   Synonyms	  
4.8	   IFI27	   interferon,	  alpha-­‐inducible	  protein	  27	   FAM14D;	  P27;	  ISG12	  
3.9	   ISG15	   ISG15	  ubiquitin-­‐like	  modifier	   G1P2;	  UCRP;	  IFI15	  
2.6	   IFIT3	   interferon-­‐induced	  protein	  with	  tetratricopeptide	  repeats	  3	   IFIT4;	  IRG2;	  RIG-­‐G;	  IFI60	  
2.5	   OAS3	   2'-­‐5'-­‐oligoadenylate	  synthetase	  3	   MGC133260;	  p100	  
2.3	   STAT1	   signal	  transducer	  and	  activator	  of	  transcription	  1	   ISGF-­‐3	  
2.2	   SIGMAR1	   sigma	  non-­‐opioid	  intracellular	  receptor	  1	   FLJ25585;	  SR-­‐BP1	  
2.2	   IFI6	   interferon,	  alpha-­‐inducible	  protein	  6	   IFI-­‐6-­‐16;	  6-­‐16;	  IFI616;	  G1P3	  
2.1	   OAS1	   2',5'-­‐oligoadenylate	  synthetase	  1	   OIAS;	  OIASI;	  IFI-­‐4	  
2.0	   OAS2	   2'-­‐5'-­‐oligoadenylate	  synthetase	  2	   MGC78578	  
2.0	   MX1	   myxovirus	  (influenza	  virus)	  resistance	  1	   MxA;	  IFI78;	  MX;	  IFI-­‐78K	  
1.9	   WARS	   tryptophanyl-­‐tRNA	  synthetase	   IFI53;	  IFP53;	  GAMMA-­‐2	  
1.8	   IFI44L	   interferon-­‐induced	  protein	  44-­‐like	   C1orf29;	  GS3686	  
1.8	   IFI30	   interferon,	  gamma-­‐inducible	  protein	  30	   IP30;	  GILT;	  IFI-­‐30	  
1.7	   IFITM3	   interferon	  induced	  transmembrane	  protein	  3	   1-­‐8U;	  IP15	  
1.7	   CXCL10	   chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  10	   IFI10;	  mob-­‐1;	  INP10;	  IP-­‐10	  
1.6	   STAT2	   signal	  transducer	  and	  activator	  of	  transcription	  2	   P113	  
1.5	   IFI44	   interferon-­‐induced	  protein	  44	   p44;	  MTAP44	  
-­‐1.7	   MAGED2	   melanoma	  antigen	  family	  D,	  2	   JCL-­‐1;	  BCG1;	  11B6	  
-­‐2.6	   DEFA1B	   defensin,	  alpha	  1B	   	  	  
-­‐2.9	   DEFA3	   defensin,	  alpha	  3,	  neutrophil-­‐specific	   HNP3;	  HNP-­‐3;	  DEF3;	  HP-­‐3	  
-­‐3.3	   DEFA1	   defensin,	  alpha	  1	   MRS;	  DEFA2;	  HP-­‐1;	  HNP-­‐1	  
Table	  3.3	  Differentially	  regulated	  genes	  in	  human	  CD34+CD117+	  HSCs	  16h	  after	  treatment	  with	  IFNα+pIC	  in	  vivo	  
Increase	  of	  gene	  expression	  in	  human	  CD34+CD117+	  HSCs	  FACS-­‐sorted	  from	  xenotransplanted	  mice,	  16	  hours	  after	  
treatment	  with	   IFNα	  +pIC	  compared	  to	  human	  HSCs	  from	  PBS	  treated	  mice;	  False	  discovery	  rate	  (FDR)	  <5%;	  blue	  
banded	  rows	  mark	  known	  interferon	  response	  genes.	  
As expected we did not find any cell cycle related genes differentially 
regulated after IFNα + pIC treatment in human HSCs, which correlates with the 
lack of cell cycle induction in these cells determined by FACS analysis. Strikingly 
however human HSCs from LPS treated xenotransplanted mice showed increased 
expression of the cyclin-dependent kinase inhibitors p19 (INK4D; CDKN2D), and 
p21Cip1 (CDKN1A) as well as of Cyclin D1 (CCND1), all of which are involved in 
regulation of cell cycle progression through the G1 and S transition. The cyclin 
dependent kinase inhibitor p21 plays an important role in controlling cell cycle 
progression during the G1 phase by inhibiting cyclin-CDK2/CDK1 complexes as 
well as the S phase by inhibiting activity of cyclin E-CDK4 and cyclin D1-
CDK4/CDK6 complexes [Harper et al., 1993; Sherr and Roberts, 1999]. Likewise 
p19 plays a crucial role during G1/S transition by forming complexes with CDK4 




	   	  
and CDK6 and preventing activation of these kinases. Its expression oscillates in a 
cell cycle dependent manner and is lowest during the G1 phase and highest 
during the S phase [Chan et al., 1995; Hirai et al., 1995]. Finally Cyclin D1 is 
crucial for G1/S transition as part of a complex with CDK4/6 [De Vivo et al., 
2011]. Increased expression of Cyclin D1 and p19 and p21 at the same time 
could be explained by a feedback loop, leading to a reacquisition of quiescence 
following the activation of HSCs. Notably in our analysis HSCs don’t progress 
through the cell cycle simultaneously. Hence the data can also be interpreted as 
an increased proportion of cells in either the G1 and S phase, compared to G0 
phase, where a part of the cells shows elevated levels of Cyclin D1 while another 
part shown elevated levels of p19/p21. To elucidate this possibility, analysis 
would have to be performed on a single cell level. 
 
Fold	  change	   Symbol	   Definition	   Synonyms	  
4.8	   UBD	   ubiquitin	  D	   UBD-­‐3;	  FAT10	  
3.6	   CXCL9	   chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  9	   MIG;	  Humig;	  CMK	  
3.5	   IFIT3	   interferon-­‐induced	  protein	  with	  tetratricopeptide	  repeats	  3	   ISG60;	  IRG2;	  RIG-­‐G;	  IFI60	  
2.9	   IFI27	   	  	   FAM14D;	  P27;	  ISG12	  
2.8	   OAS3	   2'-­‐5'-­‐oligoadenylate	  synthetase	  3	   MGC133260;	  p100	  
2.8	   DDIT4	   DNA-­‐damage-­‐inducible	  transcript	  4	   RTP801;	  Dig2;	  REDD1	  
2.7	   STAT1	   signal	  transducer	  and	  activator	  of	  transcription	  1	   ISGF-­‐3	  
2.6	   JUN	   jun	  oncogene	   AP1;	  c-­‐Jun	  
2.6	   WARS	   tryptophanyl-­‐tRNA	  synthetase	   IFI53;	  IFP53;	  GAMMA-­‐2	  
2.5	   ISG15	   ISG15	  ubiquitin-­‐like	  modifier	   G1P2;	  UCRP;	  IFI15	  
2.2	   ISG20	   interferon	  stimulated	  exonuclease	  gene	   CD25;	  HEM45	  
2.0	   E2F2	   E2F	  transcription	  factor	  2	   E2F-­‐2	  
1.8	   CDKN2D	   cyclin-­‐dependent	  kinase	  inhibitor	  2D	  (p19,	  inhibits	  CDK4)	   p19-­‐INK4D;	  INK4D;	  p19	  
1.8	   CDKN1A	   cyclin-­‐dependent	  kinase	  inhibitor	  1A	  (p21,	  Cip1)	   P21;	  MDA-­‐6;	  CIP1	  
1.8	   CCND1	   cyclin	  D1	   PRAD1;	  BCL1;	  U21B31	  
1.7	   IFI30	   interferon,	  gamma-­‐inducible	  protein	  30	   IP30;	  GILT;	  IFI-­‐30	  
1.6	   MDM2	   Mdm2	  p53	  binding	  protein	  homolog	   hdm2;	  HDMX	  
-­‐1.7	   PROM1	   prominin	  1	   AC133;	  PROML1;	  CD133	  
-­‐2.6	   DEFA1B	   defensin,	  alpha	  1B	   	  
-­‐2.7	   DEFA3	   defensin,	  alpha	  3,	  neutrophil-­‐specific	   HNP3;	  DEF3;	  HP-­‐3	  
-­‐3.2	   DEFA1	   defensin,	  alpha	  1	   MRS;	  DEF1;	  HP-­‐1;	  HNP-­‐1	  
Table	  3.4	  Differentially	  regulated	  genes	  in	  human	  CD34+CD117+	  HSCs	  16h	  after	  treatment	  with	  LPS	  in	  vivo	  
Increase	  of	  gene	  expression	  in	  human	  CD34+CD117+	  HSCs	  FACS-­‐sorted	  from	  xenotransplanted	  mice,	  16	  hours	  after	  
treatment	  with	  LPS	  compared	  to	  human	  HSCs	  from	  PBS	  treated	  mice;	  False	  discovery	  rate	  (FDR)	  <5%;	  blue	  banded	  
rows	  mark	  known	  interferon	  response	  genes.	  




	   	  
Gene ontology analysis highlighted immune responses and response to IFN 
as the most prominently changed processes after both IFNα + pIC as well as LPS 
treatment (Fig 3.22 A). Comparison of GO networks and processes showed a 
higher induction of processes involved in antigen presentation and responses to 
RNA viral infection after treatment with IFNα + pIC (Fig. 3.22 B). Strikingly 
processes involved in proliferation and G1/S transition were highly induced after 
LPS treatment while they were not affected after administration of IFNα and pIC 
(Fig 3.22 B). This finding reflects the cell cycle induction by LPS, which was not 
observed after treatment with IFNα and pIC. 
In summary the changes in gene expression patterns of human HSCs in our 
xenotransplantation mouse model after simultaneous treatment with IFNα + pIC 
or treatment with LPS reflect the changes observed in mouse HSCs. As expected 
in both human and mouse HSCs induction of interferon response genes and genes 
involved in immune responses are the most prominently changed genes. Notably 
the CIP/KIP family of kinase inhibitors seems to be crucial for regulation of the 
cell cycle after IFNα or LPS treatment, with expression of p57KIP2 affected in 
mouse HSCs and p21CIP in human HSCs. Interestingly the same family was 
recently shown to be crucial for regulation of HSC quiescence during homeostasis 
[Tesio and Trumpp, 2011]. 
As a next step it will be crucial to compare the expression profile of mouse 
HSCs and human HSCs after IFNα treatment in detail. While mouse HSCs are 
activated by IFNα, human HSCs seem to respond only partly e.g. by expression of 
IFNα response genes, but show no induction of the cell cycle. Investigating these 
differences will not only help us understand why human HSCs are not efficiently 
activated in this xenotransplantation model, but also help us to understand the 
activation process in mouse HSCs in more detail. Additionally comparison of 
these gene expression profiles could also provide valuable new insight into the 
involvement of cells of the stem cell niche, as human cells in our 
xenotransplantation model might miss crucial crosstalk with surrounding mouse 
cells. 




	   	  
 
Figure	  3.22	  Gene	  ontology	  analysis	  of	  human	  HSCs	  after	  treatment	  with	  IFNα 	  +	  pIC	  or	  LPS	  
(A)	  Most	  significantly	  changed	  GO	  processes	   in	  human	  CD34+CD117+	  HSCs,	  16	  hours	  after	  treatment	  of	  mice	  with	  
LPS;	   analyzed	  with	  Metacore	   software	  V6.10	   (Thomson	  Reuters).	  Orange	  bars	   represent	  p-­‐values	   for	   LPS	   treated	  
HSCs.	  Fold	  change	  >1.5	  and	  FDR<10%	  (B)	  Comparison	  of	  process	  networks	  changed	   in	  CD34+CD117+	  human	  HSCs	  
after	  in	  vivo	  treatment	  of	  xenotransplanted	  mice	  with	  IFNα	  +	  pIC	  (orange	  bars)	  or	  LPS	  (blue	  bars).	  Fold	  change	  >1.5	  
and	  FDR<10%	  
  




	   	  
3.6 Activation of leukemic stem cells in a mouse model of CML 
Chronic myeloid leukemia (CML) is characterized by a chromosomal 
translocation, leading to the formation of the BCR-Abl fusion kinase [Daley et al., 
1990]. Inhibition of BCR-Abl by tyrosine kinase inhibitors (TKI) like Imatinib 
specifically targets BCR-Abl expressing leukemic cells (LSCs) and leads to rapid 
hematologic and cytogenetic responses [O'Brien et al., 2003]. Nonetheless, LSCs 
are not efficiently eliminated by TKI treatment, and residual LSCs can lead to 
relapse of the disease if the treatment is discontinued [Goldman, 2009]. One 
possible reason for the resistance of LSCs is their dormancy, which seems to be 
similar to the resistance of quiescent HSCs in the mouse to cytotoxic substances. 
Interestingly mathematical modeling on the effects of TKI treatment in CML 
suggests that the resistance of leukemic clones can be explained by a selective 
effect of TKIs exclusively on proliferating cells [Roeder et al., 2006]. Strikingly this 
model further suggests that activation of leukemic stem cells in combination with 
TKI treatment might fully eradicate all leukemic clones. As recently shown IFNα 
can efficiently drive quiescent HSCs into proliferation in vivo [Essers et al., 2009]. 
Therefore activation of LSCs by IFNα followed by targeted therapy with TKIs 
might be a way to eliminate LSCs and lead to a cure of the disease. 
To get further insight on the feasibility of such combination therapies we 
investigated the effects of IFNα on leukemic stem cells in a mouse model for 
chronic myeloid leukemia [Koschmieder et al., 2005]. In these SCLtTA/BCR-Abl 
mice the transactivator protein tTA is under the control of the murine stem cell 
leukemia (SCL) gene 3’ enhancer, and the P210 BCR-Abl transgene under control 
of a tet-responsive element (TRE). This allows to induction of human BCR-Abl 
expression specifically in hematopoietic stem and progenitor cells by withdrawal 
of Doxycycline (Fig 3.23). 
To confirm the induction of a CML like disease in these mice, Dox 
treatment was stopped in 4 week-old mice and mice were analyzed 6 weeks later 
for signs of leukemia. As expected spleen size in double transgenic (dtg) mice, 




	   	  
carrying the SCLtTA and the BCR/ABl transgene, was increased compared to 
single transgenic (stg) littermate controls, carrying only one of the transgenes (Fig 
3.24 A+B).  
As reported [Koschmieder et al., 2005] the number of LSK HSPCs 
increased in double transgenic mice in the bone marrow as well as in the spleen 
(Fig 2.23). Furthermore we observed an increase in mature CD11b+Gr1hi 
granulocytes as well as immature CD11b+Gr1lo granulocytes in both bone marrow 
and spleen of double transgenic animals, thus confirming published data on these 
mice (Fig 3.24 D). Moreover the number of B-cells was decreased in double 
transgenic animals in bone marrow and spleen, and the number of erythrocytes 




Figure	  3.23	  SCLtTA/BCR-­‐ABL	  mouse	  model	  for	  chronic	  myeloid	  leukemia	  
Mice expressing the tet trans-activator protein tTA under control of the Stem cell leukemia gene (SCL) 3’ 
enhancer were crossed with mice carrying the BCR-ABL transgene under control of a tet responsive element 
(TRE). Upon withdrawal of Doxycycline, double transgenic litters express the BCR-ABL transgene specifically 
in stem and progenitor cells of the hematopoietic system. 
 
  




	   	  
Figure	  3.24	  Analysis	  of	  leukemia	  in	  SCLtTA/BCR-­‐ABL	  double	  transgenic	  mice	  6	  weeks	  off	  Dox	  treatment	  
(A)	  Spleen	  weight	  of	  single	  transgenic	  (stg;	  either	  SCLtTA	  or	  BCR-­‐ABL)	  and	  double	  transgenic	  (dtg;	  SCLtTA	  and	  BCR-­‐
ABL	   transgene)	   mice,	   6	   weeks	   after	   discontinuation	   of	   Dox	   treatment.	   (B)	   Picture	   of	   spleens	   from	   stg	   and	   dtg	  
animals	  (C)	  FACS	  analysis	  of	  LSK	  cells	  in	  the	  bone	  marrow	  of	  stg	  and	  dtg	  mice	  and	  quantification	  of	  analysis	  in	  bone	  
marrow	  and	  spleen.	  (D)	  FACS	  analysis	  of	  mature	  CD11b+Gr-­‐1hi	  and	  immature	  CD11b+Gr-­‐1lo	  granulocytes	  in	  the	  bone	  
marrow	  of	  stg	  and	  dtg	  mice	  and	  quantification	  of	  analysis	  in	  bone	  marrow	  and	  spleen.	  
Notably we observed high variation in the onset of leukemia between 
different batches of mice, with some mice having string signs of leukemia 6 weeks 
after stop of Doxycycline, while other mice did not show signs of disease 12 




	   	  
weeks after Doxycycline stop. A high variation in the aggressiveness of the 
disease was already previously described by Koschmieder and colleagues 
[Koschmieder et al., 2005]. This variability in the onset of the disease could be 
explained due to different expression levels of - between mice homozygous or 
heterozygous for the transgenes as well as by different levels of expression in 
individual mice. 
	  
3.6.1 Establishment of a transplantation model for leukemic cells 
A big caveat of the SCLtTA/BCR-ABL mouse model is that all HSC and 
progenitor cells in double transgenic animals express the BCR-ABL transgene and 
are potential leukemic stem cells. While treatment of double transgenic mice with 
Imatinib temporarily leads to normalization of blood counts, upon cessation of 
the treatment the BCR-ABL transgene is re-expressed and the leukemia relapses 
[Schemionek et al., 2010]. As there are no wild type HSCs which can take over 
the place of LSCs during treatment with the TKIs and lead to potential cure of this 
disease in this model, it is not suitable to investigate a combination therapy with 
IFNα and Imatinib. 
To model chronic myeloid leukemia more closely resembling the situation 
in human patients, we generated mixed bone marrow chimeras, harboring wild 
type HSCs and CML LSCs from SCLtTA/BCR-ABL double transgenic mice. 
Therefore FVB/N wildtype mice were lethally irradiated with 2x 500 rad and 24 
hours later transplanted with a mixture of 50% FVB/N wildtype and 50% 
SCLtTA/BCR-ABL single or double transgenic unfractionated bone marrow cells. 
Dox treatment was stopped directly after transplantation. Seven weeks after 
transplantation cell counts in peripheral blood were analysed. 
  




	   	  
 
Figure	  3.25	  Analysis	  of	  SCLtTA/BCR-­‐ABL	  bone	  marrow	  chimeras	  
(A)	   Analysis	   of	   cell	   counts	   in	   peripheral	   blood	   of	   mixed	   bone	  marrow	   chimeras	   from	   SCLtTA/BCR-­‐ABL	   single	   or	  
double	   transgenic	  mice	   and	   FVB/N	  wildtype	  mice,	   7	  weeks	   after	   cessation	   of	   Doxycycline	   treatment;	   cell	   counts	  
were	   determined	   with	   a	   Hemavet	   counter	   (Drew	   Scientific)	   (B)	   Analysis	   of	   mixed	   bone	   marrow	   chimeras	   from	  
SCLtTA/BCR-­‐ABL	  single	  or	  double	  transgenic	  mice	  and	  FVB/N	  wildtype	  mice,	  11	  weeks	  after	  cessation	  of	  Doxycycline	  
treatment;	  Lineage	  negative	  cells,	  LSK	  cells,	  granulocytes	  and	  erythrocytes	  were	  analyzed	  by	  FACS	  analysis.	  	  




	   	  
Mice transplanted with bone marrow from double transgenic mice showed 
increased numbers of total white blood cells, monocytes as well as neutrophils, 
while mice transplanted with bone marrow from single transgenic mice showed 
no increase (Fig 3.25 A). Four weeks later we analyzed spleen and bone marrow. 
Spleen weight was slightly increased in double transgenic bone marrow chimeras, 
but less pronounced than in SCLtTA/BCR-ABL mice at the same time point (Fig 
3.25 B). Similarly the number of LSK cells was slightly increased in double 
transgenic mice.  Interestingly we observed a strong increase in the number of 
undifferentiated lineage negative cells (Fig 3.25 B). This could potentially be due 
to inability of leukemic blasts to fully differentiate. Notably we further observed a 
strong increase in immature CD11b+Gr-1lo and mature CD11b+Gr-1hi granulocytes 
and a strong decrease of erythrocytes in bone marrow of double transgenic mice. 
Taken together FVB/N mice transplanted with a mixture of wildtype cells 
and SCLtTA/BCR-ABL double transgenic cells develop a CML like disease within 
few weeks after transplantation. They show an increase of white blood cells, 
especially monocytes and granulocytes, as well as strong symptoms of anemia 
while the increase in spleen size was only modest. 
 
3.6.2 Activation of leukemic stem cells by IFNα 
While healthy HSCs are efficiently activated by IFNα in vivo in the mouse, 
the effect of IFNα on LSC is still unknown. To investigate whether IFNα activates 
leukemic stem cells in our model of CML, we injected SCLtTA/BCR-ABL single or 
double transgenic mice 8-12 weeks after cessation of Dox treatment with 
poly-(I)-(C) and analyzed HSPCs 16 hours later by FACS analysis.  
As expected Ki67/Hoechst cell cycle analysis revealed a decrease of single 
transgenic LSK cells in G0 phase and an increase of LSK cells in S phase of the cell 
cycle after treatment with poly-(I)-(C) (Fig. 3.26 C). This increase was far less 
pronounced in LSK cells from double transgenic animals. Notably only in a part 
of double transgenic mice cell cycle was induced in HSPCs, while all single 
transgenic mice showed a decrease of quiescent HSCs (Fig 3.26 D). Moreover, 




	   	  
single transgenic mice showed an up-regulation of Sca-1 expression similar to 
wild type FVB/N mice (Fig 3.26 A). Interestingly amongst SCLtTA/BCR-ABL 
double transgenic mice only few showed an increase in Sca-1 expression similar 
to the Sca-1 expression levels observed in single transgenic mice, while in the 
majority of double transgenic mice showed unchanged levels of Sca-1 expression 
(Fig 3.26 A). Similarly an increase of phenotypic LSK cells was only observed in a 
few double transgenic mice, while all single transgenic mice had increased 
proportions of LSK cells (Fig 3.26 B). This suggests that, unlike normal HSCs, 
leukemic stem cells in our CML mouse model are not uniformly activated by 
IFNα. 
Interestingly a recent report showed that expression of BCR-ABL 
desensitizes CML cells to IFNα by accelerating the degradation of its receptor in 
vitro [Bhattacharya et al., 2011]. A similar degradation of the IFNα receptor in 
vivo could thus explain why LSC that express BCR-ABL are not efficiently 
activated. 
Strikingly only a part of double transgenic SCLtTA/BCR-ABL mice did not 
respond, while other mice showed activation of HSPC similar to wild type mice. 
This is in concordance with the variation in onset of leukemia that we observed. 
Both phenotypes could be dependent on the level of BCR-ABL expressed in 
individual mice. Importantly our genotyping strategies do not currently show, 
whether mice are homo- or heterozygous for the BCR-ABL transgene. In future 
studies it will be crucial to employ such PCR strategies to set up mating strategies 
with less variability in BCR-ABL expression. Furthermore monitoring BCR-ABL 
expression in individual mice e.g. by quantitative Real-time PCR could allow even 
more accurate measurements. 
Notably inhibition of BCR-ABL kinase activity by the TKI Imatinib 
increased the anti-proliferative effects of IFNα on CML cells in vitro [Bhattacharya 
et al., 2011]. This finding is very interesting as it suggests that treatment with TKIs 
might render leukemic stem cells again susceptible to activation by IFNα also in 
vivo, by preventing the degradation of the IFNα-receptor. Hence the exact timing 




	   	  
for the administration of IFNα and TKIs in combination therapies might be 




Figure	  3.26	  Effects	  of	  IFNα 	  treatment	  leukemic	  stem	  cells	  in	  SCLtTA/BCR-­‐ABL	  mice	  
(A)	  FACS	  analysis	  of	  LSK	  cells	  in	  single	  and	  double	  transgenic	  SCLtTA/BCR-­‐ABL	  mice,	  16	  hours	  after	  in	  vivo	  treatment	  
with	  PBS	  or	  poly-­‐(I)-­‐(C).	  (B)	  Quantification	  of	  LSK	  cells	  determined	  by	  FACS	  analysis	  in	  single	  and	  double	  transgenic	  
SCLtTA/BCR-­‐ABL	  mice,	  16	  hours	  after	  in	  vivo	  treatment	  with	  PBS	  or	  poly-­‐(I)-­‐(C).	  (C)	  Cells	  cycle	  profile	  determined	  by	  
Ki67/Hoechst	  cell	  cycle	  analysis	  of	  LSK	  cells	  of	  single	  and	  double	  transgenic	  SCLtTA/BCR-­‐ABL	  mice,	  16	  hours	  after	  in	  
vivo	   treatment	  with	   PBS	  or	   poly-­‐(I)-­‐(C).	   (D)	  Quantification	  of	   LSK	   cells	   determined	  by	   FACS	   analysis	   in	   single	   and	  










	   	  
3.7 Effects of IFNα  on stem cells in the skin 
The hematopoietic system was the first where two different pools of stem 
cells were described. On one hand homeostatic HSCs, which are crucial for the 
maintenance of the hematopoietic system, and on the other hand dormant HSCs, 
which are cycling very infrequently but are crucial for response to injuries 
[Wilson et al., 2008]. Recently similarly to the hematopoietic system different 
roles for populations of more actively cycling and dormant stem cells have also 
been proposed for tissue stem cells in the intestine and skin [Fuchs, 2009; Takeda 
et al., 2011; Tian et al., 2011].  
The signals regulating the balance of activated and dormant tissue stem 
cells are still largely unknown. As IFNα can potently activate HSCs in vivo we 
decided to elucidate whether it has similar effects on stem cells in the skin. 
Therefore C57BL/6 mice were twice injected poly-(I)-(C) i.p., 3 days and 24 hours 
before analysis. The skin was isolated and digested over night in trypsin to 
separate the epidermis from the dermis. The epidermis was scratched off, cells 
were suspended and used for FACS analysis. Stem cells in the skin are highly 
enriched within the CD34+α6-integrinhi as well as CD34+α6-integringlow 
population, which contain nearly all quiescent label-retaining cells of the 
epidermis [Blanpain et al., 2004]. As expected during homeostasis only CD34- 
cells expressed Ki67, while no Ki67 expression was detectable in either CD34+α6-
integrinhi or CD34+α6-integringlow skin stem cells (Fig 3.27 A). We did not observe 
any change of Ki67 expression following treatment with poly-(I)-(C) in skin stem 
cells (Fig 3.27 B). Notably as expected HSCs were highly activated and actively 
cycling in the same mice (Data not shown). 
Besides IFNα also bacterial infections and LPS treatment activate HSCs. To 
elucidate the effect of LPS on stem cells in the skin mice were injected LPS and 
skin stem cells were isolated 24 hours later. Similarly to poly-(I)-(C) also LPS 
activated HSCs as expected, but CD34+α6-integrinhi and CD34+α6-integringlow 
skin stem cells did not show any up-regulation of Ki67 expression (Fig 3.27). 




	   	  
In summary systemic in vivo treatment with either poly-(I)-(C) or LPS did 
not activate stem cells in the skin. These findings suggest that stem cells from 
other regenerative organs beside the hematopoietic system are not activated by 




Figure	  3.27	  Effects	  of	  IFNα 	  and	  LPS	  treatment	  on	  stem	  cells	  of	  the	  skin	  
(A)	   FACS	   gating	   strategy	   and	  Ki67	   expression	   in	   7AAD-­‐CD34+α6-­‐integrinhi	   and	   7AAD-­‐CD34+α6-­‐integrinlo	   stem	   cells	  
from	  the	  epidermis.	  (B)	  Ki67	  expression	  in	  7AAD-­‐CD34+	  skin	  stem	  cells	  from	  C57BL/6	  mice	  after	  two	  i.p.	  injections	  of	  
PBS	   or	   poly-­‐(I)-­‐(C)	   3	   days	   and	   24	   hours	   before	   analysis.	   (C)	   Ki67	   expression	   in	   7AAD-­‐CD34+	   skin	   stem	   cells	   from	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4 DISCUSSION 
4.1 Novel insights into IFNα-induced HSC activation 
In the mouse the majority of HSCs is quiescent during homeostasis, 
however they can be rapidly activated by IFNα in vivo. This activation of HSCs by 
IFNα is dependent on the IFNα−receptor, STAT1 as well as Sca-1 [Essers et al., 
2009]. Additionally the HSC bone marrow niche plays an important role in the 
activation of HSCs by IFNα, as isolated HSCs are not activated by IFNα in vitro. 
Importantly the exact mechanism leading to cell cycle activation within HSCs is 
currently still unknown. Moreover while the interaction of IFNα and the 
IFNα-receptor on HSCs is crucial for the activation, it is still unclear how the bone 
marrow niche and other extra cellular factors play into this activation process. 
Therefore to better understand the activation of HSCs by IFNα in vivo we 
performed microarray analysis of FACS purified LK SLAM HSCs 16 hours after 
treatment with IFNα (Fig 3.1). As expected the most prominent gene ontology 
networks induced by IFNα within HSCs were known IFN response genes (Fig 3.2 
and Tab 3.1). Furthermore the expression of the cytokines Cxcl10 and Ccl5 was 
induced, while the expression of the extracellular matrix protein Matrilin 4 and of 
several cell cycle regulating genes was reduced in a Sca-1 dependent manner 
(Tab 3.1). 
 




	   	  
4.1.1 Potential roles of interferon response genes in HSC activation 
While the exact function of many of the interferon response genes is still 
elusive, a few of them are particularly interesting in regards to activation of HSCs 
by IFNα, as they have been linked to regulation of proliferation in other contexts. 
Amongst these genes are the RNA sensor Rig-I (Ddx58), the interferon-induced 
protein 44 (Ifi44) and the Lrg47 family of proteins (Iigp1 and Irgm) as well as the 
Ifitm family members Ifitm1 and Ifitm3, which are described in more detail in 
chapter 4.2 (Tab 3.1). 
The DEAD-box protein 58 (DDX58), also known as retinoic acid-inducible 
gene 1 protein (Rig-I), is strongly induced in LK SLAM HSCs after IFNα treatment 
(Fig 3.15). It is a key receptor for intracellular RNA and a sensor of RNA viral 
infection, and further crucial in the induction of type I IFN responses as well as 
other inflammatory cytokines during viral infections via Irf3/7 and NF-κB 
pathways, respectively [Takeuchi and Akira, 2008]. Strikingly recent reports 
however linked Rig-I to a novel role independent of viral infections. Rig-I is a 
negative regulator of proliferation and survival of granulocytes during terminal 
granulocytic differentiation in acute myeloid leukemia and disruption of Rig-I in 
mice leads to development of a myeloproliferative disorder [Zhang et al., 2008b]. 
Furthermore Rig-I negatively regulates AML leukemia cell proliferation, by 
inducing activation of STAT1 [Jiang et al., 2011]. While similar to RIG-I also IFNα 
has anti-proliferative effects on differentiated cells, it conversely has 
pro-proliferative effects on HSCs in vivo. It is therefore tempting to speculate that 
Rig-I might also have different effects on HSCs or that even the cell cycle 
activation by IFNα is mediated by regulation of STAT1 signaling via Rig-I. 
Similar to Rig-I also Ifi44 is associated with viral infections however its 
function is less well described [Hallen et al., 2007]. Interestingly Ifi44 expression 
is enriched in LK SLAM HSCs already during homeostasis and further highly 
induced after treatment with IFNα (Fig 3.16). Overexpression of Ifi44 induces an 
anti-proliferative state in vitro, even in cells unresponsive to IFNα [Hallen et al., 
2007].  




	   	  
Another highly induced family of IFN response genes with a recent link to 
HSC regulation is the family of interferon-inducible GTPases Iigp1, Iigp2, Igtp 
(Irgm3) and Irgm (Iigp3). They are members of the p47 family of GTPases, which 
are key mediators of immune defense against intra-cellular pathogens 
[MacMicking, 2004; Taylor et al., 2004]. All four family members are highly 
induced after IFNα treatment in LK SLAM HSCs (Tab 3.1). Furthermore expression 
of Iigp1 was highly enriched within HSCs already during homeostasis (Fig 3.15). 
Strikingly Irgm is crucial for the regulation of baseline proliferation in HSCs and 
HSCs deficient for Irgm are hyper-proliferative and functionally impaired. 
Moreover HSCs deficient for Irgm do not normally respond to infectious stimuli 
like IFNγ. [Feng et al., 2008] Irgm is a negative regulator of IFNγ signaling, and 
deletion of the IFNγ-receptor in Irgm deficient mice rescues the phenotype in 
HSCs [King et al., 2011]. Whether other p47 family members might play similarly 
critical roles in regulation of IFNα induced HSC activation is still unknown. 
In summary most of the IFN response genes were traditionally associated 
with immune defense mechanisms against intra-cellular pathogens, especially 
viruses. However some of these genes – including Rig-I, the p47-GTPase family or 
Ifi44 – might also play a role in HSCs unrelated to viral infection. While they all 
have anti-proliferative effects in vitro similar to IFNα, their role in vivo especially 
in HSCs is still elusive and needs to be further investigated. 
One way to address this questions could be lenti-viral overexpression or 
shRNA mediated knock-down of these genes in HSCs. Notably Elisa Laurenti in 
our laboratory recently developed a system which allows inducible 
overexpression or knock-down of genes specifically in HSCs in vivo [Laurenti et 
al., 2010]. In this model HSCs are harvested from tTR-KRAB mice, expressing a 
doxycycline regulated tTR-KRAB repressor protein, and tranduced by a lentiviral 
vector containing a cDNA or shRNA under a tet-O sequence. Subsequently 
administration of Doxycycline allows induction of gene expression in HSCs and 
their progeny [Laurenti et al., 2010]. 
 




	   	  
4.1.2 Key regulators of the cell cycle in IFNα induced HSC activation 
Another class of genes, which is very interesting in regards to IFNα 
induced activation of HSCs, are cell cycle regulators and transcription factors, 
including p57, Reprimo, Maged1 or Evi1. Interestingly treatment of mice with 
IFNα leads to down-regulation of all four of these genes in LK SLAM HSCs. 
Moreover strikingly the expression of none of these genes was significantly 
changed in LK SLAM HSCs of Sca-1-/- mice, indicating a regulation of these genes 
down-stream of Sca-1 (Tab 3.1 and Chapter 3.2). 
The cyclin dependent kinase inhibitor p57Kip2 (Cdkn1c) belongs to the 
Cip/Kip family of kinase inhibitors, together with p21Cip1/Waf1 and p27KIP1, and plays 
an important role in the negative regulation of cell cycle progression. Interestingly 
recent reports showed that p57Kip2 is crucial for the maintenance of HSC 
dormancy during homeostasis, and loss of p57Kip2 leads to reduction of HSCs in 
the G0 phase of the cell cycle [Matsumoto et al., 2011; Zou et al., 2011]. 
Strikingly Sca-1-/- mice did not show a significant down-regulation of p57Kip2 after 
IFNα treatment, which suggests that expression of p57Kip2 might be regulated in a 
Sca-1 dependent manner. 
Similarly to p57Kip2 also expression of Reprimo (Rprm) was reduced in LK 
SLAM HSCs after IFNα treatment. Reprimo is induced in a p53-dependent manner 
and loss or hyper-methylation of Reprimo has been associated with tumor 
progression and poor prognosis in gastric and pancreatic adenocarcinomas 
[Bernal et al., 2008; Luo et al., 2011; Sato et al., 2006]. Ectopic expression of 
Reprimo in vitro leads to G2 arrest and inhibition of nuclear translocation of cyclin 
B1 [Ohki et al., 2000]. 
 




	   	  
Figure	  4.1	  Potential	  roles	  of	  candidate	  genes	  in	  IFNα -­‐induced	  HSC	  activation	  
IFNα	  binds	  to	  the	  IFNα-­‐receptor	  (IFNAR)	  on	  the	  HSCs,	  this	  leads	  to	  phosphorylation	  of	  STAT1	  and	  PKB,	  this	  in	  turn	  
leads	   to	   expression	   of	   IFNα	   target	   genes	   and	   Sca-­‐1.	   Together	   these	   processes	   lead	   to	   activation	   of	  HSCs.	  Genes	  
identified	   in	  our	   screens,	  which	  are	  potentially	   involved	   in	   this	  process	  are	  shaded	   in	  grey.	  Red	  triangle	   indicates	  
down-­‐regulation	  by	  IFNα,	  green	  triangle	  indicates	  up-­‐regulation	  by	  IFNα.	  
Maged1 (NRAGE) is a member of the type II melanoma antigen family and 
was shown to block cell cycle progression and enhance apoptosis [Barker and 
Salehi, 2002]. While the role of Maged1 in the hematopoietic system is unknown, 
it plays a crucial role in skeletal muscles during wound healing. In adult muscle 
stem cells expression levels of Maged1 are low during homeostasis, but highly 
induced after injury and crucial for induction of p21Cip1/Waf1 expression and 
reacquisition of G0 phase after muscle regeneration [Nguyen et al., 2010]. Further 
evidence for an important role of Maged1 in the regulation of proliferation was 
reported in human breast cancer cells, where ectopic expression of Maged1 
induces expression of p53 and p21Cip1/Waf1 [Du et al., 2009]. Taken together lower 
levels of Maged1 are associated with low expression of p21Cip1/Waf1 and active 
progression through the cell cycle. 




	   	  
In summary down-regulation of kinase inhibitors of the CIP/KIP family 
could be a crucial step in the activation of HSCs by IFNα. Interestingly we 
observed decreased expression of p57Kip2, Reprimo as well as Maged1 following 
IFNα treatment only in HSCs of wild type mice, while mice deficient of Sca-1 
showed no significant down-regulation. This suggests that CIP/KIP kinase 
inhibitors are regulated in a Sca-1-/- dependent manner, however the exact link to 
Sca-1 requires further investigation. 
The transcription factor Ecotropic viral integration site 1 protein homolog 
(Evi1; also known as Mecom and Prdm3) plays a crucial role in embryonic 
development and in regulation of proliferation, by interacting with both 
co-repressors and co-activators. Evi1 is one of the dominant oncogenes in murine 
and human myeloid leukemias, including acute and chronic myeloid leukemia 
and myelodisplastic syndrome, where it is associated with poor prognosis 
[Goyama and Kurokawa, 2010; Nucifora, 1997]. In the hematopoietic system 
Evi1 expression is highly enriched in long-term HSCs [Kataoka et al., 2011]. 
Heterozygosity of Evi1 in HSCs leads to impairment of self-renewal capacity, 
while Evi1 deficient HSCs cannot maintain hematopoiesis and lose their 
repopulating capacity [Goyama et al., 2008; Kataoka et al., 2011]. Contrarily 
overexpression of Evi1 suppresses differentiation and boosts self-renewal [Kataoka 
et al., 2011]. In the course of viral infections IFNα is an important mediator of cell 
cycle arrest in differentiated cells, while HSCs are simultaneously activated and 
produce new progeny. Decreased expression of Evi1 in LK SLAM HSCs of mice 
after IFNα treatment might indicate that in the emergency situation of a viral 
infection HSCs enter an active cell cycle primarily not to self-renew but rather to 
differentiate to quickly re-establish a pool of effector cells that was not in contact 
with viral pathogens. It might therefore play a crucial part not in the activation 
process itself, but in the fate of newly generated progeny cells. To elucidate the 
role of Evi1 further it will be crucial to investigate the expression of Evi1 after 
IFNα treatment over time and correlate it to the number of HSCs as well as 




	   	  
differentiated cells. Notably also the expression of Evi-1 was only significantly 
decreased in wild type mice, but not in Sca-1-/- mice. 
 
4.1.3 Cytokines and extracellular matrix proteins in the IFN response 
Another interesting classes of genes induced by IFNα in LK SLAM HSCs are 
cytokines and extra-cellular matrix proteins, in particular Cxcl10, Ccl5 and 
Matrilin4. 
C-X-C-motif chemokine 10 (Cxcl10; also known as interferon induced 
protein 10, IP10) is a small cytokine that is secreted by many cell types after 
stimulation by IFNα, IFNγ or LPS [Angiolillo et al., 1995] and is also highly 
induced in HSCs independent of the presence of Sca-1 (Tab 3.1). Cxcl10 is 
crucial for efficient control of viral replication and recruitment of lymphocytes to 
the sites of infection [Dufour et al., 2002]. Interestingly, similar to IFNα, Cxcl10 
has anti-proliferative effects on a variety of cell types including endothelial cells 
and reduces proliferation as well as invasiveness of melanoma cells [Antonicelli 
et al., 2011; Campanella et al., 2010]. The effects of Cxcl10 on HSCs are still 
unknown. 
Chemokine ligand 5 (Ccl5; also known as RANTES) is a chemotactic 
cytokine that is, similar to Cxcl10, crucial for the recruitment of leukocytes to sites 
of inflammation [Appay and Rowland-Jones, 2001]. It has been linked to 
induction of proliferation in several cell types, including NK-cells and hepatic 
stellate cells [Maghazachi et al., 1996; Schwabe et al., 2003]. Interestingly Ccl5 
was recently shown to be important for lineage choice during differentiation. 
Overexpression of Ccl5 in HSPCs leads to decreased output of T-cells but 
increased output of myeloid progenitor cells. Conversely deletion of Ccl5 leads to 
a decrease in myeloid-biased and increase of lymphoid-biased HSCs [Ergen et al., 
2012]. Hence both, induction of proliferation of the HSCs themselves, as well a 
mediation of lineage choice of progenitor cells in the presence of viral pathogens 
are potential roles of Ccl5 during the IFN response. 
 




	   	  
Cxcl10 as well as Ccl5, could be crucial for HSC activation both 
intrinsically as well as by influencing cells of the niche. As both cytokines 
influence cell proliferation it could be possible that they are part of an autocrine 
activation loop, where IFNα leads to production of Cxcl10 and Ccl5 within the 
HSCs, which in turn further induce proliferation of HSCs. To test this hypothesis a 
first step could be to analyze the effects of administration of ectopic Cxcl10 and 
Ccl5 on HSCs in vivo. Another possibility is an effect of this cytokines on cells of 
the niche, which might also need to be stimulated for efficient HSC activation.  
The hematopoietic stem cells niche environment is crucial not only for the 
maintenance of HSCs but also for their activation by IFNα, as HSCs are activated 
by IFNα only in vivo but not in vitro, where the HSC niche is missing [Essers et 
al., 2009]. One important component of this niche are extra-cellular matrix 
proteins. The matrilin family of non-collagenous extracellular matrix proteins has 
four described members and is still poorly characterized. During embryogenesis 
Matrilin4 is expressed in the dermis and connective tissue of internal organs, in 
adult mice expression was described in epithelial, muscle and nervous tissue 
[Klatt et al., 2002]. Surprisingly expression of Matrilin 4 in the hematopoietic 
system is highly enriched in LK SLAM HSCs (Fig 3.16), and strongly down-
regulated after treatment with IFNα (Fig 3.16 and Tab 3.1). It is still unclear how 
exactly the location and lodgement of HSCs is influenced by IFNα treatment, but 
it is intriguing to speculate that the HSC itself could participate in relocation from 
a dormant niche position to a more active niche position by influencing its 
environment and extra-cellular matrix. To elucidate this further it will be crucial 
to perform immunohistochemical analysis of HSCs in the bone marrow niche 
after IFNα treatment. 
Taken together we identified several candidate genes, which could be key 
players in the activation of quiescent HSCs, including a diverse set of interferon 
response genes, cell cycle regulators as well as cytokines and chemokines. 
However this analysis is based on RNA expression and hence might miss critical 
processes, which are regulated on a post-transcriptional or even post-translational 




	   	  
level. One possibility to systematically address this further would be proteomics 
approaches of HSCs following similar treatment schemes as investigated in this 
study. 
  




	   	  
4.2 Role of the Ifitm protein family in the hematopoietic system 
Similar to the other interferon response genes described above also the 
Ifitm protein family members Ifitm1 and Ifitm3 were induced in LK SLAM HSCs 
after treatment with both IFNα as well as LPS (Fig 3.6, Tab 3.1 and Tab 3.2). This 
induction was independent of Sca-1 and similarly observed in Sca-1 deficient 
mice. Notably the Ifitm protein family had been linked to IFN-induced inhibition 
of proliferation in vitro as well as to regulation of factors crucial in the HSC niche 
before, as described in Chapter 3.3. We therefore decided to investigate its 
function within HSCs in more detail.  
 
4.2.1 Expression of the Ifitm protein family is highly enriched in HSCs 
Interestingly the expression of the Ifitm family, comprising Ifitm1, 2, 3, 5 
and 6, is very heterogeneous in the hematopoietic system. Interestingly Ifitm1, 2 
and 3 are strongly enriched within hematopoietic stem and progenitor cells on the 
RNA and at least Ifitm3 also on the protein level (Fig 3.7 and 3.10). Furthermore 
analysis of Ifitm3EGFP mice, heterozygous for knock-in of EGFP in the Ifitm3 
locus, showed that both the frequency of cells expressing Ifitm3 as well as the 
level of expression within individual cells was highest in HSCs and declining in 
more committed progenitor cells (Fig 3.8). Immune-fluorescence analysis 
suggested localization of Ifitm3 on both the membrane as well as the 
endoplasmatic reticulum as described before in human HeLa cells (Fig 3.10) 
[Yount et al., 2010].  
 
4.2.2 Induction of Ifitm expression differs between different cell types 
Expression of all five Ifitm family members was induced by IFNα in 
unfractionated bone marrow cells (Fig 3.6). Interestingly however only Ifitm1 and 
Ifitm3 were induced in LK SLAM HSCs (Fig 3.6). Furthermore treatment with IFNα 
or LPS similarly lead to increased EGFP expression in LSK cells of Ifitm3EGFP 




	   	  
heterozygous mice. Contrarily only IFNα induced expression in differentiated 
cells, while LPS failed to do so with the exception of granulocytes (Fig 3.9). These 
findings suggest that expression of ifitm family members might be regulated 
differently in different cell types as well as following different induction signals. 
 
4.2.3 The Ifitm family is dispensable for HSCs maintenance and activation by 
IFNα 
Despite the enrichment of Ifitm-expression in HSCs, IfitmDEL mice lacking 
the whole Ifitm family cluster have normal numbers of stem and progenitor cells 
as well as differentiated cells compared to wild-type mice (Fig 3.11). Moreover 
HSCs of IfitmDEL mice showed normal cycling behavior and proportions of 
dormant HSCs and are capable of forming colonies as well as reconstituting 
lethally irradiated mice similar to wild type HSCs (Fig 3.12). Moreover HSCs 
deficient for Ifitm3 or the whole Ifitm family were activated by IFNα equally 
efficient to their wild type counterparts, similarly reacquire reacquired a quiescent 
state and are affected by chronic stimulation (Fig 3.13). 
Taken together the Ifitm protein family is not required for maintenance of 
HSCs, regulation of HSC quiescence or activation of HSCs by either IFNα or LPS. 
While it is difficult to formally exclude that other proteins might compensate for 
the loss of the Ifitm family, we did not observe increased expression of other 
proteins in our microarray screen in HSCs of Ifitm deficient mice (Fig 3.14). 
Microarray analysis further revealed that the Ifitm family is unlikely to be 
involved in regulation of gene expression, as we could not observe any 
differences in the transcriptome of Ifitm-deficient and wild type HSCs neither 
during homeostasis nor during IFNα induced activation. This findings strongly 
suggests that the Ifitm proteins do not have regulatory functions within HSCs, at 
least on the transcriptional level, but are rather terminal effectors. 
 




	   	  
4.2.4 The Ifitm family as protection mechanism for HSCs during viral infections 
Interestingly such an effector function has recently been shown. 
Particularly the Ifitm family is a key player in restricting entry and spread of many 
different enveloped viruses. These include viruses as diverse as influenza H1N1, 
Dengue virus, SARS corona virus, Hepatits C virus or human immunodeficiency 
virus (HIV) [Brass et al., 2009; Huang et al., 2011; Lu et al., 2011; Raychoudhuri 
et al., 2011]. Moreover Ifitm3 also in vivo restricts the morbidity and mortality 
associated with influenza infections in mice [Everitt et al., 2012]. 
Strikingly Ifitm proteins inhibit already the entry of viruses into the 
cytoplasm, at least in part by preventing cytosolic entry of the virus from 
endosomes [Feeley et al., 2011]. Furthermore they also interfere with viral 
replication, although the mechanism is still unknown [Lu et al., 2011]. Antiviral 
activity of Ifitm proteins is not only regulated on the expression level, but at least 
in part by post-translational modifications. While S-palmitoylation enhances the 
membrane affinity and anti-viral activity of ifitm3, lysine ubiquitination decreases 
antiviral activity [Yount et al., 2012; Yount et al., 2010]. 
Particularly interesting in regards to protection of stem cells is the fact that 
Ifitm proteins are the first viral restriction factor described to inhibit already the 
entry of the virus into the cell and therefore efficiently prevent infection. Unlike 
that in most other immune defense processes against viral pathogens the infected 
cell is eliminated either by killing through activated immune cells or by different 
triggers of apoptosis within the infected cell [Roulston et al., 1999]. Notably 
replacing infected HSCs during a viral infection would be much more risky for the 
whole organism compared to replacing more committed or differentiated cells. As 
expression of Ifitm1 and 3 is already strongly enriched in HSCs and granulocytes 
and furthermore highly induced by both IFNα as well as LPS in these cells, it is 
tempting to speculate that in the hematopoietic system this protection mechanism 
is restricted mainly to these cell types. An interesting question is why such an 
efficient protection mechanism would not be present in all hematopoietic cells. 
While there is no definitive answer to this, one possible explanation could be 




	   	  
argued with evolutionary pressure. If all cells would express Ifitm family members, 
evolutionary pressure on viruses would be much higher to overcome this, 
compared to just few cells expressing it. More differentiated cells which are easier 
to replace would be sacrificed to safe HSCs, which are crucial for the survival of 
the organism (Fig 4.2).  
In summary we propose that in the course of viral infections Ifitm family 
members are crucial for protecting hematopoietic stem and progenitor cells from 
infection, while more differentiated cells are infected easier and consecutively 
replaced by cells, which are newly produced from HSCs. Using the IfitmDEL 
mouse model, we are currently investigating whether the presence of Ifitm family 
members on HSCs protect them from viral pathogens in vitro and in vivo, similar 





Figure	  4.2	  Proposed	  model	  of	  the	  Ifitm	  protein	  family	  as	  protection	  against	  viral	  pathogens	  
During	  homeostasis	  wild	  type	  HSCs	  and	  some	  differentiated	  cell	  populations	  express	  Ifitm1	  and	  Ifitm3	  at	  moderate	  
levels,	  while	  the	  majority	  of	  cells	  lack	  expression.	  This	  expression	  is	  further	  induced	  in	  the	  course	  of	  viral	  infections.	  
Expression	   of	   Ifitm	   family	   members	   renders	   these	   cells	   resistant	   to	   infection,	   and	   subsequently	   allows	   the	  
re-­‐establishment	   of	   the	   hematopoietic	   system	   from	   uninfected	   HSCs.	   Conversely,	   without	   protection	   by	   Ifitm	  
proteins,	  also	  HSCs	  are	  efficiently	  infected	  and	  the	  viral	  pathogens	  cannot	  be	  efficiently	  cleared.	  




	   	  
 
4.3 Activation of human HSCs in a xenotransplantation mouse 
model 
As previously described hematopoietic stem cells in the mouse are 
efficiently activated by IFNα [Essers et al., 2009]. Notably interferon is used in 
human patients to treat a variety of different diseases, ranging from viral infection 
(e.g. Hepatitis B and C viral infections) to multiple sclerosis and hematologic 
malignancies including chronic myeloid leukemia (CML) [Cooksley, 2004; 
Goldstein and Laszlo, 1988; Paolicelli et al., 2009; Shepherd et al., 2000]. 
Therefore it is crucial to get a better understanding on the influence of IFNα on 
human HSCs, particularly in regards to possible combination therapies with other 
drugs (for a detailed discussion for CML see chapter 4.4). As the investigation of 
the effects of IFNα on human HSCs cannot be performed in vitro, as IFNα only 
activates HSCs in vivo, we established a xenotransplantation model where human 
cord blood CD34 enriched cells are transplanted intra femurally into immune 
compromised NSG mice to establish a human hematopoietic system within a 
mouse bone marrow niche (Fig 3.17). 
 
4.3.1 Human HSCs do not achieve quiescence in NSG mice 
Human HSCs showed efficient long-term engraftment in NSG mice and 
furthermore gave rise to human CD19+ B-cells and CD11b+ monocytes (Fig 3.17 
and data not shown). Interestingly however cell cycle analysis showed that 
human CD34+CD38- HSCs were less quiescent compared to mouse HSCs with 
only 20-30% of human HSCs in the G0 phase of the cell cycle compared to about 
75% in mouse LSK SLAM HSCs (Fig 3.19 and 3.21). Furthermore while a 
subpopulation of mouse HSCs are long-term dormant and can be identified by 
label retaining assays 100 days after initial labeling [Wilson et al., 2008], we 
could not detect any label retaining human HSCs as described in chapter 3.5. 
One possible explanation for the lower quiescence of human HSCs could be the 




	   	  
less strict definition of human HSCs compared to their mouse counterparts, and 
therefore a higher proportion of highly cycling progenitor cells within the HSC 
subset. Interestingly however a recent report showed, that single human 
CD34+CD38-CD90+RholoCD49f+ positive HSCs are capable to long-term 
multi-lineage engraft mice [Notta et al., 2011]. Notably we did not observe further 
enrichment of cells in the G0 phase in CD34
+CD38-CD90+CD49f+ HSCs compared 
to CD34+CD38- HSCs (data not shown). Therefore whereas human HSCs cannot 
be defined as precisely as mouse HSCs this discrepancy is unlikely to account for 
the big difference in quiescence. 
Another possible explanation why human HSCs are less quiescent than 
mouse HSCs is the foreign mouse niche environment human HSCs face in our 
xenotransplantation model. Beside cell intrinsic regulator of HSC quiescence like 
p21 CIP, p53 or p57 KIP2 also extrinsic factors and the interaction of HSCs with their 
niche is crucial for the maintenance of quiescence [Wilson and Trumpp, 2006]. 
Amongst the most important niche cells for the maintenance of HSC quiescence 
are bone lining osteoblasts and Nestin+ mesenchymal stem cells (MSCs), which 
both supply HSCs with factors crucial for their quiescence, including Ang-1, TPO 
or SCF [Ehninger and Trumpp, 2011]. Further crucial extrinsic factors include 
N-cadherins, integrins and osteopontin. It is well possible that one or several of 
these important interactions is functionally impaired between mouse niche cells 
and human HSCs, leading to impaired quiescence in human HSCs. Approaches 
how to solve this problem are described below in chapter 4.3.3. 
 
4.3.2 Human HSCs are not activated by interferon but are activated by LPS 
To elucidate whether IFNα activates human HSCs similar to mouse HSCs, 
we treated xenotransplanted mice with different sub-types of type I interferon, 
including IFNα 1b, IFNα 2a and IFNα 2b. Surprisingly we did not observe any 
evidence for cell cycle activation, neither an increase in human HSCs 
incorporating BrdU nor a decrease in human HSCs in the G0 phase of the cell 
cycle (Fig 3.18, 3.19 and data not shown). Notably treatment of mice with human 




	   	  
IFNα 1b as well as with poly-(I)-(C) efficiently activates mouse HSCs (Fig 3.19). 
Similarly to IFNα also the type II interferon, IFNγ, as well as the type III interferon, 
IFNλ, did not lead to activation of human HSCs (Fig 3.21). In striking contrast to 
IFNα, treatment of mice with LPS efficiently activated human HSCs. This was 
evident by a change in cell surface protein expression, most notably up-regulation 
of CD38, as well as decrease of human HSCs in the G0 phase of the cell cycle (Fig 
3.20 and 3.21).  
There are several possible explanations why IFNα is not able to activate 
human HSCs in our xenotransplantation mouse model. As mouse IFNα efficiently 
activates mouse HSCs in vivo but fails to do so in vitro [Essers et al., 2009], it is 
evident that some HSC extrinsic factors are crucial for the activation of HSCs, 
similar to the factors important for the acquisition and maintenance of quiescence 
of HSCs described above. It is possible that these extrinsic factors could be 
missing in our xenotransplantation setting, or alternatively not able to activate 
human HSCs. Furthermore as described above human HSCs are actively cycling 
in our model, with no cells being long-term quiescent and only 20-30% of human 
HSCs in the G0 phase at homeostasis compared to 75% in mouse HSCs (Fig 3.21). 
It is possible that in such an actively cycling population no further activation can 
be detected. However activation of mouse HSCs can be detected also in less 
stringently defined populations e.g. LSK cells, which also show a similarly low 
level of quiescent cells during homeostasis (data not shown). Moreover activation 
of human HSCs could be detected after treatment with LPS. 
While the activation processes of HSCs by IFNα and LPS in the mouse 
share some similar mechanisms (Tab 3.1 and 3.2), some crucial steps are 
different. Similar to IFNα also activation of HSCs by LPS is dependent on the 
niche environment [Marieke Essers, personal communication]. However whether 
the same components from the niche are crucial in both cases is still under 
investigation. It is therefore possible that crucial factors for the activation by IFNα 
are missing in the xenotransplantation setting, while the ones crucial for 
activation by LPS are present. Another explanation could be the effect of LPS on 




	   	  
bone marrow cellularity. Treatment of mice with LPS leads to a pronounced 
decrease in bone marrow cellularity (data not shown), and this decreased bone 
marrow cellularity could in turn leads to activation of human HSCs, independent 
of the initial LPS stimulus. 
Microarray analysis of human HSCs after treatment with IFNα + poly-(I)-(C) 
or LPS showed that human HSCs at least partly respond to IFNα (Tab 3.3). While 
no changes in cell cycle regulators could be detected in human HSCs of IFNα 
treated mice, a strong IFNα response cluster was apparent (Tab 3.3 and Fig 3.22). 
Strikingly LPS treated mice similarly showed a strong induction of interferon 
response genes, but additionally also increased expression of cell cycle related 
genes, correlating with the cell cycle induction in HSCs in these mice (Tab 3.4 
and Fig 3.22). In particular human HSCs of xenotransplanted mice treated with 
LPS showed increased expression of the cyclin-dependent kinase inhibitors p19 
and p21Cip1 as well as Cyclin D1, which are all key regulators of the G1/S 
transition. 
Comparison of the gene expression in human HSCs after treatment with 
IFNα or LPS might provide novel insights into pathways that require interaction 
with the HSC niche environment, as activation of such pathways should be 
detectable after LPS treatment but not after treatment with IFNα. Furthermore 
similarly comparing the expression profile after IFNα treatment in mouse and 
human HSCs might provide novel insights. To address this we are currently 
comparing these microarray expression profiles, and moreover also compare the 
expression of differentially regulated genes that are possibly involved in HSC 
activation, between mouse and human HSCs within the same mouse by qPCR. 
 
4.3.3 Outlook and possible improvements for the xenotransplantation mouse 
model 
As discussed above one major problem in our xenotransplantation mouse 
model is the foreign mouse niche environment, which could be an explanation 
for both, the low quiescence of human HSCs observed in our model, as well as 




	   	  
the lack of activation of human HSCs by IFNα (Fig 4.3). To overcome this lack of 
compatibility between human HSCs and the mouse niche cells one possibility is 
to humanize the niche environment similar to the hematopoietic system. This 
could be achieved by transplantation of human stromal cells, e.g. osteoblasts and 
mesenchymal stem cells. Notably previous reports showed that the 
co-transplantation of human mesenchymal stem cells improved the engraftment 
of human CD34+ HSPCs in NOD/SCID mice [Noort et al., 2002]. Alternatively or 
additionally NSG mice that produce human cytokines could be used as host 
mice. Interestingly a recent report showed improved engraftment of human AML 
samples in NSG mice expressing the three human cytokines IL3, SCF and GM-CSF 
[Wunderlich et al., 2010]. 
Another approach to elucidate crucial components of the bone marrow 
niche for IFN induced HSC activation could be reconstructing the hematopoietic 
stem cell niche in vitro. This offers the advantage that different stromal 
compartments of the niche like endothelial cells, mesenchymal stem cells or 
osteoblasts as well as soluble factors can be added either separately or 
simultaneously and therefore their role in HSC maintenance and activation 
unraveled. Notably the three dimensional structure of the bone marrow niche 
might have to be taken into account, which might require sophisticated 3D 
culture models. Indeed such 3D co-culture models recently showed that 
co-culture of human cord blood HSCs  with stromal cells like osteoblasts and 
MSCs increases the proportion of quiescent HSCs in culture [de Barros et al., 
2010; Di Maggio et al., 2011]. Beside components of the niche also culture 
conditions might be very important for such an approach. HSCs in the bone 
marrow reside at the lowest end of an oxygen gradient under hypoxic conditions 
[Jang and Sharkis, 2007; Parmar et al., 2007]. Notably low oxygen culture 
conditions also increase the survival and self-renewal of HSCs also in vitro [Danet 
et al., 2003]. It would be very interesting to investigate whether HSCs cultured 
under such advanced culture conditions can be efficiently activated by IFNα also 
in vitro, contrarily to the single culture of HSCs. Notably the defined setup of 
these cultures allows the removal of single components which might allow to 




	   	  
identify which of the stromal components are crucial for HSCs activation and 
which are dispensable. 
In conclusion, the stromal cells of the bone marrow HSC niche are very 
critical components, not only for HSC maintenance but also for quiescence and 
activation of HSCs. Hence improving the xenotransplantation model by modeling 
the niche environment as close as possible to a human niche might be crucial to 
investigate the mechanism of activation of human HSCs in vivo. Similarly, 
reconstruction of a niche environment similar to the in vivo situation is crucial to 
study the activating effects of IFNα on HSCs in-vitro. 
 
 
Figure	  4.3	  Incompatibility	  between	  mouse	  stromal	  cells	  and	  human	  HSCs	  
Mouse	  HSCs	   are	  quiescent	  during	  homeostasis,	   but	   can	  be	  efficiently	   activated	  by	   IFNα.	   Both	  direct	   interactions	  
with	   stromal	   cells	   from	   the	   niche	   as	   well	   as	   secreted	   factors	   are	   crucial	   for	   maintenance	   of	   quiescence	   and	  
activation	   of	   HSCs.	   In	   our	   xenotransplantation	   model	   human	   HSCs	   do	   not	   become	   quiescent	   and	   cannot	   be	  
activated	  by	  IFNα.	  This	  can	  be	  explained	  by	  incompatibility	  in	  the	  crosstalk	  between	  the	  murine	  bone	  marrow	  niche	  
with	  human	  HSCs.	   It	   is	   currently	  unknown	  whether	  HSCs	   in	  humans	  are	  dormant	  during	  homeostasis	  and	  can	  be	  
activated	   by	   IFNα	   similar	   to	   the	  mouse.	   To	   elucidate	   this	   advanced	   xenotransplantation	  models	  will	   be	   needed,	  
which	  also	  include	  a	  humanization	  of	  the	  stromal	  niche	  compartment,	  and	  hence	  allow	  efficient	  cross-­‐talk	  between	  
human	  HSCs	  and	  their	  niche.	  
  




	   	  
4.4 Activation of leukemic stem cells in a mouse model for CML 
As described in chapter 1.4 chronic myeloid leukemia (CML) is a chronic 
myeoloproliferative disease, characterized by a chromosomal translocation, 
leading to the formation of the Philadelphia chromosome and the BCR-ABL fusion 
kinase [Daley et al., 1990]. While inhibition of the BCR-ABL kinase by tyrosine 
kinase inhibitors (TKI) like Imatinib specifically targets BCR-ABL expressing cells 
and leads to rapid remission of the disease [O'Brien et al., 2003], leukemic stem 
cells (LSCs) are not efficiently eliminated by TKI treatment. These residual LSCs 
can lead to rapid relapse of the disease upon cessation or interruption of TKI 
treatment [Goldman, 2009]. Therefore treatment approaches that can lead to the 
elimination of residual LSCs are of high clinical interest. One such approach is the 
activation of LSCs by IFNα, followed by elimination of activated LSCs by Imatinib 
[Essers and Trumpp, 2010]. However unlike for HSCs the effects of IFNα on HSCs 
is currently unknown. To elucidate the effects of IFNα on leukemic stem cells and 
the feasibility of such approaches we employed a mouse model for chronic 
myeloid leukemia and investigated the effect of IFNα on LSCs in this model in 
vivo.  
 
4.4.1 Establishment of a mouse model to elucidate effects of IFNα on CML 
LSCs 
To elucidate the effects of IFNα on leukemic stem cells we obtained a 
mouse model for chronic myeloid leukemia, which allows the expression of the 
BCR-ABL transgene specifically in hematopoietic stem and progenitor cells in a 
Dox inducible manner [Koschmieder et al., 2005]. These mice express the 
transactivator protein tTA under the control of the murine stem cell leukemia 
(SCL) gene 3’ enhancer, and the P210 BCR-ABL transgene under control of a 
tet-responsive element (TRE) (Fig 3.23). 
As expected mice expressing the both transgenes developed a CML like 
disease within few weeks after the cessation of Doxycycline treatment. These 




	   	  
symptoms included increase in spleen size, increase of LSK cells and increase in 
differentiated und undifferentiated granulocytes in the bone marrow and spleen 
(Fig 3.24). Notably a major caveat of this model is that unlike in human patients 
all HSPCs express the BCR-ABL transgene and hence the model is not suitable to 
study effects of TKI treatment and combinations of TKIs with IFNα on LSCs. 
To address this we generated bone marrow chimeras, which harbor both 
leukemic as well as normal hematopoietic cells. Within few weeks after cessation 
of Dox treatment SCLtTA/BCR-ABL bone marrow chimeras showed signs of 
leukemia (Fig 3.25). Notably in the model we employed it is not possible to 
distinguish normal HSCs from LSCs. This model could be markedly improved by 
using wild type FVB/N CD45.2 mice, which differ in CD45 antigen expression 
from the SCLtTA/BCR-ABL strain, which express the CD45.1 antigen (Fig 4.4).  
 
 
Figure	  4.4	  Transplantation	  mouse	  model	  to	  investigate	  the	  effects	  of	  IFNα 	  and	  TKIs	  on	  LSCs	  
Model	   for	   the	  generation	  of	  mixed	  bone	  marrow	  chimeras	  of	  FVB/N	  CD45.2	  wild	   type	  mice	  and	  SCLtTA/BCR-­‐ABL	  
double	  transgenic	  mice.	  This	  model	  allows	  detection	  of	  single	  leukemic	  cells	  by	  the	  CD45.2	  antigen,	  and	  therefore	  
allows	  monitoring	  of	  treatment	  success	  and	  minimal	  residual	  disease.	  	  
	  




	   	  
This allows to detect even very low numbers of leukemic stem cells within 
a majority of normal cells and hence monitor whether residual LSCs can be 
efficiently removed by treatment with IFNα in combination with TKIs. We are 
currently employing such a model and investigating the effects of IFNα and TKIs 
as single agents as well as in combination. 
In conclusion SCLtTA/BCR-ABL bone marrow chimeras develop a CML 
like disease within weeks after transplantation and are suitable for investigating 
the effects of different treatment regimens on leukemic stem cells. They resemble 
the situation in a human patient, where leukemic cells are present next to healthy 
hematopoietic cells, more closely than the original SCLtTA/BCR-ABL model. 
Furthermore the use of strains expressing different isotypes of CD45 offers the 
possibility to track individual leukemic cells and is therefore superior for the 
analysis of minimal residual disease and the effects of combined therapies on 
LSCs. 
 
4.4.2 Activation of leukemic stem cells by IFNα 
The most crucial question for a potential combination therapy with IFNα 
and TKIs is whether IFNα activates leukemic stem cells similar to normal HSCs. 
To address this we investigated the effects of IFNα on HSCs of SCLtTA/BCR-ABL 
single and double transgenic mice. As expected we observed up-regulation of 
Sca-1 expression and induction of proliferation in HSCs from single transgenic 
mice (Fig 3.26). Surprisingly only a part of double transgenic mice showed a 
similar reaction while the majority did not show any activation of LSCs by IFNα 
(Fig 3.26). 
Interestingly a recent report suggested that expression of BCR-ABL in 
leukemic cells leads to down-regulation of the IFNAR and hence to decreased 
responsiveness of these cells to IFNα in vitro [Bhattacharya et al., 2011]. This 
down-regulation is mediated by protein kinase D2, which is activated by 
BCR-ABL and in turn promotes phosphorylation-dependent degradation of the 
IFNAR-1-chain of the IFNAR, leading to an attenuation of IFNα signaling. 




	   	  
Interestingly inhibition of the BCR-ABL kinase by the TKI Imatinib increased the 
anti-proliferative effects of IFNα on CML cells in vitro, suggesting that the down-
regulation of the IFNAR is reversible by inhibition of BCR-ABL [Bhattacharya et 
al., 2011]. This is important as this finding further highlights the crucial aspect of 
timing the two components IFNα and TKI right (Fig 4.5 A). A crucial next step will 
therefore be to investigate whether pre-treatment with TKIs also in vivo restores 
the responsiveness of CML LSCs to IFNα. 
 
 
Figure	  4.5	  Model	  of	  a	  possible	  combination	  therapy	  of	  IFNα 	  and	  TKIs	  to	  eliminate	  leukemic	  stem	  cells	  
(A)	  LSCs	  are	   less	  responsive	  to	   IFNα	  compared	  to	  HSCs,	  due	  to	  BCR-­‐ABL	  dependent	  degradation	  of	  the	   IFNAR.	  By	  
inhibiting	   the	  BCR-­‐ABL	  kinase	  with	  TKIs	   the	  sensitivity	  of	   LSCs	   to	   IFNα	   can	  be	   restored.	   (B)	  While	   treatment	  with	  
TKIs	  alone	  efficiently	  targets	  the	  bulk	  of	  leukemic	  cells,	  quiescent	  LSCs	  remain	  unharmed	  and	  can	  lead	  to	  relapse	  of	  
leukemia.	  Combination	   therapy	  with	  TKIs	  and	   IFNα	  might	  be	  a	  possibility	   to	  eliminate	  also	   these	   residual	   clones.	  
After	  pre-­‐treatment	  with	  TKIs,	  LSCs	  can	  be	  activated	  by	  IFNα	  and	  eliminated	  by	  another	  cycle	  of	  TKI	  treatment.	  	  




	   	  
In conclusion the bone marrow transplantation model described above 
will be a crucial tool to determine the optimal targeting strategy in this 
combination therapy. Judging from our data an optimal approach might include 
pre-treatment with Imatinib or other TKIs, to restore full responsiveness of LSCs to 
IFNα, followed by activation of LSCs by IFNα, followed again by treatment with 
TKIs to eradicate activated LSCs (Fig 4.5 B). Importantly it might be crucial to 
interrupt treatment with TKIs briefly at the time of treatment with IFNα, as TKI 
treatment itself drives LSCs into quiescence and might therefore counteract the 
effects of IFNα [Graham et al., 2002]. 
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5 MATERIALS & METHODS 
5.1 Mouse strains 
All animal experiments were conducted in accordance with the German Law for 
Protection of Animals and the National Institute of Health Guidelines for Care and 
Use of Laboratory Animals. Mice were maintained in the animal facility of the 
German Cancer research Center under specific pathogen-free conditions (SPF) 
and housed in individually ventilated cages (IVC). If not specified differently all 
mice used for experiments were between 6 and 12 weeks old at the beginning of 
the respective experiment. NSG mice used for intra femoral transplantations were 
between 8 and 14 weeks at the time of transplantation. 
 
Wild-type mice  
Wild-type and immune compromised mouse strains were ordered from the 
following companies: 
 
Common	  Name	   Strain	  Name	   Company	  
C57Bl/6	   C57BL/6	  JOlaHsd	   Harlan	  Laboratories	  
Ly5.1	   C57/BL6	  -­‐	  Ly	  5.1	   Charley	  River,	  Italy	  
NSG	   NOD.Cg-­‐Prkdc<scid>Il2rgytm1Wjl>/SzJ	   Jackson	  Laboratory	  
FVB/N	   FVB/N	  Crl	   Charles	  River,	  Sulzfeld	  
Table	  5.1	  Commercially	  obtained	  mouse	  strains	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NSG mice 
As host mice for the xenotransplantation the NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) 
strain was chosen. NSG mice combine the phenotype of severe combined 
immune deficiency mutation (scid) with deficiency of the IL2-receptor γ chain. As 
a result they lack mature B- and T-cells, functional NK cells and are deficient in 
cytokine signaling [Ishikawa et al., 2005; Shultz et al., 2005]. They therefore 
accept human cells without graft rejection. NSG mice were obtained from Jackson 
Laboratory. 
 
Ifitm3EGFP and IfitmDEL 
Ifitm3EGFP and IfitmDEL mice were obtained from the laboratory of Prof. Azim 
Surani [Lange et al., 2008]. Ifitm3EGFP mice were generated by targeted insertion 
of EGFP 30 nucleotides downstream from and in frame with the Ifitm3 start codon 
(Fig 5.1), and the mutant ES cells were used to transmit the allele onto the 
C57BL/6J background. Ifitm3EGFP homozygous mice lack Ifitm3 expression but 
express EGFP instead, while heterozygous mice have one intact copy of Ifitm3 
and simultaneously express EGFP. Ifitm3 null mice had no observed phenotype 




Figure	  5.1	  Schematic	  of	  the	  targeting	  strategy	  used	  to	  generate	  the	  Ifitm3EGFP	  allele	  
(adapted	  from	  [Lange	  et	  al.,	  2008])	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IfitmDEL mice were engineered by deletion of a 120-kb region on chromosome 7 
(Fig 5.2), harboring the entire Ifitm family cluster but no other known genes 
[Lange et al., 2008]. IfitmDEL mice were backcrossed on a C57BL/6J background. 
The number of homozygous animals born from intercrosses of IfitmDEL 




Figure	  5.2	  Schematic	  of	  the	  targeting	  strategy	  used	  to	  generate	  the	  IfitmDEL	  allele	  
(adapted	  from	  [Lange	  et	  al.,	  2008])	  
 
Sca-1 KO and IFNAR KO 
Mice deficient for Sca-1 or the IFNα receptor were maintained on a C57Bl/6 
background as described before [Ito et al., 2003; Muller et al., 1994]. 
 
SCLtTA-BCR Abl 
SCLtTA-BCR Abl mice, which allow the targeted expression of the BCR-ABL 
kinase in hematopoietic stem and progenitor cells using a tet-off system, were 
obtained from the laboratory of Dr. Steffen Koschmieder [Koschmieder et al., 
2005]. In these mice the transactivator protein tTA was placed under the control 
of the murine stem cell leukemia (SCL) gene 3’ enhancer, and the P210 BCR-ABL 
transgene under control of a tet-responsive element (TRE). This allows to 
induction of BCR-ABL expression in hematopoietic stem cells by withdrawal of 
Doxycycline (Fig 3.23). Within few weeks after induction of BCR-ABL kinase 
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expression mice develop a disease closely resembling the chronic phase of 
chronic myeloid leukemia [Koschmieder et al., 2005]. The BCR-ABL mouse line 
was kept on a FVB/N genetic background. 
Mice were supplied with 2g/l Doxycycline in the drinking water, containing 5 
cubes of sugar (Dox water). Mating cages were kept on Dox water permanently. 
Disease development was induced in 6-10 week old mice by exchange of 
Doxycycline water with pure water and blood counts of mice were monitored 
routinely starting at six weeks after induction. For transplantation of the disease 
bone marrow cells were isolated from single or double transgenic mice, which 
were still on Dox water, and transplanted in wildtype FVB/N mice. Doxycycline 
treatment was stopped at the timepoint of transplantation. 
 
5.2 Genotyping 
To determine the genotype of mice DNA was extracted from tail biopsies (PCR 
Tail Lysis reagent, Peqlab) and genotyping PCR were performed. All PCR 
protocols used Taq Polymerase (Invitrogen), 10x PCR buffer (670mM TrisHCL 
pH8.8, 67mM MgCl2, 1,7mg/ml BSA; 166mM (NH4)2SO4) with final 
concentrations of 10% DMSO or 0,12% Triton X100 and 2µM primers. 
Amplification was performed for 35 cycles with an annealing temperature of 
60°C, with the exception of genotyping for the BCR-ABL transgene (40 cycles, 
58°C annealing temperature), SCLtTA transgene (40 cycles, 59°C annealing 
temperature) and IfitmDEL locus (45 cycles, 62°C annealing temperature). The 
primers used for genotyping are listed in Table 5.2. 
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PCR	  name	   Primer	  name	   Sequence	   Product	  size	  
IFNAR	  wt	   UM4	   AAG	  ATG	  TGC	  TGT	  TCC	  CTT	  CCT	  CTG	  CTC	  TGA	   wt:	  150	  bp	  
	  
UM5	   ATT	  ATT	  AAA	  AGA	  AAA	  GAC	  GAG	  GCG	  AAG	  TGG	  
	  
IFNAR	  KO	   725	   TCA	  GCG	  CAG	  GGG	  CGC	  CCG	  GTT	  CTT	  T	   KO:	  350bp	  
	  
727	   ATC	  GAC	  AAG	  ACC	  GGC	  TTC	  CAT	  CCG	  A	  
	  
IfitmEGFP	   WT	  fwd	   GAC	  TGC	  ATA	  GCC	  ACC	  GAA	  GAT	  ATT	  CC	   wt:	  600bp	  
	  
TG	  fwd	   CCC	  ATC	  TCA	  GCC	  ACC	  TCA	  TAT	  TCT	  TCC	   KO:	  300bp	  
	  
WT+TG	  rev	   GCA	  GAA	  GAA	  CGG	  CAT	  CAA	  GGT	  G	  
	  
IfitmDEL	  wt	   WT	  fwd	   AAC	  ATG	  CCT	  TGC	  ATC	  CCT	  GGA	  GTT	  CCT	  TCT	  AAA	  GGA	   wt:	  450bp	  
	  
WT	  rev	   CCC	  TAA	  AAC	  ACT	  TAG	  CAG	  TGA	  CCC	  CTC	  ACA	  AGC	  C	  
	  
IfitmDEL	  KO	   KO	  fwd	   ACT	  CTA	  GCC	  AGA	  GTC	  TTG	  CAT	  TTC	  TCA	  GTC	  CTA	  AAC	   KO:	  650bp	  
	  
KO	  rev	   TCT	  AGT	  ACA	  GTC	  GGT	  AAG	  AAC	  AAA	  ATA	  GTG	  TCT	  ATC	  A	  
	  
BCR-­‐ABL	  tg	   sense	   GAG	  CGT	  GCA	  GAG	  TGG	  AGG	  GAG	  AAC	   tg:	  500bp	  
	  
anti-­‐sense	   GGT	  ACC	  AGG	  AGT	  GTT	  TCT	  CCA	  GAC	  TG	  
	  
SCLtTA	  enh	   SCLenh	  wt	  R	   AGA	  ACA	  GAA	  TTC	  AGG	  GTC	  TTC	  CTT	   wt:	  350bp	  
	  
SCLenh	  wt	  F	   GGG	  CAG	  TTG	  ATG	  TGT	  TTG	  TG	   KO:	  750bp	  
	  
tTA5	  F	   TTT	  CGA	  TCT	  GGA	  CAT	  GTT	  GG	  
	  
Table	  5.2	  Primers	  used	  for	  genotyping	  
 
5.3 Isolation of cells from bone marrow, spleen and blood 
Bone marrow was isolated from hind legs (femur and tibia) or hind legs, fore legs 
(humerus) and hips (ilium) depending on the amount of cells required for the 
experiment. Muscles and connective tissue was removed and bones were crushed 
in RPMI medium with 2% FCS (Gibco or PAN Biotech). Similarly spleen was 
minced in RPMI with 2% FCS and cells suspended by pipetting up and down. The 
cell suspension was filtered through a 40µm mesh and cell numbers were 
determined with a ViCell automated cell counter  (Beckman Coulter) or manually 
using a Neubauer chamber. If necessary lineage depletion was performed by 
incubating the cell suspension with a mixture of monoclonal antibodies against 
CD11b (M1/70), Gr-1 (RB6.8C5), CD4 (GK1.5), CD8a (53.6.7), Ter119 (Ter119) 
and B220 (RA3-6B2) for 30 minutes on ice. Subsequently the cells were washed 
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and incubated 15 min on ice with anti-rat IgG-coated Dynabeads (4,5µm 
supermagnetic polystyrene beads, Invitrogen), 1ml of beads per 250x106 cells. 
The labeled cells were depleted using a magnet and the remaining lineage 
depleted cells were washed and again counted. For all washing steps cells were 
washed with PBS 2% FCS followed by centrifugation at 1600rpm for 5 min at 4°C 
(Eppendorf 5810r centrifuge). 
For analysis of blood chimerism and monitoring of leukemia development 6 drops 
of blood were collected in tubes covered with EDTA. Red blood cells were lysed 
with ACK lysis buffer (Life Technologies, #A10492-01) according to 
manufacturers protocol. The remaining cells were washed as described above and 
subsequently used for determining blood counts with a Hemavet cell counter 
(Drew Scientific) or for FACS analysis as described below. 
 
5.4 Isolation of stem cells from the skin 
Mice were shaved with depilatory cream; skin was harvested and cut into pieces. 
The skin was placed in a petri dish and incubated floating in trypsin 0,25% 
(Gibco) for 16 to 24 hours at 4°C. The epidermal layer was peeled off with a razor 
blade, the epidermis was chopped with scissors in suspended in HBSS (Gibco). 
The suspension was pressed through a 40µm cell strainer and washed with HBSS. 
The suspension was centrifuged at 1200rpm for 5 min at 4°C (Eppendorf 5810r 
centrifuge) and filtered again through a new 40µm cell strainer. Finally the cells 
were counted and used for FACS analysis as described below. 
 
5.5 Fluorescence activated cell sorting (FACS) 
FACS analysis was performed on BD LSR II (Becton Dickinson), BD Fortessa 
(Becton Dickinson) or CyAn ADP (Beckman Coulter) flow cytometers. Cell sorting 
was performed with BD FACSVantage, BD AriaI, BD AriaII or BD AriaIII (all 
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(Becton Dickinson) cell sorters. Analysis of FACS data was done with FlowJo 
software (Tree Star Inc.). 
Cell surface staining was performed in a mixture of 50% PBS (+2% FCS), and 50% 
supernatant from the 24G2 hybridoma cell line, which produces rat blocking 
antibodies directed against the FcγR (CD16/32) antigen. For FACS stainings, 
which required analysis of CD16/32 expression, the stainings were performed in 
PBS 2% FCS without 24G2. Cells were incubated with antibodies for 30 minutes 
on ice. For biotin coupled antibodies cells were subsequently incubated with 
streptavidin conjugates for 20 minutes on ice. 
 
The following anti-mouse antibodies were used for FACS analysis: 
Gr-1 (Ly-6G, RB6-8C5)-FITC and -biotin, Ter119-FITC and -biotin, B220 
(RA3-6B2)-FITC and -biotin, CD11b-FITC and -biotin, CD4 (clone GK1.5)-FITC 
and -biotin and CD8a (53.6.7)-FITC and -biotin were purified and conjugated in 
the laboratory following standard protocols. CD34 (RAM34)-FITC, cKit 
(2B8) -PE, -PE-Cy5, -PE-Cy7, -APC, and -APC-Cy7, Sca-1 
(D7) -APC, -APC-e780, -Alexa700 and (2B8)-biotin, CD48 (HM48-1)-PE, -PB, 
CD4 (GK1.5)-PE-Cy7, CD8 (53-6.7)-PE-Cy7, CD11b (M1/70)-PE-Cy7, Gr1 
(RB6-8C5)-PE-Cy7, B220 (RA3-6B2)-PE-Cy7, Ter119-PE-Cy7, CD45 
(30-F11) -FITC, CD45.1 (A20)-FITC and PE-Cy7 and CD45.2 (104)-Pacific Blue 
and Alexa647 were all purchased from eBioscience. CD150 (TC15-12F12.2)-PE 
and PE-Cy5 as well as CD48-Pacific Blue were purchased from Biolegend. 
The following anti-human antibodies were used for FACS analysis: 
CD4 (RPA-T4)-biotin, CD8 (RPA-T8)-biotin, CD11b (ILRF44)-biotin, CD34 
(581/CD34)-PE and -APC, CD38 (HIT2)-PE and -PE-Cy5, CD49f (GoH3)-PE-Cy5, 
CD90 (5E10)-PE-Cy5 and CD117 (104D2)-PE-Cy7 were all purchased from 
Becton Dickinson. CD16 (eBio CB16)-biotin, CD19 (HIB19)-biotin and -APC, 
CD11b (ILRF44)-PE-Cy7, CD235a (HIR2)-biotin, CD49f (eBioGoH3)-PE and CD45 
(HI30)-PE were all purchased from eBioscience. 
The following Streptavidin conjugates were used for FACS analysis: 
APC-e780 (eBioscience) or PE-TexasRed (BD Biosciences) 
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5.6 BrdU incorporation assays and Ki67/Hoechst cell cycle analysis 
Cell cycle profile and proliferation of HSCs was analyzed by combining 
cell surface stainings as described above with Ki67/Hoechst analysis or BrdU 
incorporation assays. 
For BrdU analysis mice were injected i.p. with 360µg/mouse BrdU (Sigma) 
12 hours prior to analysis unless indicated differently. BM cells were harvested 
and cell surface stainings performed as described above. Cells were fixed and 
permeabilized with a BrdU staining kit (BD Biosciences) with Cytofix/Cytoperm 
and Cytoperm plus according to manufacturers protocol. Samples were incubated 
with DNAse I for one hour at 37°C, followed by intra-cellular staining with 
anti-BrdU-FITC or –APC antibodies in Permwash solution (BD Biosciences). 
For Ki67/Hoechst analysis cells were fixed with Cytofix/Cytoperm (BD 
Biosciences), and incubated with anti-Ki67-FITC or -Alexa647 antibodies (BD 
Biosciences) in Permwash solution over night. Before analysis cells were 
incubated for 10 min with 1:200 diluted Hoechst33342 (Invitrogen) on ice.  
 
5.7 Immunofluorescence 
Unfractionated bone marrow cells or FACS sorted hematopoietic 
populations were fixed with Cytofix/Cytoperm (BD Biosciences) for 15min at 4°C. 
Cells were spun down on SuperFrost Ultra Plus slides (Menzel) with a Cytospin 4 
Cytocentrifuge (Thermo Fisher Scientific). Samples were blocked with 15% goat 
serum (DAKO) in PBS for one hour at 4°C to reduce unspecific binding of 
antibodies. Slides were incubated with a rabbit polyclonal primary Antibody 
against Ifitm3 (Abcam #ab15592) 1:100 diluted in blocking solution over night at 
4°C in a humidified chamber. Slides were washed in PBS and incubated for one 
hour at 4°C with anti-rabbit IgG F(AB)2 fragment conjugated with DyLight 549 or 
Dylight 649 diluted 1:100 in PBS (Jackson ImmunoResearch). Slides were washed 
again and mounted with ProLong Gold mounting medium containing DAPI 
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(Invitrogen). Finally slides were analyzed on a Zeiss Cell Observer and 
documented with an AxioCam HR (Zeiss). 
 
5.8 RNA isolation and Reverse Transcription 
For microarrays of mouse samples, cells were sorted directly in RLT lysis buffer 
and RNA was isolated with the RNeasy micro kit (Quiagen) according to 
manufacturers instructions, including an RNAase free DNAse digestion step to 
digest DNA. 
For all qPCR samples as well as human microarrays, cells were FACS sorted 
directly in extraction buffer (Arcturus PicoPure Kit) and RNA was isolated with the 
PicoPure RNA isolation kit (Arcturus) according to manufacturers instructions, 
including an RNAse free DNAse step to digest DNA. 
RNA was reverse transcribed with the SuperScript VILO cDNA synthesis kit 
(Invitrogen) according to manufacturers instructions. Resulting cDNA was diluted 
1:4 or 1:10 before use for downstream reactions. 
 
5.9 Microarray analysis 
RNA was isolated with RNeasy micro kit (Quiagen) or Picopure RNA isolation kit 
(Arcturus) as described, including digestion of DNA by RNAse-free DNAse. After 
isolation RNA quality was checked and quantity determined with an Agilent 
Bioanalyzer 2100 (Agilent). Samples of insufficient quality (RIN score below 7) 
were excluded from analysis; samples of insufficient quantity (below 2,5ng) were 
pooled with other samples or excluded as well. Samples of sufficient quality and 
quantity were amplified with the Ovation PicoSL WTA system and labeled with 
the BiotinIl Module (Nugene). After amplification and labeling samples were 
hybridized to the respective microarray, MouseRef-6 V2.0 (Illumina) for mouse 
samples and HumanHT-12 (Illumina) for human samples. 
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5.10 Quantitative Real-time PCR analysis 
Quantification of mRNA expression by quantitative Real-time PCR (qPCR) was 
performed using the ABI Power SYBR Green Master Mix (Applied Biosystems) on 
a Light Cycler 480 (Roche) according to the manufacturers instructions. The 
following amplification protocol was used: 95°C for 10min; 50 cycles of 95°C for 
15s, 60°C for 45s, followed by acquisition of fluorescence; 95°C for 10s; 65°C for 
1 min and increase of temperature by 0.11°C/min up to 95°C continuous 
acquisition for melting curve; 40°C 5min. Results were analyzed using the 
supplied LightCycler software (Roche). 
Primers for qPCR reactions were designed with the Assay Design Center of the 
Universal Probe Library (Roche 1 ) or Primer3 2  [Rozen and Skaletsky, 2000]. 
Sequences of genes were obtained from ENSEMBL3 or GenBank4. Sdha, B2m and 
Oaz1 were used as housekeeping genes for normalization of gene expression, 
with the exception of quantification after treatment with IFNα or LPS, where only 
Sdha and Oaz1 were used as B2m is induced by both treatments. 
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Gene	   Primer	   Sequence	   Product	  size	   Efficiency	  
Sdha	   fwd	   AAG	  TTG	  AGA	  TTT	  GCC	  GAT	  GG	  	  
	  
74bp	   1,98	  
	  




B2m	   fwd	   TTC	  TGG	  TGC	  CTT	  GTC	  TCA	  CTG	  A	   105bp	   1,88	  
	  
rev	   CAG	  TAT	  GTT	  CGG	  CTT	  CCC	  ATT	  C	  
	  
	  
Oaz1	   fwd	   TTT	  CAG	  CTA	  GCA	  TCC	  TGT	  ACT	  CC	   77bp	   2,04	  
	  
rev	   GAC	  CCT	  GGT	  CTT	  GTC	  GTT	  AGA	  
	  
	  
Ifitm1	   fwd	   TGA	  GAT	  CTC	  CAC	  GCC	  TGA	  C	   122bp	   1,98	  
	  
rev	   CCA	  CCA	  TCT	  TCC	  TGT	  CCC	  TA	   	  
	  
Ifitm2	   fwd	   TGG	  TCT	  GGT	  CCC	  TGT	  TCA	  AT	   119bp	   1,87	  
	  
rev	   CTG	  GGC	  TCC	  AAC	  CAC	  ATC	   	  
	  
Ifitm3	   fwd	   AGC	  CTA	  TGC	  CTA	  CTC	  CGT	  GA	   56bpp	   1,92	  
	  
rev	   CAG	  TCA	  CAT	  CAC	  CCA	  CCA	  TC	   	  
	  
Ifitm5	   fwd	   AGG	  ACA	  ACC	  ATG	  TCA	  GGT	  CAG	   78bp	   2,03	  
	  
rev	   GCA	  GGG	  ATC	  GAG	  GTG	  CTA	  T	   	  
	  
Ifitm6	   fwd	   TCA	  CAT	  TAC	  CTG	  GTC	  TAC	  ATT	  TAA	  CAC	   111bp	   1,97	  
	  
rev	   ATG	  TCG	  CCC	  ACC	  ATC	  TTC	   	  
	  
Ifit1	   fwd	   CCA	  TCC	  CAA	  GGA	  TAC	  ATA	  CTC	  AC	   74bp	   2,03	  
	  
rev	   TTC	  TAC	  AGC	  TCA	  CAG	  GAG	  TCC	  A	   	  
	  
Ifit3	   fwd	   GAA	  TGG	  TTT	  TGG	  GGT	  TTG	  G	   78bp	   2,24	  
	  
rev	   TTG	  TCC	  TCA	  GGT	  TCA	  TGG	  TG	  
	  
	  
Iigp1	   fwd	   CTT	  GCA	  AAG	  GAC	  CAG	  GAT	  TT	   76bp	   2,29	  
	  
rev	   TCC	  CCT	  GAG	  ACA	  GAA	  TTT	  GC	  
	  
	  
Oas3	   fwd	   TGC	  CTG	  CCT	  TTG	  ATG	  TCC	   76bp	   1,98	  
	  
rev	   GAG	  GGA	  GGA	  GTA	  CAC	  GTT	  GG	  
	  
	  
Ddx58	   fwd	   GAG	  AGT	  CAC	  GGG	  ACC	  CAC	  T	   70bp	   1,94	  
	  
rev	   CGG	  TCT	  TAG	  CAT	  CTC	  CAA	  CG	  
	  
	  
Table	  5.3	  Primers	  used	  for	  Real-­‐time	  PCR	  analysis	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5.11 Statistical analysis 
Statistics were calculated and Graphs designed with Microsoft Excel (Microsoft) or 
GraphPad Prism (GraphPad Software). If not specified differently graphs show the 
mean expression and error bars indicate standard error of the mean (SEM). 
Significance of differences between samples was determined using unpaired two-
tailed t-tests. 
Indication of significance: * p<0.05 
    ** p<0.01 
    *** p<0.005 
    **** p<0.001 
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AGM	   Aorta-­‐gonad	  mesonephros	  
Akt	   PKB,	  Protein	  kinase	  B	  
Ang-­‐1	   Angiopoietin-­‐1	  
BM	   Bone	  marrow	  
BrdU	   5-­‐bromo-­‐2-­‐deoxyuridine	  
CAR	   CXC-­‐12	  abundant	  reticular	  cell	  
c-­‐Kit	   v-­‐kit	  Hardy-­‐Zuckerman	  4	  feline	  sarcoma	  cellular	  homologue	  
CLP	   Common	  lymphoid	  progenitor	  
CMP	   Common	  myeloid	  progenitor	  
c-­‐MPL	   TPO	  receptor	  
CXCL12	   Stromal-­‐derived	  factor-­‐1	  (SDF-­‐1)	  
DNA	   Deoxyribonucleic	  acid	  
Dox	   Doxycycline	  
EGFP	   Enhanced	  Green	  Fluorescent	  Protein	  
FACS	   Fluorescence-­‐activated	  cell	  sorting	  
G-­‐CSF	   Granulocyte-­‐colony	  stimulating	  factor	  
GMP	   Granulocyte	  monocyte/macrophage	  progenitor	  
HSC	   Hematopoietic	  stem	  cells	  
IFN	   Interferon	  
i.f.	   intrafemural	  
i.p.	   intraperitoneal	  
i.v.	   intravenous	  
IVC	   Individually	  ventilated	  cage	  
KO	   Knock-­‐out	  
LRC	   Label	  retaining	  cell	  
MAPK	   Mitogen-­‐activated	  protein	  kinase	  




	   	  
MEP	   Megakaryocyte	  erythroid	  progenitor	  
mRNA	   Messenger	  Ribonucleic	  acid	  
MMP	   Matrix	  Metalloprotease	  
MPP	   Multi-­‐potent	  progenitor	  cell	  
MSC	   Mesenchymal	  stem	  cell	  
mTor	   Mammalian	  target	  of	  Rapamycin	  
NK	   Natural	  Killer	  Cell	  
PCR	   Polymerase	  chain	  reaction	  
PKB	   Protein	  kinase	  B,	  Akt	  
PBL	   Peripheral	  blood	  
pIC	   Polyinosinic:polycytidylic	  acid	  
qRT-­‐PCR	   Quantitative	  Real-­‐time	  polymerase	  chain	  reaction	  
ROS	   Reactive	  oxygen	  species	  
Sca-­‐1	   Stem	  cell	  antigen	  1	  
SCF	   Stem	  cell	  factor,	  c-­‐Kit	  ligand	  
SLAM	   Signaling	  lymphocyte	  activation	  molecule	  
SPF	   Specific	  pathogen	  free	  
STAT1	   Signal-­‐transducer	  and	  activator	  of	  transcription	  1	  
TPO	   Thrombopoietin	  
Table	  7.1	  Abbreviations	  
 
 	  




	   	  
7.2 Cell surface markers used to define hematopoietic populations 
 
Mouse hematopoietic cells: 
Population	   Cell	  surface	  phenotype	  
linneg	   CD11b-­‐Gr-­‐1-­‐B220-­‐CD4-­‐CD8-­‐Ter119-­‐	  
LSK	   linnegCD117+Sca-­‐1+	  
LSK	  SLAM	   linnegCD117+Sca-­‐1+CD150+CD48-­‐	  
LK	  SLAM	   linnegCD117+CD150+CD48-­‐	  
LSK	  SLAM	  CD34-­‐	   linnegCD117+Sca-­‐1+CD150+CD48-­‐CD34-­‐	  
MPP1/2	   linnegCD117+Sca-­‐1+CD150+CD48+	  
MPP3/4	   linnegCD117+Sca-­‐1+CD150-­‐	  
CMP	   linnegCD117+Sca-­‐1-­‐IL7R-­‐CD34+FcγRlo	  
GMP	   linnegCD117+Sca-­‐1-­‐IL7R-­‐CD34+FcγRhi	  
MEP	   linnegCD117+Sca-­‐1-­‐IL7R-­‐CD34-­‐FcγRlo	  
CLP	   linnegCD117loSca-­‐1loIL7R+CD135+	  
T-­‐cells	   CD4+	  or	  CD8+	  
B-­‐cells	   B220+	  
Erythrocytes	   Ter119+	  
Granulocytes	   CD11b+Gr-­‐1+	  
Megakaryocytes	   CD41+	  
Table	  7.2	  Markers	  used	  to	  identify	  mouse	  HSCs	  
 
 
Human hematopoietic cells: 
Population	   Cell	  surface	  phenotype	  
linneg	   CD11b-­‐CD16-­‐CD19-­‐CD4-­‐CD8-­‐CD235a-­‐	  
CD34+CD38-­‐	  HSCs	   linnegCD34+CD38-­‐	  
CD34+CD117+	  HSCs	   linnegCD34+CD117+	  
Progenitor	  cells	   linnegCD34+	  CD38+	  
T-­‐cells	   CD4+	  or	  CD8+	  
B-­‐cells	   CD19+	  
Erythrocytes	   CD235a+	  
Monocytes	   CD11b+	  
Table	  7.3	  Markers	  used	  to	  identify	  human	  HSCs	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